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ABSTRACT 
 
 
 
Paranjape, Geeta S.,Ph.D.,University of Missouri-Saint Louis, May 2012.  Aβ(1-42) 
Protofibrils But Not Fibrils Activate Microglia. Major Professor: Michael R. Nichols. 
 
 
 
One of the hallmark features of the Alzheimer’s disease (AD) brain is the extracellular 
deposition of amyloid-β protein (Aβ) in both fibrillar (senile plaques) and diffuse forms. 
Significant proinflammatory markers including activated microglia and cytokines have 
been detected surrounding the plaques but are absent in diffuse areas suggesting that 
microglial activation is sensitive to Aβ structure. Since Aβ displays structural 
polymorphism in vitro, we sought to determine the relationship between Aβ aggregation 
state and microglial proinflammatory response. Size exclusion chromatography (SEC) 
purification of freshly reconstituted Aβ(1-42) in NaOH/F12 cell culture medium isolated 
classical 100 nm long curvilinear protofibrils which stimulated a robust production of 
microglial TNFα. The Aβ(1-42) protofibrils produced a concentration-dependent 
response in the low micromolar range. In contrast to Aβ(1-42), Aβ(1-40) required a pre-
incubation of 24h at 25⁰C in order to produce protofibrils. Although both preparations 
were similar in morphology, Aβ(1-42) protofibrils were a much better stimulator of 
microglia than Aβ(1-40) protofibrils. Aβ(1-40) containing the Arctic mutation (E22G) 
formed protofibrils as soon as 3h after reconstitution , yet they were largely ineffective in 
 xvii 
 
stimulating microglia. None of the Aβ protofibril preparations were toxic to microglia 
suggesting that Aβ(1-42) protofibrils activate microglia in a manner independent of 
toxicity. As expected, freshly-purified Aβ(1-42) or Aβ(1-40) monomer were not effective 
in stimulating microglia, but surprisingly, neither were Aβ(1-42) fibrils even though they 
exhibited extensive Thioflavin-T fluorescence compared to protofibrils. These findings 
suggest that Aβ(1-42) protofibrils are the most effective inducers of a proinflammatory 
response in mouse microglia. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
1.1 Protein misfolding and amyloids 
 
 
 
Protein folding represents one of the most fundamental and ubiquitous self-
assembly processes in biological systems by which proteins adopt native, three- 
dimensional structure.  Since only correctly folded protein can perform its normal 
biological function, this process requires precision and fidelity (Dobson, 2003).  
Therefore, biological systems have evolved the mechanisms involving chaperones and 
proteasomal systems.  Chaperones involve  a set of proteins which assist the folding 
process by directing the nascent proteins towards the correct pathway of folding, and if 
such mechanisms fail, proteasomal proteins degrade the misfolded proteins before 
causing further damage to the living organism (Sherman and Goldberg, 2001).  
One of the major consequences of failure of a protein to fold correctly or retain its 
correct structure is its aggregation into insoluble filamentous polymers, rich in β-sheet 
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structure (Selkoe, 2003).  When normally soluble proteins get deposited in the 
extracellular tissue (typically 10 nm in diameter fibrils) the condition is referred to as 
amyloids (Selkoe, 2003).  Examples include amylin protein in diabetic pancreas and 
immunoglobulins in multiple myeloma (Selkoe, 2003).  The term amyloid was first used 
by German pathologist Rudolf Virchow in 1854 to describe waxy tissue deposits for their 
resemblance to starch (Kyle, 2001).  Later, amyloids were found to be proteinaceous 
rather than starchy, but the term amyloid is still widely used to describe extracellular 
protein aggregates (Kyle, 2001).  Although some amyloids have been reported to carry 
out a functional role in bacteria, fungi, and mammals, most of the amyloids have been 
commonly associated with disease.  The examples of functional amyloids include 
Escherichia coli protein curlin (Chapman, et al., 2002), spider silk, and mammalian 
protein Pmel17 (Fowler, et al., 2006).  These benefit the host in processes like cell 
adhesion, propagation, and biosynthesis of melanin, pigment deposition and release of 
hormones.  The formation of functional amyloids is under tight regulation, emphasizing 
the importance for balancing their formation and clearance (Fowler, et al., 2007).   
There is a class of emerging diseases in which intracellular proteins accumulate 
within the cells.  Such aggregates resemble extracellular amyloids in their characterstic β-
sheet rich structure, birefringence with aniline dyes like congo-red and insolubility.  
These diseases are broadly categorized as conformational diseases (Carrell and Lomas, 
1997).  Some of the well studied examples include Prion diseases, Huntington disease, 
Alzheimer’s disease (AD), Parkinson’s disease and Lewy body dementia.  Table 1.1 lists 
some of the examples of such diseases and underlying protein pathology.  Among these 
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diseases, AD is particularly different in that it shows accumulation of amyloid-forming 
protein both extracellularly and intracellularly (Selkoe, 2003).   
All these amyloidogenic proteins listed in Table 1.1 are diverse in their size, 
structure, location, function and sequence, yet they can form β-sheet rich aggregates with 
a distinct cross-beta X-ray diffraction pattern.  Interestingly, a series of studies from the 
Dobson laboratory have demonstrated that diverse and structurally unrelated proteins can 
be manipulated to form amyloids under a set of specific environmental conditions.  Such 
amyloids are not only morphologically indistinguishable from those associated with the 
disease but can also exhibit cytotoxicity.  These studies suggest that widely different 
amyloids might share a common mechanism of pathogenicity (Chiti, et al., 1999; 
Bucciantini, et al., 2002).  This accentuates the need to understand the structural basis of 
aggregation on protein folding to make the disease amenable to intervention.  
 
 
 
1.2 Alzheimer’s disease 
 
 
 
Alzheimer’s disease (AD) is a debilitating progressive neurodegenerative disorder 
characterized by severe loss of memory and disruption of an individual’s ability to think 
and co-ordinate different behavioral processes including speech and task performance 
(Thies and Bleiler, 2011).  Extensive neuronal loss is observed particularly in the basal 
forebrain and hippocampus, resulting into significant shrinkage of brain as compared to 
normal age matched controls.  This pathology is believed to contribute towards cognitive 
decline in AD (Selkoe, 2011). 
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Table 1.1 Some human brain diseases that are characterized by misfolding and 
aggregation of proteins. 
5 
 
AD is the most frequent cause of dementia in the aging population.  It has been 
reported that worldwide, there were 26.6 million cases of AD in 2006, which are 
projected to increase by almost four times by the year 2050 without further development 
of a potential therapy (Hampel, et al., 2010).  It is the sixth leading cause of death in the 
United States alone with currently 5.2 million Americans afflicted with AD.  The total 
cost of healthcare and other related services spent towards AD is estimated to be $183 
billion in the year 2011, reflecting the huge socioeconomic impact of AD (Thies and 
Bleiler, 2011).  Since the onset of AD is age-dependent and the general population is 
aging, significant efforts are currently being directed toward a basic understanding of 
AD.  
 
 
 
1.3 AD Pathology 
 
 
 
Alzheimer’s disease was first diagnosed in 1906 by Bavarian psychiatrist Alois 
Alzheimer (Selkoe and Podlisny, 2002).  During the postmortem analysis of brain slices, 
he found two distinctive microscopic lesions, namely senile plaques (SP) and 
neurofibrillary tangles (NFT) in the cerebral cortex.  Amyloid β protein (Aβ) was found 
to be a major constituent protein of senile plaques (Glenner and Wong, 1984) while 
hyperphosphorylated Tau protein constitutes neurofibrillary tangles (Grundke-Iqbal, et 
al., 1986).  Apart from the senile plaques, Aβ is also found in variable amounts in the 
walls of arterioles, arteries, capillaries, venuoles of meninges and parenchyma in AD 
patients. 
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Long after their discovery, these lesions still form the basis of a definitive 
diagnosis of AD postmortem (Selkoe, 1994).  The progressive development of 
neurofibrillary tangles and abnormal dendritic structures (neuropil threads) follows a 
predictable course of occurrence within the AD brain, forming the basis for Braak and 
Braak staging of AD brain.  Braak staging involves six stages; Braak stage I-II represents 
entorhinal NFTs with no dementia, III-IV represents limbic NFTs with mild cognitive 
impairement.  Further progression to neocortical NFTs in the stage V-VI is concluded as 
end stage severe dementia with significant neuronal loss.  However, the neuronal 
alterations are observed even before Braak I (Braak and Braak, 1991, 1995).  
 
 
 
1.3.1 Neurofibrillary tangles 
 
 
 
Neurofibrillary tangles are intraneuronal fibrils of hyperphosphorylated tau 
protein (Grundke-Iqbal, et al., 1986).  These 10 nm in diameter fibrils are typically 
observed as paired helical filaments (PHF) mixed with some straight filaments.  Tau 
tangles are observed in AD brains particularly in the entorhinal cortex, hippocampal 
formation, amygdale and association cortices of the frontal, temporal, and parietal lobes.  
Intracellularly, NFTs were found not only in the neurons but also in dystrophic neurites 
(swollen axons and dendrites) present within and outside of the amyloid plaque (Braak 
and Braak, 1995).  
Under normal conditions, tau is a heat stable, soluble, microtubule-associated 
protein, and plays an important role in the assembly and stabilization of microtubules in 
vitro.  Microtubules form an important unit of the cytoskeleton, and in the central nervous 
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system play an important role in axonal transport and neurotransmission (Weingarten, et 
al., 1975).  Hyperphosphorylated tau forms oligomers, which are believed to convert later 
into highly insoluble fibrils (Maeda, et al., 2006; Maeda, et al., 2007).  It is not clear 
whether phosphorylation induces fibril formation, but it does reduce the affinity of tau for 
microtubules.  As a consequence, microtubules destabilize and promote degeneration of 
affected neurons in AD. (Bramblett, et al., 1993).  Within the tangles, 
hyperphosphorylated tau is shown to be associated with ubiquitin, which is a major 
component of the proteasomal system.  Complexation with ubiquitin is regarded as an 
unsuccessful attempt of proteasomal system to clear tau aggregates from the brain 
(Selkoe, 2011).  Formation of tau tangles can occur independently of amyloid plaques in 
other tauopathies like progressive supranuclear palsy cortico-basal ganglionic 
degeneration, Guam Parkinsonism dementia complex, Niemann–Pick type C, pugilistic 
dementia, and Pick’s diseases, and in some cases leads to dementia as well (Sanchez, et 
al., 2001; Binder, et al., 2005; Guillozet-Bongaarts, et al., 2007; Alonso, et al., 2008). 
 
 
 
1.3.2 Senile plaques 
 
 
 
 Senile or neuritic plaques consist of extracellular deposits of the Aβ protein and 
are associated with dystrophic neurites (axons and dendrites) and activated immune cells 
including astrocytes, and microglia (Wisniewski, et al., 1989).  The dystrophic neurites 
located in the proximity of senile plaques display cytoplasmic inclusions as dense bodies, 
which show immunoreactivity for the amyloid precursor protein (APP) and ubiquitin, 
suggesting the presence of abnormal ubiquitination process.  Several studies have shown 
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the presence of heparin sulfate, glycoproteins, carbohydrate residues, advanced glycation 
end products (Vitek, et al., 1994), racemic amino acids and isopeptide bonds in addition 
to Aβ within the senile plaques (Glabe, 2001).  This indicates that senile plaques display 
an array of different molecules along with activated immune cells.  Several of these 
molecules represent long lived proteins and components of the proteasome (Glabe, 2001). 
Protein sequencing studies showed that senile plaques contains Aβ protein that 
can exist as 40- or 42- amino acid variants differing only at their carboxy terminus 
(Glenner and Wong, 1984; Iwatsubo, et al., 1994).  Although insoluble Aβ fibrils form 
the core of a mature neuritic plaque, several immunological studies have detected the 
presence of other forms of Aβ within and surrrounding other plaque-like deposits 
(Tagliavini, et al., 1988).  These Aβ species are poorly characterized but are believed to 
be largely amorphous.  Collection of such species gives rise to diffuse plaques, which in 
contrast to the classical plaque, lack the presence of swollen neurites and altered glia 
giving it an undefined appearance.  Extensive studies now support that diffuse and 
compact plaques are not the two extremes of Aβ morphologies within the AD brain but, 
in fact, they represent a continnum in which Aβ species of varying size and structure exist 
in a complex equillibrium (Selkoe, 1994).  These species display varying degrees of 
altered neuritis and gliosis associated with them.  It is believed that the diffuse plaques 
are “preamyloid”, which ultimately evolve into mature senile plaques (Lemere, et al., 
1996).  
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1.4 Generation of Aβ from amyloid precursor protein (APP) 
 
 
Aβ peptide is a product of a sequential proteolytic cleavage of a larger precursor 
protein called amyloid precursor protein (APP) (Kang, et al., 1987) (Figure 1.1).  APP is 
a single membrane-spanning glycoprotein containing 695 amino acid residues.  The 
single gene encoding APP is located on chromosome 21, which provides an explanation 
for AD-like pathology seen in individuals with Down’s syndrome having trisomy 21 
(three copies) in terms of gene dosage effect (Kang, et al., 1987; Goate, et al., 1989).  
While glia can produce APP, neurons are the major source of APP within the brain 
(Selkoe, 1994).  
APP belongs to an evolutionarily conserved protein family, which shares 
similarity with the NOTCH family of receptors.  Notch proteins are important 
determinants of cell fate during early development.  A mouse deficient in APP did not 
show any adverse phenotypes.  However, a double knockout (KO) mice with a combined 
deficiency of both APP and its homolog resulted in a lethal phenotype (von Koch, et al., 
1997; Heber, et al., 2000).  Different “loss of function” and “gain of function” mutants of 
APP in a variety of model systems including mouse, zebrafish, Caenorhabditis elegans, 
Drosophila melanogaster have indicated a role for APP in cell adhesion, neuron 
migration, synaptogenesis and early neuronal development (Selkoe and Podlisny, 2002; 
Guo, et al., 2011).  APP KO mice not only showed behavioral defects in locomotor 
activity and passive avoidance learning, but also displayed defective long term 
potentiation (LTP) and increase in gliosis (Dawson, et al., 1999; Phinney, et al., 1999; 
Seabrook, et al., 1999; Senechal, et al., 2008).  
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Figure 1.1  Generation of Aβ from APP by proteolytic processing (reproduced from 
(Li, et al., 2009a).  Stepwise proteolytic processing of APP by α-, β-, and γ-secretases. 
Major cleavage sites of the three secretases in APP are indicated by dashed horizontal 
lines. The transmembrane domain is shown as a cylinder. The Aβ-domain is shown in 
orange, and the APP intracellular domain (AICD) in green. Aβ, amyloid β peptide; 
AICD, APP intracellular domain; APP, amyloid precursor protein; C83, 83-residue APP 
C-terminal fragment; C99, 99-residue APP C-terminal fragment. 
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The APP gene undergoes alternative splicing to generate multiple isoforms of 
different amino acid lengths (Kang, et al., 1987).  APP processing also involves post 
translational modifications like O- and N-linked glycosylation, sulfation and 
phosphorylation in addition to its cleavage by a number of proteolytic enzymes called 
secretases to release various fragments of APP (Selkoe, 1994).  One of the noteworthy 
features of APP is its constitutive processing by regulated intramembrane proteolysis 
(RIP).  APP is acted upon by α- or β-secretase to release the soluble ectodomain α-sCTF 
or β-sCTF respectively.  The remaining membrane bound CTF (c83 or c95) is then 
cleaved by γ-secretase to give rise to p3 or Aβ respectively.  With α-, γ-secretase, Aβ 
domain is cleaved in the middle, preventing the formation of intact Aβ (Sisodia, et al., 
1990).  On the other hand, β-secretase, also known as β-site APP-cleaving enzyme 
(BACE-1), acts near the N-terminus of the Aβ domain, followed by γ-secretase cleavage 
in an intramembrane fashion.  Thus, resulting intact Aβ peptide contains 28 residues from 
outside the membrane and 12-14 residues of transmembrane domain.  Since γ-secretase 
cleavage is heterogeneous, it produces Aβ of 37-43 amino acid in length (Seubert, et al., 
1993).  Aβ(1-40) is the predominant variant produced as a result of amyloidogenic 
pathway followed by Aβ(1-42).  γ-secretase is a multiprotein complex consisting of 4 
proteins.  These include presinilin 1 (PS-1), an aspartyl protease which carries out the 
catalysis along with Nicastrin, APH-1 and Presinilin 2 (PS-2).  Together they form an 
active enzyme complex (De Strooper, et al., 1998; Edbauer, et al., 2003).  
Both Aβ (1-40) and (1-42) are found to be constitutively present in CSF of normal 
individuals in nanomolar concentrations.  Due to the presence of Aβ in CSF, other 
biologic fluids and conditioned cell culture media under normal circumstances of APP 
12 
 
processing, it is believed that AD represents an impairment in the balance between Aβ 
production and clearance (Seubert, et al., 1992; Shoji, et al., 1992; Haass, et al., 1994; 
Walsh, et al., 2000).  Therefore, proteins that are a part of amyloidogenic processing of 
APP, including BACE-1, γ-secretase, make obvious and major drug targets against AD.  
 
 
 
1.5 Genetic basis of AD 
 
 
 
Although, most of the AD cases are typically late onset (LOAD) and sporadic in 
nature, familial forms of the disease were identified after the discovery of APP (Selkoe 
and Podlisny, 2002).  AD is categorized to be of a familial form based on the history of 
an AD type-demented individual in the family.  Approximately 10% of the AD cases are 
familial, which follow the autosomal dominant, Mendelian pattern of inheritance.  The 
rest of the cases display a more complex pattern of inheritance. 50% of early onset AD 
(EOAD) cases are linked to mutations in three genes namely APP, PS1 and PS2, which 
have a role in the processing of APP as discussed earlier in section 1.4, and generate 
amyloidogenic Aβ(1-42) peptide to a greater extent (Selkoe and Podlisny, 2002). So far, 
33 mutations in APP, 194 mutations in PS1 and 20 mutations in PS2 are reported to exist 
worldwide based on the AD and frontotemporal dementia (FTD) mutation database 
(http://www.molgen.ua.ac.be/ADMutations).  
APP mutations are less common and their carriers are heterozygotes.  Most of the 
APP missense mutations leading to AD are located within or near α, β or λ-secretase 
cleavage sites, external to the Aβ sequence, and appear to operate via gain of toxic 
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amyloidogenic function mechanism (Selkoe and Podlisny, 2002; Selkoe, 2011).  
Typically mutations in β-secretase lead to increased levels of total Aβ.  α-secretase 
mutants generate Aβ, which in turn accelerates amyloidosis, and γ-secretase mutants 
increase the ratio of Aβ(1-42) to Aβ(1-40) by increasing the production of longer Aβ 
peptide, which  is more prone to aggregation (Mullan, et al., 1992; Citron, et al., 1994; 
Suzuki, et al., 1994; Scheuner, et al., 1996; Selkoe, 2011). 
Intra-Aβ mutant phenotypes differ in the distribution of deposits, levels of Aβ and 
other AD related cognitive symptoms.  E22Q (Dutch), A21G (Flemish), E22K (Italian), 
E22G (Arctic), and D23N (Iowa) are some of the well studied intra Aβ mutations.  These 
mutant peptides appear to affect the biochemistry of Aβ aggregation and fibrillization 
kinetics during in vitro studies.   E22Q (Dutch) and A21G (Flemish) mutants result in the 
intracerebral haemorrhage whereas the E22G (Arctic) mutation leads to rapid formation 
of protofibrils in vitro (Levy, et al., 1990; Hendriks, et al., 1992; Nilsberth, et al., 2001).   
The identification of genetic mutations causing AD have led to the development 
of a number of animal model systems, especially in mice, which display differential 
degrees of amyloid plaque burden and have provided important insights into the 
mechanism of AD and development of therapeutic strategies (Duyckaerts, et al., 2008).  
A transgenic mice bearing a mutant human PS1 showed an increase in Aβ production, 
behavioral deficits, impaired calcium homeostasis, altered axonal transport and tau 
phosphorylation (Mattson, et al., 2001; Lazarov, et al., 2007).  Double transgenic mice 
harboring both APP and BACE1 mutations showed an increased number of diffuse 
deposits and resulted in decreased Aβ levels accompanied by severe neurodegeneration.  
BACE-1 knockout (KO) mice not only ameliorated amyloid pathology by decreasing Aβ 
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production, but also were able to rescue the behavioral and neurodegenerative deficits in 
several studies underscoring the importance of BACE-1 in AD pathogenesis.  APP and 
PS1 double transgenic mice harboring 5 different FAD mutations (5XFAD) can develop 
lesions as early as two months of age.  APP/PS1 double KO mice were not viable or had 
severe cognitive deficiency with large quantities of C99 fragments.  These and several 
other studies strongly support a causal role of Aβ in AD pathogenesis via impairment of 
normal APP processing. 
In late onset familial and sporadic cases, the prevalence of apolipoprotein A4 
(ApoE4) allele is linked to the predisposition of AD, which accounts for more than 95% 
of AD cases (Mahley, 1988; Corder, et al., 1993; Saunders, et al., 1993; Strittmatter, et 
al., 1993).  The Apo E protein plays an important role in lipid metabolism and cholesterol 
homeostasis in the brain (Mahley, 1988).  Apo E gene occurs in 4 different isoforms E1, 
E2, E3 and E4. Apo E4 allele-bearing individuals tend to develop AD in a manner that is 
dependent of dose of ApoE4 allele, although the presence of Apo E4 is neither necessary 
nor sufficient to cause AD (Daw, et al., 2000; Kowalska, 2004).  Tumor necrosis factor α 
(TNFα), interlekin 1 (IL-1) and α2-macroglobulin are also considered to be susceptibility 
genes for AD (Daw, et al., 2000).  ApoE isoform-dependent predisposition to AD can be 
explained by a variety of mechanisms, including modulation in total Aβ levels, formation 
of plaques and their clearance, tau tangle formation and impairment of neuronal signaling 
pathways (LaDu, et al., 1994; Beffert and Poirier, 1996; Herz and Beffert, 2000; 
Holtzman, et al., 2000; Raber, et al., 2000; Huang, et al., 2001; Buttini, et al., 2002; 
Huang, 2011).  However, the exact contribution of ApoE isoform to AD pathogenesis 
remains unclear.  Altogether, both in vitro and in vivo genetic studies of AD have 
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implicated an important role for Aβ in AD pathogenesis via a number of diverse 
mechanisms, and in combination with different susceptibility genes, provide a basis for a 
potential combinatorial therapeutic approach. 
 
 
 
1.6 Central role of Aβ in the AD pathogenesis 
 
 
 
In AD, accumulation of Aβ preceeds the appearance of tau tangles, but taupathies 
do not induce secondary deposition of Aβ.  The most solid support for a causal role of Aβ 
came from the fact that EOAD occurs due to mutations in the genes primarily involved in 
the processing of Aβ, which give rise to clinically similar AD phenotypes as in LOAD 
cases.  Moreover, intra-Aβ mutations develop AD pathology by altering the aggregation 
kinetics of Aβ.  In contrast, mutations in tau cause tauopathy and dementia, but do not 
display amyloid plaques (Spillantini, et al., 1998).  Thus, tauopathies can be regarded as a 
result of different neurologic insults rather than being specifically an outcome of AD 
(Hardy and Selkoe, 2002; Selkoe, 2011). 
When mice expressing mutant tau were crossed with Tg2576 transgenic mice 
bearing a mutated APP, the tau tangle formation was enhanced as compared to single Tg 
mice with tau mutation (Lewis, et al., 2001).  Aβ alone induced phosphorylation of tau 
and loss of cholinergic neurons in rat primary septal culture but caused neurotoxicity in 
hippocampal cultured neurons only in the presence of tau (Rapoport, et al., 2002; Zheng, 
et al., 2002). 
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Even though development of animal models which perfectly reproduce the full 
phenotype of AD has been elusive, several models of AD carrying FAD mutations have 
shown an increase in amyloid plaques in the absence of NFTs (Games, et al., 1995; Duff, 
et al., 1996; Hsiao, et al., 1996; Chen, et al., 2000; Lewis, et al., 2001) and still have 
some memory and learning deficiency (Wong, et al., 2002).  The fact that Down’s 
syndrome patients develop diffuse amyloid plaques very early in their lifetime, followed 
by classic neuritic plaque and tangles in their thirties and forties accompanied by AD-like 
dementia, strongly favors the hypothesis that Aβ deposition precedes AD pathogenesis 
(Lemere, et al., 1996).  Some normal aged individuals and AD patients display the 
presence of diffuse plaques without any cognitive dysfunction, which in part is believed 
to be due to lack of transition of diffuse plaques into neuritic plaques (Selkoe, 2000). 
Also, both active immunization studies using synthetic Aβ and passive 
immunization studies using anti-Aβ antibodies of AD transgenic mice prevented not only 
amyloid deposition but also reduced related neuritic dystrophy and astrogliosis.  This 
indicates the potential of Aβ as an effective target for preventing AD (Schenk, et al., 
1999; Bard, et al., 2000; Janus, et al., 2000).  Collectively, these observations suggest that 
Aβ deposition might be the primary event in AD pathogenesis, followed by interaction of 
tau and other risk factors like ApoE with Aβ to display a complete phenotype of AD 
(Hardy, et al., 1998). 
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1.7 Aggregation of Aβ 
 
 
 
Aβ protein has a high propensity to self aggregate in an orderly manner to form 
long fibrils 4-10 nm in diameter.  Under normal conditions, monomeric Aβ is highly 
soluble.  By some yet unknown mechanism, Aβ starts to self aggregate forming amyloids 
which get deposited in the brain.  Between the two carboxy terminal variants of Aβ, Aβ 
(1-42) has a much higher propensity to aggregate than Aβ (1-40) (Jarrett, et al., 1993).  
This difference is attributed to the presence of two additional amino acids on carboxy 
terminal namely, Isoleucine and Valine, making Aβ (1-42) slightly more hydrophobic 
than Aβ (1-40).  Moreover, Aβ (1-42) is resistant to degradation by proteases like 
collagenase and pepsin (Glenner and Wong, 1984; Masters, et al., 1985a).  
Interestingly when Down’s syndrome brains were used as model system to gain 
insights into the initiation and progression of AD, Aβ(1-42) was the first form to get 
deposited in the diffuse plaques in the earlier stages while Aβ (1-40) was predominant 
variant in vascular tissue and neuritic plaques during later stages (Lemere, et al., 1996).  
Also, FAD cases display elevated Aβ(1-42) levels (Hsiao, et al., 1996), and higher Aβ(1-
42) plasma concentration is a susceptibility factor for AD (Mayeux, et al., 1999).  All 
these observation suggests a critical role for Aβ(1-42), which is believed to be a result of 
its higher aggregation propensity (Jarrett, et al., 1993).  
Synthetic Aβ peptides readily form fibrils in vitro that are indistinguishable from 
those directly isolated from AD brains (Kirschner, et al., 1987; Halverson, et al., 1990; 
Barrow and Zagorski, 1991; Hilbich, et al., 1991).  This work had a huge impact on the 
Aβ field since it further led to a number of studies to understand the structure, 
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mechanism, kinetics, and intermediates of the fibril assembly process at the molecular 
level which are still under active investigation.  The Aβ sequence has 14 consecutive 
hydrophobic residues at the C-terminus with a prevalence of valine and isoleucine, which 
are β-branched residues, and the presence of glycine every fourth residue (Jarrett and 
Lansbury, 1992).  Consequently, peptides with a longer carboxy terminus are less soluble 
in aqueous media than the shorter fragments containing N-terminal residues, particularly 
at physiologic pH.  Despite the differences in the solubility, they retain the ability to form 
amyloid fibrils.  The central part containing residues 19-28 was found to be crucial for 
fibril formation, and the length of the carboxy terminal was found to contribute towards 
the stability of fibrils by stabilizing β-sheets.  Accordingly, Aβ (1-42) fibrils are more 
stable and less soluble than other shorter carboxy variants (Gorevic, et al., 1987; Hilbich, 
et al., 1991; Burdick, et al., 1992).  The KLVFF motif at position 16-20 has been shown 
to be crucial for fibrillogenesis (Tjernberg, et al., 1996).  
Aβ-fibrillization displays a nucleation-dependent polymerization mechanism 
(Jarrett and Lansbury, 1992).  The formation of a nucleus or seed is the first step followed 
by addition of monomers to the already formed nucleus, which results in fibril elongation 
and growth.  After the linear growth phase, fibril formation reaches a plateau where the 
monomer and fibrils are in equillibrium.  Formation of the nucleus is a comparatively 
slower phase and represents a lag before linear growth into fibrils.  The extent of lag time 
is influenced by the concentration of monomer.  Nucleation represents the rate-limiting 
step of Aβ-fibrillization (Burdick, et al., 1992; Jarrett and Lansbury, 1992).  The driving 
force for fibril formation was proposed to be entropy driven based largely on the 
hydrophobic effect (Hilbich, et al., 1991).  Multiple lines of evidence for oligomeric 
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intermediates make the fibrilization process less straightforward than once thought 
(Bitan, et al., 2003)  
Aβ aggregation is influenced by a number of parameters in vitro including pH, 
concentration, temperature, length of the hydrophobic carboxy terminus, and time of 
incubation after solubilization of Aβ (Burdick, et al., 1992).  The rate and extent of 
aggregation is higher at acidic pH as compared to neutral pH.  In fact, pH 5-6 was found 
to increase the rate of formation of plaque-like insoluble aggregates due to the 
insolubility of Aβ around its isoelectric point (5.5) (Barrow and Zagorski, 1991; Burdick, 
et al., 1992).  The pH dependence of Aβ-aggregation has several important biological 
implications.  It is postulated that fibril formation might take place in the low pH 
environment of lysosomes during APP processing, and its leakage outside the cells can 
nucleate extracellular fibril formation (LaFerla, et al., 2007). 
 
 
 
1.8 Kinetics of Aβ aggregation 
 
 
 
Understanding the kinetics of Aβ fibrillization in terms of rate constants is 
valuable for the development of pharmacological agents which can interfere with plaque 
formation.  In nucleation-dependent polymerization, a certain critical concentration of 
monomer is required, above which the formation of polymer ensues (Harper and 
Lansbury, 1997).  Two pathways are proposed for Aβ-fibrillogenesis based on the 
aggregation reactions monitored by quasielastic light scattering (QLS) spectroscopy also 
known as dynamic light scattering (DLS), which is sensitive to the light scattered by 
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aggregation species of different sizes. QLS thus determines the hydrodynamic radius 
(RH) of the particles based on their average diffusion coefficients.  
In one pathway of fibrillogenesis, when the concentration of monomer exceeds 
critical concentration, Aβ form micelles, which are in equilibrium with monomer.  
Micelles increase the local concentration of Aβ monomer, which in turn favors the 
formation of a nucleus (Lomakin, et al., 1997) (Figure 1.2).  In fact, surface tension 
measurements showed that Aβ forms miceller structures by reducing the surface tension 
of water in a manner similar to that of amphipathic detergents (Soreghan, et al., 1994).  
The nucleus then acts as a site for elongation by further addition of monomers resulting 
in fibrillization.  Therefore, in such a case, the rate of initial elongation is independent of 
initial monomer concentration.  When monomer concentration is below the critical 
concentration, the fibrillization can be influenced by the number of pre-existing 
heterogeneous or non-Aβ nuclei (Hartley, et al., 2008).  Thus, Aβ fibrillization is 
proposed to be governed by three main parameters, namely rate constant of nucleation kn, 
rate constant of elongation ke and critical concentration c*.  However, in a dynamic 
biological environment, various other parameters might influence the fibrillization of Aβ 
in a complex manner, for example by complexation of Aβ monomers with a protein to 
form a nucleus for fibril elongation (Lomakin, et al., 1996; Lomakin, et al., 1997; 
Hartley, et al., 2008). 
Aβ (1-40) has an almost 5-fold higher critical concentration than Aβ (1-42) 
(Harper and Lansbury, 1997).  In vivo concentrations of Aβ are in the nanomolar range, 
which is much lower than the critical concentration.  It is believed that local 
supersaturation is achieved and conserved for a timescale, which allows the  
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Figure 1.2  Kinetic model of Aβ fibrillogenesis (reproduced from Lomakin 1997).  
Aβ monomers can form fibrils in a nucleation-dependent polymerization via two different 
mechanisms.  In one mechanism,nucleation takes place on the pre-existing seeds.  In 
other mechanism, formation of micelles take place when monomer concentration C 
exceeds the critical concentration c*.  Micelles are formed in a rapid equilibrium with 
monomers, and spontaneously nucleate with a rate kn.  The seeds or nuclei are further 
elongated by addition of free monomers.  The rate constant of elongation (ke) is 
proportional to the concentration of free monomer. 
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nucleation and further polymerization within cellular compartments (Jarrett and 
Lansbury, 1992; Harper and Lansbury, 1997; Lomakin, et al., 1997). 
 
 
 
1.9 Structure of Aβ fibrils 
 
 
 
Cross-β motif is the major motif found in amyloid fibril structure (Eanes and 
Glenner, 1968).  A number of studies including X-ray diffraction (Sunde and Blake, 
1997), electron diffraction (Serpell, et al., 2000), cryogenic EM (cryo-EM) (Serpell and 
Smith, 2000), proteolysis, chemical cross linking and mutagenesis supported the 
existence of cross-β structure in amyloid fibrils.  Cross-β structure represents a pattern 
where β-sheets run nearly perpendicular to long fibril axis and backbone hydrogen bonds 
linking individual β-strands together run parallel to the long fibril axis (Eanes and 
Glenner, 1968).  
Solid state NMR structural studies are particularly useful in assigning structural 
constraints in the amyloid fibrils due to the fact that the non-crystalline and largely 
insoluble nature of fibrils make them less amenable to molecular level structural 
determination by X-ray diffraction and liquid state nuclear magnetic resonanace (NMR).  
Earlier solid state NMR studies using a nine-residue fragment Aβ (34-42) predicted the 
presence of antiparallel β-sheets with alternating hydrogen bond registries (Lansbury, et 
al., 1995).  Solid state NMR study using a longer fragment Aβ (10-35) showed the nature 
of β-sheets to be parallel (Benzinger, et al., 1998; Antzutkin, et al., 2000), which was  
found to be the most common orientation in Aβ (1-40) and Aβ (1-42) fibrils in a number 
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of studies (Antzutkin, et al., 2000; Antzutkin, et al., 2002; Balbach, et al., 2002).  This 
was further supported by several independent studies employing EM, XRD, electron 
paramagnetic resonance and Hydrogen/deuterium exchange.  Antiparallel β-sheet 
structure was found to be adopted by shorter Aβ fragments including Aβ (16-22), (34-
42), (11-25) (Balbach, et al., 2000; Petkova, et al., 2004) and also in Aβ mutant peptide 
carrying D23N (Iowa) mutation (Tycko, et al., 2009).  
The most widely accepted model of amyloid fibrils is based on solid state NMR 
studies on Aβ(1-40) fibril (Petkova, et al., 2002).  It shows residues 10-22 and 30-40 
forming β-strands flanked by a loop between residues 23-29 with residues 1-8 being 
disordered as shown (Figure 1.3).  Thus, hydrophobic residues make the core, which is 
stabilized by extensive hydrophobic interactions, whereas the polar side chains are 
exposed to the outer surface of fibrils.  Oppositely charged D23 and K28 form a salt 
bridge inside the core which along with in-register parallel β-sheet alignment contributes 
to the stability of hydrophobic interactions.   
Interestingly Aβ fibrils were shown to display subtle structural differences at the 
molecular level based on a solid state NMR study (Petkova, et al., 2005).  Moreover, 
these differences were dependent on the physical conditions employed during fibril 
growth.  More importantly, subtle differences in the molecular structure were shown to 
have a significant effect on their toxicity to neuronal culture.  Furthermore, addition of 
preformed fibril seeds to unaggregated solution formed fibrils structurally identical to the 
seeds.  This study further implicated that subtleties in the structure of Aβ fibrils were 
governed by mechanism of its nucleation rather than primary sequence of the peptide or 
thermodynamic stability of the  
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Figure 1.3 Structural model for Aβ(1-40) fibrils based on the solid state NMR 
constraints. (reproduced from (Petkova, et al., 2002)).  a. Schematic representation 
of a single cross-β unit.  The yellow arrow indicates the direction of long fibril axis, 
which is parallel to the intermolecular backbone hydrogen bonds.  Cross-β unit has 
double molecular layer, with in-register parallel β-sheet by residues 12-24 (orange 
ribbons) and 30-40 (blue ribbons).  b. Central Aβ(1-40) molecule from energy 
minimization of five-shain system, viewed down the long axis of fibril.  Color coded 
residues depicts the nature of side chains hydrophobic (green), magenta (polar), 
positive (blue) and negative (red).   
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structure (Stine, et al., 2003; Petkova, et al., 2005; Shivaprasad and Wetzel, 2006; Tycko, 
2011).  
 
 
 
1.10 Amyloid cascade hypothesis 
 
The amyloid cascade hypothesis was put forth by Hardy and Higgins in 1992 to 
describe the possible sequence of events which leads to development of AD.  The 
amyloid hypothesis proposed a causal role for Aβ in AD.  Aβ peptide itself or products of 
APP processing can be neurotoxic.  Aβ deposition into senile plaques was thought to be 
the primary event, which is followed by a number of secondary events, culminating in 
neuronal cell death and dementia.  In sporadic AD cases, which are more common than 
the familial cases, AD might be a result of one or more factors that initiate Aβ deposition 
(Hardy and Higgins 1992).  
Amyloid hypothesis is further supported by the in vitro observations that 
suggested that Aβ fibril formation is needed to exert its neurotoxicity (Mattson, et al., 
1993; Pike, et al., 1993; Lorenzo and Yankner, 1994).  One of the mechanisms of Aβ-
induced neurotoxicity is shown to be mediated by destabilization of calcium homeostasis.  
Moreover, impaired calcium metabolism resulted into hyperphosphorylation of tau and 
subsequent formation of NFTs (Mattson, et al., 1992; Mattson, et al., 1993).  This study 
suggests that tau pathology can be a seconday consequence of Aβ-accumulation.  
Moreover clinically Aβ deposition is known to preceed tangle formation (Braak and 
Braak, 1991).   
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1.11 Challenges of amyloid cascade hypothesis 
 
 
 
Recent developments in the AD field have led to some challenges for the amyloid 
cascade hypothesis.  The most significant of the challenges is that no correlation was 
observed between amyloid plaque burden and cognitive decline (Lue, et al., 1999; 
Naslund, et al., 2000).  Different parameters representing the plaque burden, including 
total Aβ, total insoluble Aβ, Aβ immunereactive plaques or thioflavin-T positive Aβ 
deposits, do not seem to correlate with synaptic loss.  In contrast to insoluble Aβ, the 
disease severity is found to be well correlated to soluble Aβ levels (Naslund 2000, Lue 
1999, McLean 1999).  Genetic mutations which lead to AD display variation not only in 
the age of disease onset but also in the AD symptoms (Hardy and Selkoe 2002).  
Also, several sensitive biophysical and immunological methods have detected the 
presence of soluble, metastable, and oligomeric intermediates.  It is not yet clear if these 
structures represent a single pathway of fibril formation or are merely the products of 
several other aggregation pathways not necessarily leading to fibril formation.  Although 
less knowledge is available on the formation and abundance of these intermediate 
species, there is fairly solid evidence for their existence and role in synaptotoxicity.  
Thus, there is emerging support for the role of oligomers as the main culprits causing 
neuronal damage well before plaque formation.  In this view, the plaques are regarded as 
the inactive sink or reservoir, where Aβ species are in equilibrium with smaller, 
potentially neurotoxic species (Koffie, et al., 2009).  This in turn might partially explain 
the failure of drugs clearing amyloid plaques in clinical trials 
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(http://newsroom.lilly.com/releasedetail.cfm?releaseID=499794).  It is speculated that 
plaque clearing drugs in fact might lead to release of toxic oligomeric species from the 
plaques, worsening the disease.  
According to recent clinical reports, a significant number of human subjects were 
found to be cognitively normal despite the presence of amyloid plaques in their brains 
(Morris, et al., 2009; Rentz, et al., 2010).  On similar lines, cognitive impairment and 
inhibition of LTP was observed well before or completely independent of plaque 
formation in transgenic animal models of AD.  (Moechars, et al., 1999; Mucke, et al., 
2000).  While these new findings do not quite fit within the framework of the amyloid 
hypothesis, there is still significant support for the role of Aβ as a primary causal agent in 
AD. 
 
 
 
1.12 Aβ oligomers 
 
 
 
Aβ oligomers are comprised of Aβ species which are soluble and remain in the 
supernatant even under the influence of high centrifugal force.  Aβ oligomers are shown 
to display a wide range of sizes and structures as evidenced by a number of biophysical 
and imaging techniques.  So far, the nomenclature of oligomers is elusive and mostly has 
been based loosely on either the actual morphology as detected by imaging techniques 
such as atomic force microscopy (AFM), EM, or in some cases, their apparent size on a 
SDS-PAGE gel.  There are a variety of reasons that complicate a standard analysis of 
oligomers.  It is now well established that a number of physical factors like pH, ionic 
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strength, temperature and time of incubation largely dictate the aggregation of Aβ, which 
in turn influences the nature of oligomers it can form.  In some cases, the Aβ solutions 
were supplemented with small amounts of either some protein factors (ADDLs) or 
organic solvents (Oda, et al., 1995; Lambert, et al., 1998; Stine, et al., 2003; Kayed, et al., 
2009) in addition to the medium in which Aβ was resuspended.  Interestingly, most of 
these oligomers were found to be present in the AD brain samples or transgenic mouse 
models with the help of specific antibodies, underscoring the relevance of in vitro 
oligomer studies in the context of actual disease pathology.  
There is mounting evidence that Aβ oligomers are responsible for synaptotoxicity, 
which provides an explanation for the observed neuronal loss well before the detection of 
plaques.  Recently, oligomeric Aβ was found to form a halo around the dense plaques by 
multiphoton in vivo imaging using an oligomer-specific NAB1 antibody, making the 
plaque composition look more complex than just a deposition of fibrillar Aβ.  
Interestingly, neuronal loss was observed in the immediate vicinity of this oligomeric 
halo (Koffie, et al., 2009).  The studies on preparation and analysis of Aβ oligomers 
started in the late nineties.  In the past couple of decades, a number of oligomeric species 
were reported, which includes protofibrils, ADDLs, annular protofibrils, prefibrillar and 
fibrillar oligomers, globulomers, paranuclei, and Aβ56*.  It is still not clear if all these 
oligomers signify the same structure or represent a unique species in its own sense.  
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1.12.1 Protofibrils 
 
 
In 1997, Harper et al, observed metastable protofibrils by AFM while studying 
fibrillization of both Aβ (1-40) and Aβ (1-42). The diameter of Aβ (1-42) protofibril was 
4.2 nm while the diameter of Aβ (1-40) protofibril was 3.1 nm.  The lengths were 
reported to be in the range of 70-100 nm, and over the time protofibrils disappeared to 
form < 1µm long fibrils of 7-8 nm diameter.  Protofibrils of both Aβ variants exhibited 
periodicity of 22 nm (Harper, et al., 1997). 
Walsh, et al (1997), independently reported the detection of small, soluble, and 
curvilinear structures, which they also called protofibrils to distinguish them from mature 
fibrils.  TEM analysis revealed protofibrils to be 100-200 nm long consistent with 
Harper, et al (1997), and 6-10 nm in diameter and had morphology similar to small fibrils 
(Walsh, et al., 1997).  Rotatory shadowing of protofibrils essentially complemented the 
morphological analysis by TEM except a large number of <10 nm protofibrils could be 
observed, and a beaded pattern of 3-6 nm periodicity was revealed within protofibrils 
(Walsh, et al., 1999). 
Protofibrils have an average RH between the range 10-50 nm based on QLS.  The 
determination of molecular weights of protofibrils is not quite straightforward because of 
the non-ideal chromatographic behavior on a size exclusion column and disaggregation 
into monomers and low molecular weight oligomers upon separation on SDS-PAGE.  
Using dialysis, radiolabeled SEC purified protofibrils were found to be in equilibrium 
with low molecular weight Aβ (Walsh, et al., 1999). 
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Walsh and colleagues (1997) used a Superdex 75 size exclusion column to 
separate protofibrils from low molecular weight Aβ.  During separation, protofibrils 
typically eluted out in the void volume.  Protofibrils are formed at physiological pH in a 
solution of considerable ionic strength. Ionic strength influences the length and rate of 
protofibril growth (Harper, et al., 1999).  Aβ (1-42) formed the protofibrils within 1 day 
of incubation, while Aβ (1-40) required a longer incubation before it formed the 
protofibrils.  The size exclusion chromatography (SEC) protofibril peak increased in size 
over time with a concomitant decrease in monomer peak, and eventually both the peaks 
declined, indicating that protofibrils are intermediates during fibrillogenesis.  
A significant amount of β-sheet content was suggested both by a significant 
thioflavin –T/Congo red binding and circular dichroism.  Although a decent amount of 
random coil and some α-helical content was observed, the CD spectrum was similar to 
fibrils.  Furthermore, substitution of residues within the hydrophobic core by glycine or 
proline, which destabilizes β-sheets, resulted in very little or no protofibril formation, 
suggesting the importance of the hydrophobic core in protofibril formation (Walsh, et al., 
1997; Walsh, et al., 1999; Kheterpal, et al., 2003).  Subsequently, HDX-MS confirmed 
that 40% of the amide protons comprising the core of protofibrils are highly protected.  
Additionally, the degree of protective structure increases from monomers to protofibrils 
to fibrils (Kheterpal, et al., 2003).  
Protofibrils displayed a significant biological activity, as they stimulated acute 
electrophysiological changes, altered metabolism and caused neurotoxicity in primary rat 
cortical neurons in contrast to LMW Aβ (Hartley, et al., 1999; Walsh, et al., 1999).  The 
direct support for biological relevance of protofibrils came from the discovery that a 
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familial APP mutation, E693G (Arctic) from a family in northern Sweden displayed a 
high propensity to form protofibrils rapidly as compared to WT.  Interestingly, Arctic 
mutation is the only mutation among other intra-Aβ mutations which produces a classical 
AD phenotype (Nilsberth, et al., 2001). 
When Aβ (1-40) WT and arctic protofibrils eluting in the void volume of 
Superdex 75 column were further subjected to a Superose 6 SEC column, different 
fractions contained protofibrils of different size (160 kDa-800 kDa) and morphology.  
Among other structures, one of the notable structures observed using EM and single 
particle averaging was annular protofibrils having an average diameter of 6-9 nm with a 
central cavity of 1.5-2 nm diameter filled with the negative stain.  These structures were 
named amyloid pores, and are believed to disrupt the membrane integrity in a fashion 
similar to bacterial pore forming toxins (Lashuel, et al., 2003).  Recently, protofibrils 
generated by aggregation of disulfide bond stabilized dimers of (AβS26C)2 inhibited LTP 
while freshly prepared (AβS26C)2 did not have any effect (O'Nuallain, et al., 2010).  
Transgenic mice harboring both Arctic and Swedish mutations formed substantial 
protofibrils well before plaque formation, and their amount was inversely correlated to 
spatial learning and memory deficits (Lord, et al., 2009).  However, in some studies, the 
biological activity of protofibrils was attributed to the ongoing polymerization process in 
the presence of monomers in addition to protofibrils (Wogulis, et al., 2005).  
Elongation of protofibrils can follow end to end annealing or addition of 
monomers to the ends (Harper, et al., 1999).  Nichols et al (2002) showed that protofibril 
growth can also occur via lateral association (Nichols, et al., 2002).  Elongation of 
protofibrils is shown to be dependent on pH, ionic strength, temperature and 
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concentration of Aβ (Harper, et al., 1999), while the dissociation into monomers was seen 
mainly after dilution.  Interestingly, some lipids are shown to disassemble fibrils 
backward into protofibrils, which are indistinguishable from those formed during forward 
assembly and also are neurotoxic (Martins, et al., 2008).  
 
 
 
1.12.2 Aβ-derived diffusible ligands (ADDLs) 
 
 
 
ADDLs are reported as small, slowly sedimenting, globular Aβ (1-42) species of 
mass between 17-42 kDa and having a diameter 4.8-5.7 nm as measured by AFM (Oda, 
et al., 1995).  ADDLs were originally prepared in the presence of clusterin (Apo J), a 
protein upregulated in the AD brain.  Clusterin slows down the aggregation of Aβ into 
fibrils, instead forming soluble, globular species (Oda, et al., 1995).  ADDLs could also 
be prepared in the absence of clusterin by either incubating Aβ (1-42) in phenol red-free 
F12 cell culture medium at 4⁰C for 24 h or at 37⁰C in brain slice culture medium for 24h 
(Lambert, et al., 1998).  
ADDLs rapidly block hippocampal LTP and act as potent neurotoxins effective at 
nanomolar concentration.  ADDL toxicity is found to be dependent on expression of Fyn, 
a tyrosine kinase of the Src family, the levels of which are upregulated in the neurons 
isolated from AD brain (Lambert, et al., 1998).  Soluble oligomers in the AD brain were 
found to be 70-fold in excess of that in age matched control brain.  Moreover, they shared 
the epitopes with ADDLs as shown by immunoreactivity to oligomer selective antibodies 
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M93 and M94 (Gong 2003) and also were able to bind synaptic terminals (Lacor, et al., 
2004).  
SEC analysis of ADDLs yielded two distinct peaks, an early eluting peak near the 
void volume of a Superdex 75 column followed by an included peak (Chromy, et al., 
2003; Hepler, et al., 2006).  Further rigorous biophysical analyses using non-denaturing 
methods like SEC-Multi-angle laser light scattering (MALLS) and analytical 
ultracentrifugation (AU) showed that the high molecular weight peak of ADDLs in fact 
consists of a polydisperse population of relatively high molecular weight oligomers (150-
1000 kDa) instead of a single molecular weight species as observed by PAGE.  SEC-
MALLS and AU definitively showed that the lower molecular weight peak represents a 
significant amount of monomer (~90%) in a total ADDL preparation.  This study 
emphasizes the dynamic nature of equilibria in an ADDL formulation, which is highly 
sensitive to type of buffer, nature of excipient, storage temperature, and time.  
Interestingly, only the high molecular weight SEC fraction exhibits the property to bind 
to neuronal axonal processes, while the monomers do not show any binding.  Aβ(1-40) 
failed to form high molecular weight ADDL species, and instead exclusively eluted out in 
a low molecular weight peak.  Aβ(1-40) LMW peak instead represented an equilibrium 
between monomers and dimers based on SEC-MALLS indicating the difference in the 
aggregation properties of two Aβ alloforms (Hepler, et al., 2006).  Under the 
supramicellar concentrations of SDS, both ADDLs and fibrils produce the same 
electrophoretic profile, suggesting the contribution of harsh detergent towards formation 
and stabilization of certain oligomers.  This makes the SDS-PAGE analysis of oligomers 
less clear (Bitan, et al., 2005; Hepler, et al., 2006).  
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1.12.3 Pre-fibrillar and fibrillar Aβ-oligomers 
 
 
 
Structural classification between different oligomeric species has become possible 
by conformation-specific antibodies in the absence of high resolution structures (Glabe, 
2008).  These antibodies can recognize specific conformations across a broad range of 
amyloid-forming proteins regardless of their primary sequence (Kayed, et al., 2003; 
Glabe, 2008).  The epitopes recognized by these antibodies represent distinct aggregation 
states of the amyloidogenic peptides.  Specifically, A11 antibody developed against 
molecular mimetic of soluble oligomers is reported to recognize soluble pre-fibrillar 
oligomers (Kayed, et al., 2003).  Moreover these pre-fibrillar oligomers are transient 
intermediates that ultimately result into the formation of fibrils.  Interestingly, All-
antibody neither stains thioflavin-S positive plaques from AD brain nor other low 
molecular weight forms or fibrils prepared in vitro (Kayed, et al., 2003). OC-antibody, 
developed in 2007, recognizes species over a wide range of size distribution that contain 
an element of fibril structure.  OC-antibody is reported to recognize structures with sizes 
corresponding to dimer to >500 kDa on a western-blot.  A11 and OC-antibodies have 
been reported to recognize mutually exclusive epitopes (Kayed, et al., 2007).  However, 
there is a broad overlap between the sizes of soluble fibrillar oligomers and prefibrillar 
oligomers.  This evidence suggests that size may not be the best criteria to distinguish 
between different oligomers.  In fact, Aβ species of same apparent size can have distinct 
conformations as shown by A11 and OC-anibodies (Glabe, 2008).   
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1.12.4 Aβ*56 
 
 
 
The Tg2576 mouse model of AD overexpresses a Swedish double mutation 
(K670N/M671L) in APP and develops significant memory deficits at 6 months of age, 
which remain stable for 7-8 months.  Since abundant Aβ plaque morphology appears 
between 9-14 months, well after the initiation of cognitive dysfunction, Lesné et al 
(2006) sought to identify an early Aβ species which would be a possible candidate for 
such a dysfunction.  They found an Aβ species in extracellular soluble brain extracts of 6-
month old Tg2576 mice.  This species migrates at an apparent size of 56 kD on SDS-
PAGE and correlates well with the development of memory deficits in Tg2576.  These 
species were designated as Aβ*56 (Lesne, et al., 2006).  Furthermore, when injected in 
normal young rats at lower nanomolar concentrations, the rats developed deficits in long 
term spatial memory in the Morris water maze.  Based on apparent molecular weight, 
Aβ*56 is considered a dodecamer, and it also shows immunoreactivity to A11-
antioligomer conformation specific antibody developed by Kayed and colleagues (2003) 
(Lesne, et al., 2006).  Interestingly, in a recent comparative study, only Aβ*56 among 
other cell derived and synthetic oligomers positively correlated to cognitive dysfunction 
in a concentration dependent manner in rats (Reed, et al., 2011).  However, in Tg2576 
mice, forms of memory other than spatial memory are also affected, as evidenced by 
impaired performance in hippocampal dependent contextual fear conditioning assay, 
decreased spine density in the dentate gyrus, and disruption in long-term potentiation 
(LTP), long before the detectable appearance of Aβ*56 (Dineley, et al., 2002; Jacobsen, 
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et al., 2006).  Thus it supports the possibility that more than one oligomeric species can 
be a candidate for causing overall neuronal dysfunction (Walsh and Selkoe, 2007). 
 
 
 
1.12.5 Annular protofibrils 
 
 
 
Annular protofibrils were observed as ring like structures when SEC isolated Aβ- 
Arctic protofibrils were incubated for longer times.  TEM analysis revealed a diameter of 
7–10 nm; inner diameter 1.5–2.0 nm and relative molecular mass of 150K–250K 
equivalent to 40–60 Aβ-Arctic (E22G) molecules.  Annular protofibrils are thought to 
represent a distinct species that shares similarity with bacterial pore forming toxins 
(Lashuel, et al., 2002; Lashuel, et al., 2003).  The β-Barrel is suggested as an underlying 
motif for this similarity.  
Kayed et al (2009) prepared homogenous populations of annular protofibrils in 
vitro by exposing pre-fibrillar oligomers (PFOs) to an air/water interface or a 
hydrophobic /hydrophilic interface.  EM analysis of these APFs revealed a stain-filled 
cavity in the middle.  Moreover, the diameter of these APFs range between 8-25 nm.  
APFs appear to undergo a rough beaded to a rather smooth morphological transition 
during prolonged incubation.  In fact, PFOs were reported to act as precursors for APFs 
upon interaction with amphipathic membranes and increased the conductance of lipid 
bilayer in a concentration dependent manner (Kayed, et al., 2009; Lasagna-Reeves, et al., 
2011).  Furthermore, APFs did not convert to fibrils even after prolonged incubation in 
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the presence of fibril seeds.  Thus APFs are believed to represent species formed 
independent of fibril formation. 
The conformation specific antibody α-APF designed to specifically recognize the 
APF epitope showed immunoreactivity to extracellular diffuse plaques and intracellularly 
around the nucleus in AD brain sections but not in age matched control brain sections.  
The immunoreactivity to α-APF was also found near membranes and vesicles within 
cellular processes and synapses in a transgenic mouse model expressing mutant APP 
(Kokubo, et al., 2009).  Recently, double immunofluorescence studies have shown the 
colocalization of activated astrocytes from AD brains with α-APF, further suggesting that 
APFs could be formed intracellularly after astrocytic uptake of soluble oligomers, which 
in turn can become detrimental by causing inactivation of glutamine synthase (Lasagna-
Reeves and Kayed, 2011).  
 
 
 
1.12.6 Paranuclei 
 
 
 
To capture early oligomers formed immediately after the preparation of Aβ(1-40) 
and (1-42) peptide, Bitan and colleagues used photo-induced crosslinking of unmodified 
proteins (PICUP), followed by their separation by SDS-PAGE to determine size 
distribution across the range of oligomers (Bitan, et al., 2001; Bitan, et al., 2003).   
Aβ(1-42), immediately after elution through SEC, rapidly formed different 
assembly states including dimers, trimers, pentamers and hexamers along with some 
higher order structures.  Based on DLS, EM and PICUP results, Bitan et al (2003) 
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proposed that Aβ(1-42) pentamers and hexamers act as paranuclei, since these species 
represent the initial, minimal structural unit for Aβ assembly into larger oligomers 
without causing significant change in the secondary structure.  In contrast to Aβ(1-42), 
Aβ(1-40) shows a completely different oligomeric distribution consisting mainly of 
monomers, dimers and trimers.  The difference in oligomer distribution was found to be 
dependent on the peptide length; Ile-41 was shown to be key determinant of paranuclei 
formation.  Moreover, inclusion of residues Ala-42 and Thr-43 increases the propensity 
of these paranuclei to assemble together to form higher order beaded structures (Bitan, et 
al., 2003).  The inability of Aβ40 to form paranuclei under similar conditions as Aβ42 is 
proposed to provide an explanation for discrepancies in alloform-specific biological 
activity. 
 
 
 
1.12.7 Cell-derived low-n oligomers 
 
 
 
Different low-n oligomers which separate at 8 (dimers) and 12 kDa (trimers) on 
SDS-PAGE have been detected in buffer-soluble fractions of AD brain tissue lysates and 
CSF (Walsh and Selkoe, 2007).  A variety of cultured cells are shown to secrete similar 
SDS stable low-n oligomers in their conditioned medium at nanomolar concentrations, 
which are physiologically relevant concentrations (Podlisny, et al., 1995; Podlisny, et al., 
1998; Walsh, et al., 2000; Walsh, et al., 2002; Cleary, et al., 2005; Shankar, et al., 2008).  
In fact, the origin of these oligomers was found to be endogenous, and traced back to the 
intracellular microsomal compartments (Walsh, et al., 2000).  
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Furthermore, these oligomers are shown to act as potent synaptoxins by causing 
loss of dendritic spines and modulation in calcium influx via NMDA receptors both in 
vitro and in vivo (Walsh, et al., 2002; Walsh, et al., 2005; Shankar, et al., 2007; Walsh 
and Selkoe, 2007).  These oligomers not only blocked long term potentiation (LTP) but 
also altered short term memory; the earliest symptoms of AD.  Moreover, these effects 
could be rescued by anti Aβ antibodies indicating the reversible nature of effects (Cleary, 
et al., 2005; Walsh and Selkoe, 2007).  
Further support came when Aβ dimers directly isolated from AD brain were able 
to disrupt memory in rats.  It was noteworthy in this study that plaques exerted toxicity 
only when solubilized to release dimers, supporting the idea that plaques might represent 
an inert reservoir of potentially toxic species (Shankar, et al., 2008).  Further structural 
investigation of dimers was achieved by specifically stabilizing Aβ dimers via formation 
of a disulfide bond between Aβ S26C monomers.  These (AβS26C)2 when aggregated, 
rapidly formed thioflavin-T positive, β-sheet rich protofibrils and were able to block LTP 
in contrast to freshly isolated (AβS26C)2.  Dimer formation strongly influenced the rate 
of PF formation, which further suggests that dimers can induce toxicity by forming 
relatively stable PFs (O'Nuallain, et al., 2010). 
 
 
1.12.8 β-amy balls 
 
 
β-amy balls were detected by light and electron microscopy as clearly defined 
spheres of 20-200 μm in diameter (Westlind-Danielsson and Arnerup, 2001).  These 
structures were reported when Aβ(1-40) was incubated at excessive concentrations like 
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300-600 μM under physiological conditions for 20 h up to 2 weeks.  Aβ(1-42) did not 
form these structures by itself but enhanced the formation of Aβ(1-40) β-amy balls.  
However, the physiological occurrence of these structures is not very clear (Westlind-
Danielsson and Arnerup, 2001; Rahimi, et al., 2008). 
 
 
1.12.9 Globulomers 
 
 
Globulomers are highly water-soluble globular oligomeric species of 38-60 kDa 
formed when Aβ(1-42) was incubated in phosphate buffered saline at 400 μM in the 
presence of 0.2 % SDS or fatty acid micelles at 37⁰C (Barghorn, et al., 2005).  Size 
determination under native conditions estimated globulomer to consist of 12 monomer 
subunits.  It is proposed to represent a pathway independent of fibril formation.  Aβ(1-42) 
globulomer-specific antibodies stained the tissues from AD brain and transgenic animals 
carrying APP mutation.  Abeta(1-42) globulomers bind dendritic processes of neurons in 
cell cultures and are potent inhibitors of long-term potentiation in rat hippocampal slices 
(Barghorn, et al., 2005; Rahimi, et al., 2008). 
 
 
 
1.12.10 Emerging model of Aβ(1-42) fibril assembly inclusive of oligomeric species   
 
 
 
The process of Aβ(1-42) fibrillogenesis is believed to be more complex based on 
the recent progress in the field of Aβ oligomers (Bitan, et al., 2003).  As discussed in 
section 1.12, a number of oligomeric structures with distinct structural and biological 
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properties have been detected both in vitro and in vivo.  The current understanding of 
Aβ(1-42) assembly includes some of these oligomeric structures, which ultimately result 
into fibril formation.  However, for some of the oligomeric structures it is not yet clear if 
they lie in the same pathway of fibril formation or exist as independent entities as a part 
of other aggregation pathways (Bitan, et al., 2003).  Based on the current understanding, 
multiple aggregation pathways may exist for Aβ(1-42) (Bitan, et al., 2003).   
According to a model described by Bitan and colleagues (Bitan, et al., 2003) 
(Figure 1.4), Aβ(1-42) monomer rapidly assembles to form paranuclei immediately after 
its dissolution.  Paranuclei are described as the intial, and minimal, structural unit for 
fibril evolution, which can oligomerize to form larger oligomeric structures.  Monomer, 
paranuclei and oligomers are predominantly believed to be unstructured (U), but might 
contain some degree of α-helix and β-sheet structure.  Moreover, these structures are 
believed to be in a complex dynamic equilibrium with each other.  Further maturation of 
these oligomers results into structural rearrangement to produce β-sheet rich protofibrils.  
Protofibrils further give rise to fibrils by a number of mechanisms including end to end 
annealing, lateral association and monomer addition to the protofibril ends (Harper, et al., 
1999; Nichols, et al., 2002).   
 
 
1.13 Modified amyloid hypothesis 
 
 
In the last couple of decades, extensive progress has been made to understand the 
role of Aβ oligomers in synaptic dysfunction seen in AD, as discussed before in section 
1.12.  Aβ oligomers seem to be more potent synaptotoxins than fibrils.  Multiphoton 
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imaging studies revealed co-localization of oligomeric Aβ and severe neuronal loss 
surrounding the periphery of senile plaques (Koffie, et al., 2009).  Aβ induced neuronal 
toxicity is also mediated by tau protein (Zempel, et al., 2011).  Dementia correlated with 
the extent of tangle formation, gliosis, and neuronal loss, but amyloid accumulation 
reached a plateau independent of disease severity (Ingelsson, et al., 2004).  This evidence 
suggests that AD represents a complex process, and although Aβ could be the initial 
trigger, it might act in combination with other factors like inflammatory processes during 
further progression. 
Recently Hyman proposed some modifications to the existing amyloid hypothesis 
(Hyman, 2011).  According to Hyman, AD could be considered to be composed of two 
stages; Aβ dependent and Aβ independent stage.  In the first stage of AD, deposition of 
soluble oligomers and fibrillar Aβ results in the local changes in the neuropil, loss of 
dendritic spines, remodeling of synapses and initiation of inflammatory processes.  
Second phase could be characterized by development of NFTs, continued neuronal loss 
and glial inflammation, which culminate in neurodegeneration and full development of 
AD phenotype.  According to this proposition, the amyloid-induced neurodegenerative 
changes initiate during the first phase of Aβ accumulation.  In the second phase, the 
amyloid deposition seems to reach a plateau.  However, the secondary consequences of 
amyloid deposition such as inflammation and neurodegeneration continue to worsen, 
resulting into the final stage of the disease.  Therefore, although the second stage is 
initiated by amyloid, treatments targeting amyloid depositions are less likely to be 
effective.  The second phase could be regarded as not completely dependent on Aβ 
(Hyman, 2011). 
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Figure 1.4.  Model of Aβ(1-42) assembly (reproduced from (Bitan, et al., 2003)).  
Aβ(1-42) monomer forms paranuclei, which further oligomerize to form larger 
oligomers.  Monomer, paranuclei and oligomers are usually unstructured (U) which 
rearrange structurally to mature into β-sheet rich protofibrils (β).  Protofibrils mature to 
form fibrils which have a high degree of β-sheet.  U, α and β represents unstructured, 
alpha helix or beta-sheet structure.  5 nm and 10 nm represent the diameters of protofibril 
or fibrils respectively. 
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This proposition can partially explain the failure of drugs targeting Aβ in the AD 
patients who have already developed mild cognitive impairement during the clinical trial.  
So it might be useful to devise therapeutic targets based on the stage of disease 
progression.  However, targeting AD in early stages is currently limited by early 
detection based on biomarkers.  Alternative therapeutic targets like proteins associated 
with neuroinflammatory pathways such as caspases could be explored (Hyman, 2011). 
 
 
 
1.14 Inflammation in AD 
 
 
 
The presence of a large number of senile plaques, NFTs and related cognitive 
dysfunction may be necessary for AD, yet it is not sufficient to develop a full 
neurodegenerative phenotype of AD in transgenic animals (Rogers, et al., 1996).  It has 
been suggested that inflammation is one of the key contributing factors to the 
development of full AD phenotype (Rogers, et al., 1996).  Inflammation is normally an 
act of the immune system to mount a non-specific response against any type of bodily 
injury.  Inflammation include a wide variety of processes that not only involve removal 
of detritus but also healing of an insult (Ferrero-Miliani, et al., 2007) using a variety of 
immune effector cells and soluble molecular mediators.  Usually inflammation is self-
limiting (acute), but under certain circumstances it continues to exist resulting into chonic 
inflammation.  Such an unregulated chronic inflammatory state becomes detrimental 
rather than beneficial to the host.  AD brain displays a state of chronic inflammation as 
reflected in Braak staging (Braak and Braak, 1991). 
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The first evidence of involvement of inflammation in AD came from the studies 
where senile plaques of AD cortical samples were found to be associated with immune 
related elements like immunoglobulins and complements using light and electron 
microscopy (Eikelenboom and Stam, 1982; Ishii and Haga, 1984), although the presence 
of immune elements was less prominent in the plaques having a component of NFTs 
(Ishii and Haga, 1984). 
AD brain displays characteristics features of classical inflammation, which 
include activated immune cells like microglia (Dickson, 1997), astrocytes, leukocytes 
(Itagaki, et al., 1989), and activation of complement system ,both within and surrounding 
the senile plaques, along with significantly elevated levels of a variety of inflammatory 
proteins as compared to non demented brains (Rogers, et al., 1996).  A number of such 
proteins are listed in table 1.2.  In situ mRNA expression studies confirmed that most of 
the inflammatory mediators are endogenously produced by local astrocytes and microglia 
(Finch and Marchalonis, 1996).  The blood-brain barrier restricts the passage of 
peripheral immune proteins such as immunoglobulins and soluble inflammatory 
molecules into the brain.  Therefore, brain was thought to be an immunologically 
privileged organ.  However, increasing evidence for the existence of complex 
inflammatory processes in the AD brain suggests that brain might have unique 
immunological properties (Akiyama, et al., 2000).  
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Table 1.2 Inflammatory markers in the AD brain (adopted from (Rogers, et al., 
1996)) 
Class of proteins elevated in Alzheimer’s 
brain
Examples
Cytokines Interleukin-1α (IL-1α), Interleukin-1β (IL-
1β), Interlekin-6 (IL-6), tumor necrosis 
factor α (TNFα)
Acute Phase Reactants α-1 -antichymotrypsin 
α-2-macroglobulin 
Serum Amyloid P 
α-1-antitrypsin 
C-reactive protein 
Classical Complement Proteins Clq, C4 ,C4d, C3,C3b,C3c, C3d, C7, C9, 
C5b-9 (MAC) 
Complement Defense Proteins Clusterin (Apo J), Vitronectin, 
Leukocyte Common Antigen CD-45
MHC-I
MHC-II HLA-DR, HLA-DP, HLA-DQ
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1.15 Involvement of immune effector cells in causing inflammation 
 
 
 
1.15.1 Neurons 
 
Neurons were not conventionally regarded as immune cells, however there is 
emerging evidence for their role in the production of inflammatory proteins.  Neurons are 
capable of producing complement proteins, interleukins (IL-1 and IL-6), TNFα and M-
CSF (Akiyama, et al., 2000).  Since these inflammatory proteins are elevated in AD, it is 
thought that neurons might contribute to exacerbate AD pathology in concert with 
microglia and astrocytes (Akiyama 2000). 
 
 
 
1.15.2 Glia 
 
 
 
Glia represents the most abundant cells of the nervous system.  Glia are further 
categorized into astrocytes, microglia and oligodendrocytes, which together are 
responsible for neuronal homeostasis, synaptic plasticity and repair (Haydon, 2001).  
 
 
 
1.15.2.1 Astrocytes 
 
 
 
Astrocytes are primarily responsible for maintaining the homeostasis in the brain 
(Haydon, 2001).  Earlier, glia were considered non-excitatory, which is recently 
48 
 
challenged by a number of studies on astroglia (Winship, et al., 2007; Schummers, et al., 
2008).  In fact, astrocytes play an important regulatory role in glutamatergic 
neurotransmission by preventing glutamate excitotoxicity via a glutamate-glutamine 
shuttle system.  These processes are important for maintenance of synaptic plasticity 
linked to cognitive processes (Mattson and Rychlik, 1990; Fields and Stevens-Graham, 
2002; McKenna, 2007).  In the light of recent findings, the synapse has been redefined as 
a tripartite synapse, inclusive of not only pre and post synaptic nerve ending but astroglia 
as well (Araque, et al., 1999; Perea, et al., 2009).  
Astrocytes are interconnected by connexin gap junctions to facilitate 
redistribution of metabolites and are also known to contribute towards the blood brain 
barrier (Rawunduzy et al., 1997; Siushansian et al., 2001; Frantseva et al., 2002; Nakase 
et al., 2003).  Upregulation of intermediate filament proteins, particularly glial fibrillary 
acidic protein (GFAP), Vimentin, hypertrophic cellular processes along with altered 
expression of many proteins, are some of the classic features of reactive astroglia 
(Eddleston and Mucke, 1993; Bushong, et al., 2002; Bushong, et al., 2004).  Reactive 
astrocytes protect neurons from oxidative stress via a glutathione-dependent scavenging 
mechanism (Iwata-Ichikawa, et al., 1999).  
Activation of astrocytes leads to upregulation of a number of inflammatory 
molecules like cytokines, interleukins, growth factors, proteases and protease inhibitors.  
Area number of these molecules are known to be involved in AD pathogenesis 
(Eddleston and Mucke, 1993).  In transgenic mouse models of AD, overexpression of 
molecules like TGF-β and IL-6 in astrocytes caused increased deposition of Aβ, 
astrocytosis and behavioral decline (Wyss-Coray, et al., 1997).  In another study, Aβ 
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induced astroglial activation and subsequent release of chemokines to promote 
chemotaxis of microglia and infiltration of monocytes/macrophages towards Aβ 
(Johnstone, et al., 1999).  These chemokines are believed to further amplify the 
inflammatory response in an autocrine or paracrine manner, leading to evolution of 
lesions in several neurodegenerative disorders including AD (Aloisi, et al., 1992).  In a 
very recent study by DaRocha Souto et al (2011), brain oligomeric Aβ was correlated 
particularly to astrocytic inflammatory response and neuronal loss in APP/tau double 
transgenic mice suggesting that astrocytes may be activated in the earlier stages of AD 
and contribute to  AD progression (DaRocha-Souto, et al., 2011). 
 
 
 
1.15.2.2 Microglia 
 
 
Microglia are the resident immune cells of the CNS, constituting 12% of the total 
glial population (Gonzalez-Scarano and Baltuch, 1999).  As opposed to astrocytes and 
oligodendrocytes, microglia have mesodermal origin, and display molecular markers 
representative of both monocyte and macrophage line.  Microglial progenitors were 
known to cross the blood brain barrier (BBB) during early embryonic stages and populate 
within the brain.  However, recent observations suggest that peripheral monocytes can 
infiltrate the blood-brain barrier in response to various insults including Aβ deposition, 
and differentiate into brain macrophages, which are indistinguishable from microglia 
immunologically (Simard and Rivest, 2004; Malm, et al., 2005).  Certain cytokines can 
also alter the expression of specific cell surface receptors in a microglial subtype 
dependent manner, and thereby exert different immunomodulatory effects in response to 
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Aβ (Shimizu, et al., 2008).  The idea of structural, functional, and location-dependent 
subsets of microglial population has been proposed but lacks evidence for definitive 
markers that can distinguish between different subsets (Graeber and Streit, 2010). 
Structurally, microglia can exhibit diverse morphologies, ranging from round, 
amoeboid to more ramified, depending on the environment (Graeber, 2010).  Therefore, 
before the advent of specific microglial markers, the nature and identity of microglia 
were debated.  It is now increasingly clear that microglia are extremely plastic both 
structurally and functionally (Graeber, 2010).  They can adopt different phenotypes in 
response to their environment.  In fact, time-lapse imaging experiments using in vivo two 
photon imaging revealed that microglia in normal, healthy brain continuously sample 
their micro-environment by their highly motile, labile processes, thus representing a 
constant dynamic state rather than a resting state (Nimmerjahn, et al., 2005).  Microglia 
are the professional phagocytes of the brain.  In addition to being principal immune 
effector cells, microglia are also capable of surveying the functional status of synapses 
intermittently and eliminating a defunct synapse to maintain synaptic integraity (Wake, et 
al., 2009). 
 
 
 
1.16 Activation of microglia 
 
 
 
Under an insult, microglia adopt an alternate phenotype, subsequently express or 
secrete a variety of pro and anti-inflammatory molecules, and become “activated” 
(Nimmerjahn, et al., 2005).  It is a non-specific process.  Since the threshold for 
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microglial activation is less, they can respond to a slightest perturbation rapidly, however, 
if uncontrolled, can last as long as a lifetime as exemplified by chronic inflammation in 
AD (Graeber, 2010).  Some of the most common markers used to assess microglial 
activation include HLA-DR (MHCII), CD11b, CD-45, and peripheral benzodiazepine 
receptors (PDZ or translocator protein 18 kDa) (Colton and Wilcock, 2010). 
Upon exposure to an antigen, microglia undergo classical activation, which is 
typically proinflammatory in nature and is mediated by pro-inflammatory cytokines like 
tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), interleukin 1β (IL-1β)), proteases 
(e.g., matrix metalloproteinase-9), superoxide anion, nitric oxide (NO) and reactive 
oxygen-nitrogen species.  Classical activation results in tissue defense and removal of 
antigen.  Another pathway called alternative activation exists, which is primarily 
involved in downregulation of the proinflammatory state after removal of antigen and 
ensuing tissue repair and homeostasis. 
Alternative activation is reinforced by anti-inflammatory cytokines IL-4, IL-13, 
IL-10, TGF-β and upregulation of scavenger receptors for phagocytosis of apoptotic cells 
and harmful byproducts.  Treatment of microglia with IL-4 resulted into expression of 
proteins such as arginase 1, YM1, YM2, FIZZ1 (RELMα), and the mannose receptor 
(CD206) (Colton, et al., 2006; Martinez, et al., 2009).  Moreover, expression of these 
proteins influenced the microglial phenotype to transform into alternatively activated 
macrophages.  Thus, microglia possess the ability to transform into multiple phenotypes 
with distinctive functions (Cameron and Landreth, 2010).  The balance between the 
classical and alternative activation is achieved in a successful innate immune response.  
Although in chronic inflammatory neurodenerative diseases like AD, a heterogenous 
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population of activated microglia exists simultaneously and leads to a complex 
inflammatory process (Colton and Wilcock, 2010).  
 
 
 
1.16.1 Relevance of microglial activation in AD 
 
 
 
It is now well established that microglia get activated following the exposure to 
Aβ, and upregulate the expression of a variety of pro and anti-inflammatory cytokines 
and reactive oxygen species (Meda, et al., 1995; Lorton, 1997; Yates, et al., 2000; 
Cameron and Landreth, 2010).  Particularly activated microglia were found to be 
abundant in the cortex of AD patients (Edison, et al., 2008).  Moreover, this increase in 
activated microglia did not correlate well with the total amyloid plaque buden but rather 
to the cognitive decline (Edison, et al., 2008).  Microglial activation pathways, their 
products and the relation to AD pathology have been extensively studied either using a 
variety of in vitro cell culture models like primary murine microglia, BV2 microglial cell 
line, primary human microglia cultured from AD brain or in vivo animal models of AD.  
Recent developments in “in vivo” imaging techniques have led to increased 
understanding of the dynamic nature of microglial interactions with plaques.  In vivo 
multiphoton microscopy of a transgenic mice model of AD detected recruitment of 
microglia to plaques within one day of plaque formation, which coincided with 
dystrophic neurites.  However, Aβ clearance by these microglia was not observed 
(Meyer-Luehmann, et al., 2008).  In another study, microglial recruitment to plaque was 
followed by uptake of amyloid specific dye, albeit with less efficiency.  Importantly, 
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plaque size was correlated to the number and size of plaque associated microglia 
(Bolmont, et al., 2008).  Bolmont et al also hypothesized that smaller protofibrils might 
form along the periphery of plaque, which can stimulate microglial activation and 
clearance mechanisms.  Cagnin, et al, used positron emission tomography (PET) to image 
carbon 11-labeled compound that recognizes peripheral benzodiazepine receptor (TP-18), 
which is a marker of activated microglial cells, and showed the correlation of microglial 
activation with cognitive decline and AD neuropathology (Cagnin, et al., 2001).  These 
studies strongly support that activation of microglia is one of the earliest events in the AD 
pathogenesis.  Furthermore, the activation process could be monitored as an indicator of 
disease severity by PET-based imaging as one of the biomarkers of AD progression. 
Activation of microglia needs to be under tight regulation in order to avoid 
bystander damage to the surrounding tissue.  Microglia have evolved different 
mechanisms to prevent unwanted activation.  In one of the mechanisms, microglia exhibit 
fractalkine receptors (CX3CR1), which interact with fractalkine (CX3CL1) ligand on the 
neurons and astroglia during microglial surveillance (Cardona, et al., 2006).  Similarly 
CD200 ligand on the microglial surface interacts with CD200 receptor on neurons.  These 
cell-cell interactions signal microglia to downregulate unwanted activation in a healthy 
brain.  Such receptor-ligand interactions are impaired during neurodegeneration, leading 
to chronic inflammation (Cardona, et al., 2006; Walker, et al., 2009). 
 
 
 
1.16.2 Evidence for the role of microglia in plaque evolution 
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Numerous studies have shown that upon exposure to Aβ, microglia become 
activated, rapidly move towards plaque by extending their processes and cluster around 
the plaques (Dickson, et al., 1988; Itagaki, et al., 1989; Perlmutter, et al., 1990).  Aβ also 
stimulates microglial proliferation in the vicinity of plaques, allowing their further 
accumulation in senile plaques (Bornemann, et al., 2001).  Microglia can facilitate the 
aggregation of soluble Aβ species into fibrillar species upon failure of microglial Aβ-
clearance mechanisms (Nagele, et al., 2004).  In fact,the extensive inflammation 
mediated by activated microglia accelerated plaque deposition in the PDAPP transgenic 
mice model of AD, when coexpressed with ApoE (Qiao, et al., 2001). 
Frautchy and colleagues observed increase in the density and size of microglia in 
entorhinal, occipital cortex and hippocampus, which are the primary brain regions 
showing maximum deposition of Aβ (Frautschy, et al., 1998).  They also demonstrated 
quantitatively that microglia are more concentrated within the senile plaques (Frautschy, 
et al., 1998), which is further supported by colocalization of microglia immunoreactive 
for TNFα, IL-1β with thioflavin-positive plaques (Benzing, et al., 1999).  In contrast to 
dense core plaques, diffuse plaques showed no detectable association with microglia in 
APP23 mice harboring a double Swedish mutation (Stalder, et al., 1999).  This finding is 
consistent with studies carried out on brain sections from AD patients and non-demented 
controls, which suggest that microglial association and activation increases significantly 
during transition of diffuse plaques into neuritic plaques (Mackenzie, et al., 1995; 
Cotman, et al., 1996; Sasaki, et al., 1997).  
Interestingly, microglia showed immunereactivity to Aβ(1-40) antibodies but not 
to Aβ(1-42) antibodies, which is in agreement with a previous study using brain samples 
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from AD patients that demonstrated the association of microglia only with the plaques 
containing Aβ(1-40) (Fukumoto, et al., 1996).  This observation is also supported 
indirectly by detection of fewer microglia in a PDAPP mouse model of AD, that 
expresses high levels of Aβ(1-42) (Masliah, et al., 1996).  Since Aβ(1-42) is the first form 
to get deposited in the diffuse plaques followed by Aβ(1-40) as the plaque matures 
(Iwatsubo, et al., 1994), the above studies together suggest a role for microglia in plaque 
evolution.  A number of studies have shown that microglia not only recruit themeselves 
to the Aβ deposits but also engulf Aβ using a variety of phagocytic mechanisms Simard 
et al (2006) demonstrated that bone marrow derived microglia showed efficient 
chemotaxis towards Aβ deposits and subsequent phagocytosis in transgenic mice model 
system, while resident microglia lacked this ability (Simard, et al., 2006).  It is possible 
that different microglial subsets contribute to plaque development in a differential 
manner.  Interestingly, in a P301S mutant human tau transgenic (Tg) mice, significant 
microglial activation preceded the development of tau tangles, suggesting that microglial 
activation might play an important role in tau pathology in addition to plaque 
developement (Yoshiyama, et al., 2007). 
 
 
 
1.17 Microglial receptors for Aβ 
 
 
 
Since microglia lack gap junctions unlike astroglia, they have to rely mostly on 
the autocrine and paracrine mechanisms for communication with each other (Graeber, 
2010).  To enable effective communication, microglia display a repertoire of diverse 
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receptors, which upon interaction with a ligand initiate a downstream signaling cascade.  
The signaling pathways represent both activating and dampening loops.  Most of these 
pathways are involved either in the production of pro-and anti-inflammatory cytokines or 
clearance of Aβ.  In fact, sometimes these pathways seem to be interdependent.  Aβ is 
shown to interact with multiple microglial receptors, affecting the functional phenotype 
of not only microglia themselves but also of the surrounding cells via secreted 
immunomodulators (Figure 1.5) (Salminen, et al., 2009).  
 
 
 
1.17.1 Toll-like receptors (TLRs)  
 
 
 
TLRs are pattern recognition receptors, which recognize pathogen associated 
molecular patterns (PAMPs).  Since they are capable of recognizing and responding to 
patterns common to many different pathogens rather than a specific pathogen, they are 
principal to the innate immune system.  TLRs can form homogeneous or heterogeneous 
complexes for interaction with ligand.  Multiple costimulatory molecules and small 
glycosylphosphatidyl-inositol (GPI) anchored proteins like CD14 are known to complex 
with TLRs to initiate downstream signaling (Kielian, 2006; Salminen, et al., 2009).  The 
downstream signaling involves a change in proinflammatory gene expression via 
activation of nuclear factor kappa B (NF-κB) transcription factor (Kielian, 2006). 
Aβ induced microglial activation by binding to CD14 coreceptor, which could be 
blocked by the use of antibodies against CD-14 or genetic deficiency of CD-14.   
Moreover, microglial activation was dependent on the aggregation state of Aβ in 
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Figure 1.5  Schematic representation of different signaling components involved in 
AD pathogenesis. (reproduced from (Salminen, et al., 2009)).  Aβ oligomers and fibrils 
activate overlapping signaling pathways via interaction with different innate receptors 
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such a way that only fibrillar Aβ was an effective activator, while non fibrillar Aβ had no 
effect (Fassbender, et al., 2004).  (Fassbender, et al., 2004).  Aggregated Aβ(1-42) also 
caused TLR-4 mediated  release of proinflammatory mediators in murine microglia 
Aβ(1-42).  This study was futher supported by the increased expression of TLR4 
observed in the brains of transgenic mice and AD patients (Walter, et al., 2007).  In 
another study, TLR2 along with TLR4 and CD14 resulted into fibrillar Aβ-induced 
microglial activation via Src-Vav-Rac and p38MAPK, and generation of reactive oxygen 
species (Reed-Geaghan, et al., 2009).  Moreover, in a transgenic AD mouse model, 
deficiency of CD14 reduced plaque burden and was accompanied by alteration in both 
microglial activation phenotype and inflammatory milieu (Reed-Geaghan, et al., 2010).  
Aβ(1-40) is also reported to enhance the pro-inflammatory cytokine production by TLR2 
and TLR4 agonists but antagonizes TLR9-induced inflammation in primary murine 
microglia, indicating that different TLR members can both activate and dampen 
inflammatory pathways in response to Aβ (Lotz, et al., 2005).  In a recent study, CD36 (a 
class B scavenger receptor highly expressed on microglia in AD brains), has been shown 
to interact with fibrillar Aβ(1-42) to produce reactive oxygen species and NF-κB 
dependent upregulation of cytokines via complexation with TLR4 and TLR6 heterodimer 
(Stewart, et al., 2010).  Interestingly, this signaling was independent of MD-2 and CD14, 
the well established coreceptors for Aβ-induced signaling, and instead activated MyD88 
and TRIF-dependent pathways (Coraci, et al., 2002; Stewart, et al., 2010).  Furthermore, 
this study did not observe involvement of TLR2 in Aβ(1-42) fibril-induced inflammation.  
However, in another study, fibrillar Aβ stimulated MyD88-dependent production of 
proinflammatory cytokines via TLR2 in primary murine microglia (Jana, et al., 2008).  
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Recently, TLR2 was shown to be a primary receptor for oligomeric Aβ (Liu, et al., 2011).  
In addition to a role as proinflammatory mediator, TLRs are known to contribute towards 
microglia-mediated neuronal degeneration (Lehnardt, et al., 2003) and Aβ-uptake (Chen, 
et al., 2006).  TLRs are reported to be regulated by TREMs (triggering receptors 
expressed on myeloid cell).  TREM-1 and TREM-2 proteins form complexes with the 
DAP12 adapter proteins and trigger a signaling pathway. TREM-1 acts to amplify TLR 
mediated inflammation, while TREM-2 downregulates cytokine release in macrophages 
and activates phagocytosis in microglia (Klesney-Tait, et al., 2006).  Interestingly, 
TREM-2 expression is upregulated in microglia associated with amyloid plaques in 
transgenic AD mice.  TREMs can modulate TLR-associated  inflammation and 
phagocytosis by a feedback system (Frank, et al., 2008). 
 
 
 
1.17.2 Receptors for advanced glycation end products (RAGE) 
 
 
 
RAGE belongs to an immunoglobulin superfamily.  It is believed that RAGE 
recognize a particular structural determinant, rather than a specific molecule, similar to 
pattern recognition receptors.  It recognizes multiple ligands, such as β-sheet rich fibrils 
of amyloidogenic proteins such as Aβ, amylin and prions (Schmidt, et al., 2000).  
Expression of RAGE is significantly elevated in Alzheimer's disease brain, especially in 
neurons and microglia proximal to amyloid plaques.  Aβ displays affinity for RAGE in 
nanomolar range.  RAGE plays an important role in microglial chemotaxis, cytokine 
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production, and also represents a major source of oxidative stress in neurons, which is 
believed to contribute towards AD pathogenesis (Yan, et al., 1996). 
The importance of RAGE in AD was observed in a study using primary human 
microglia (Lue, et al., 2001).  When microglia from human AD brains were cultured with 
focal deposits of Aβ(1-42), the expression of growth factor, M-CSF, was significantly 
elevated compared to microglia cultured from non-demented brains.  M-CSF is a 
macrophage-colony stimulating factor which promotes microglial activation and 
chemotaxis.  This effect could be blocked by anti-RAGE antibodies in primary human 
microglia from AD brains. Also, M-CSF led to further increase in RAGE expression 
suggesting a feedback mechanism for RAGE expression (Lue, et al., 2001).  Circulating 
Aβ binds to RAGE on endothelial cells, which facilitates the transfer of Aβ across BBB.  
Once across the BBB, Aβ acculumates in the brain in the absence of efficient elimination 
mechanisms (Li, et al., 2009b).  In a transgenic AD mouse model inhibition of RAGE 
was able to reduce neurovascular stress caused by reactive oxygen species downstream of 
RAGE-Aβ interaction (Deane, et al., 2003).  The involvement of RAGE in AD 
pathogenesis was further potentiated when a double transgenic mouse model displaying 
mutant APP and overexpression of neuronal RAGE led to altered synaptic plasticity and 
increased neuronal pathology (Arancio, et al., 2004).  Recently, a transgenic mouse 
model expressing mutant APP in neurons was also manipulated to overexpress RAGE in 
microglia.  This genetic manipulation led to a wide range of effects, including increased 
production of inflammatory cytokines, increased infiltration of microglia and astrocytes, 
accumulation of Aβ, reduced acetylcholine esterase (AChE) activity, and accelerated 
impairment in spatial memory.  These deteriorating effects could be reduced significantly 
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by inhibiting RAGE-mediated signaling (Fang, et al., 2010).  There appears to be an age-
dependent decrease in RAGE expression in transgenic mice bearing Swedish mutation in 
APP, which is thought to be biologically relevant (Cui, et al., 2011). 
 
 
 
1.17.3 Scavenger receptors (SR) 
 
 
 
SR class is activated by a variety of diverse ligands, including modified 
lipoproteins, anionic polysaccharides and Aβ (Husemann, et al., 2002).  Some of the SR 
family members include SR class A, SR class B, SR class C, macrophage receptor 
containing a collagenous domain (MARCO), and endothelial cell scavenger receptor 
(SR-EC), CD68 (Husemann, et al., 2002). 
SRs mediate adhesion of microglia to Aβ fibrils (El Khoury, et al., 1996), 
chemotactic recruitment of microglia to amyloid deposits via the Src-kinase pathway 
(Moore, et al., 2002), and internalization of aggregated Aβ (Paresce, et al., 1996).  
Bamberger and colleagues also reported a role for B-class scavenger receptor CD36 in 
complex with integrin-associated protein CD47, and alpha(6)beta(1)-integrin in 
mediating the production of IL1-β and reactive oxygen species in murine microglia 
stimulated with Aβ fibrils (Bamberger, et al., 2003).  Engagement of this receptor 
complex also results in the phagocytosis of fibrillar Aβ (Koenigsknecht-Talboo and 
Landreth, 2005).  Interestingly, CD36 is found to be overexpressed on microglia in 
human AD brains, suggesting its biological relevance (Coraci, et al., 2002; Moore, et al., 
2002).  Recently, MARCO (SR-A) has been shown to physically interact with formyl 
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peptide like receptors to activate glial signal transduction pathways in response to Aβ 
(Brandenburg, et al., 2010). 
 
 
 
1.17.4 Peroxisome proliferator-activated receptor (PPAR) 
 
 
 
PPARs is a family of three (α/γ/δ) nuclear receptors that act as whole body lipid 
sensors, and have been used widely for Type II diabetes mellitus treatments and recently 
have displayed potential as an anti-AD target (Landreth, et al., 2008). 
PPARγ enhances anti-inflammatory signaling by downregulating NF-κB 
dependent expression of proinflammatory genes like matrix metalloproteinase (MMP), 
cycloxtgenase 2 (COX-2), and inducible nitric oxide synthase (iNOS) (Combs, et al., 
2000).  In fact, acute 7 day oral treatment with the PPARγ agonist not only reduced the 
number of activated microglia and reactive astrocytes in the hippocampus and cortex but 
also reduced the plaque burden in 10-month-old APPV717I mice (Heneka, et al., 2005).  
PPARγ enhances Aβ clearance by stimulating a cellular metalloprotease, which acts 
independently of insulin degrading enzyme (IDE) (Camacho, et al., 2004; Espuny-
Camacho, et al., 2010)  
 
 
 
1.17.5 N-Formyl peptide receptors (FPR) 
 
 
 
FPRL-1 and FPRL-2 belong to FPRs, which are seven-transmembrane, G protein-
coupled receptors that are activated by chemotactic peptides including Aβ (Le, et al., 
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2001).  Microglial FPRs are capable of both inducing phagocytosis and inflammation via 
an increase in oxidative stress against Aβ (Tiffany, et al., 2001).  Like some other 
receptors, FPRL-1 was highly expressed on the CD11b positive microglia, which were in  
close proximity to senile plaques in the brain tissue of AD patients (Paresce, et al., 1996; 
Le, et al., 2001), . 
FPRL-1 facilitated rapid internalization of Aβ(1-42), followed by its  intracellular 
degradation in mononuclear phagocytes.  Moreover, FPRL-1 receptors were able to 
recycle back to the cell surface under a lower concentration of Aβ.  However, continued 
exposure of Aβ seems to result in the intracellular formation of Congo Red-positive 
fibrillar aggregates, possibly by overburdening the FPRL-1 mediated clearance of Aβ 
(Yazawa, et al., 2001).  Prior treatment with FPR agonist resulted in the desensitization of 
FPRs for mediating Aβ-induced effects, indicating the saturable nature of the receptor 
(Tiffany, et al., 2001).  Interferon-γ (IFNγ) and CD40 ligand synergistically increase the 
expression of FPRL-2, a mouse homolog of human FPRL-1 via activation of MAPK and 
IkappaB-alpha in mouse microglia (Chen, et al., 2007).  Recently FPRL-2 activation in 
mouse microglia is shown to be dependent on the conformation of Aβ in such a way that 
smaller oligomers (trimers and tetramers as detected by native and denaturing gel 
electrophoresis) were better stimulators than larger oligomers and fibrils(Heurtaux, et al., 
2010).  All these inflammatory responses taking place downstream of Aβ-FPRL-1 
interaction are mediated by Gi- protein, as demonstrated by its sensitivity to pertussis 
toxin (Lorton, 1997; Tiffany, et al., 2001) 
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1.17.6 NOD-like receptors (NLRs) and inflammasome 
 
 
 
NLRs are expressed mainly on microglia and human astrocytes and play a pivotal 
role in the regulation of IL-1β and other pro-inflammtory cytokine production in response 
to a number of PAMPs and DAMPs (danger-associated molecular patterns), which 
includes Aβ (Halle, et al., 2008).  IL-1β is strongly elevated in response to Aβ based on a 
number of in vitro and in vivo studies.  IL-1β is synthesized as a 35 kDa pro-IL-1β 
precursor, which is then cleaved by inflammasome to generate a mature 17 kDa IL-1β 
subunit.  Inflammasome is a complex of proteins comprising of a NLR protein, caspase 
and the adaptor protein ASC (apoptosis-associated speck-like protein containing a 
CARD).  NLRs act as sensors of IL-1β concentration, which after reaching a critical 
concentration, in turn increases the expression and generation of active IL-1β.  However, 
NLRs require a primary signal from other PRRs like TLRs (Masters and O'Neill, 2011). 
Aβ(1-42) fibrils were shown to stimulate the production of IL-1β in murine 
microglia via activation of NALP-3 inflammasome (Halle, et al., 2008). NALP-3 
dependent release of IL-1β not only resulted into chemotaxis and activation of microglia 
but also induced production of other inflammatory mediators like nitric oxide and TNFα 
via autocrine and paracrine mechanisms.  However, the activation of the NALP-3 
pathway required cathepsin-B mediated internalization of Aβ, and subsequent impairment 
in lysosomal function upstream of NALP-3 inflammasome (Halle, et al., 2008).  
White et al (2005) showed that Aβ(1-42) oligomers were more effective in 
inducing IL-1β than fibrillar Aβ(1-42).  Interestingly, oligomer-induced IL-1β release 
decreased while fibril-induced IL-1β release increased over time although, underlying 
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receptors mediating these effects were not studied in this particular study(White, et al., 
2005).  
 
 
 
1.18 Molecular mediators 
 
 
1.18.1 Cytokines 
 
 
Among a plethora of inflammatory mediator molecules involved in AD, some of 
the most prominent molecules include proteins of complement pathway and 
proinflammtory cytokines.   The pro-inflammatory cytokines, including TNFα, IL-1, and 
TGF-β, are upregulated in microglia near senile plaques (Griffin et al1995, Dickson et al 
1993) (Table 1.2).  These cytokines have the ability to coordinate and amplify most of the 
inflammatory pathways by altering the gene expression of APP, complement and acute 
phase proteins in astrocytes, neurons and microglia themselves (Potter, et al., 1992; 
Barnum, et al., 1993).  
 
 
 
1.18.1.1 TNFα 
 
 
 
TNFα is produced as a type II transmembrane homotrimer, which is cleaved by a 
metalloprotease, TNF α converting enzyme (TACE) to release 51 kDa, soluble trimer 
(Wajant, et al., 2003).  Each subunit is composed of an antiparallel β-sandwich (Arai, et 
al., 1990).  TNFα production is one of the earliest events upon exposure to Aβ (Medeiros, 
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et al., 2007), and its levels are significantly elevated in AD serum, CSF, cortex and glial 
cells.  Microglia and astroglia are the primary sources of TNFα in the CNS.  
Both neurotrophic and neurotoxic effects of TNFα on AD pathology could be 
explained by the presence of two distinct TNF receptors; TNF receptor type 1 (TNF-R1; 
CD120a; p55/60) and TNF receptor type 2 (TNF-R2; CD120b; p75/80).  Membrane 
bound TNF can activate both the receptor types whereas soluble TNF only activates type 
2 receptor.  TNF-R1 has a death domain, which can interact with death domains from 
other proteins, resulting into the activation of caspases and apoptotic pathway.  TNF-R2 
lack a death domain but can alter gene expression via members of TNF receptor-
associated factor (TRAF) family.  TNF induces activation of NF-κB transcription factor, 
which in turn regulates the expression of a large number of proinflammatory cytokines 
including IL1, IL8, IL6 and GM-CSF and survival factors like manganese superoxide 
dismutase (MnSOD).  Crosstalk between both the receptors leads to further amplification 
of the signal.  As the name suggests, TNFα is known to cause cell death by necrosis, 
which is different from apoptotic cell death both morphologically and mechanistically.  
Necrosis does not require caspases or ATP and is linked to inflammation in vivo.  Most 
commonly, TNFα indirectly triggers apoptosis or necrosis via generation of ROS. 
TNFα protects neurons from Aβ-induced damage by decreasing oxidative stress 
and glutamate toxicity via NF-κB dependent transcriptional regulation (Barger, et al., 
1995), upregulating receptors involved in microglial chemotaxis towards Aβ for 
clearance (Cui, et al., 2002), and expressing anti-apoptotic factor (bcl-1).  Intrathecal 
TNFα negatively correlated with levels of apoptotic markers and tau protein in the AD 
brain as compared to non demented controls (Tarkowski, et al., 1999).  Deficiency of 
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TNF receptors (TNFR) suppressed microglial activation and led to greater neuronal loss 
in vivo (Bruce, et al., 1996).  On the other hand, TNFα mediate Aβ-induced inhibition of 
LTP in vivo (Wang, et al., 2005) and  iNOS- dependent apoptosis of neurons (Combs, et 
al., 2001).  In fact, blockage of TNFα action by pharmacological inhibitors or genetic 
deficiency reduced cognitive dysfunction caused by Aβ (Medeiros, et al., 2007).  TNFα 
can exacerbate AD by stimulating the expression of APOE (Bales, et al., 2000) and Aβ 
(Blasko, et al., 1999).  Moreover, genetic linkage analysis revealed an association 
between the TNF, TNFR1 and TNFR2 genes and the occurrence of late onset AD (Perry, 
et al., 2001).  
 
 
 
1.18.1.2 TGF 
 
 
 
TGFs are a family of peptide growth factors and play a key role in tissue 
development, homeostasis, repair, promote microglial chemotaxis and are potent 
modulators of inflammatory responses induced by both astrocytes and microglia, (Yao, et 
al., 1990).  TGF-β on one hand enhances microglial clearance of Aβ, reduces plaque 
burden and neuronal degeneration (Wyss-Coray, et al., 2001; Tesseur, et al., 2006), but 
on the other hand its overexpression is linked to amyloid deposition in AD brain tissue 
and cerebral amyloid angiopathy (CAA) (Wyss-Coray, et al., 1997).  All three different 
isoforms of TGF-β are implicated in AD, however they affect the cellular distribution and 
degradation of Aβ in an isoform specific manner (Harris-White, et al., 1998). 
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1.18.1.3 IL-1 
 
 
 
IL-1 exists as two different forms; IL-1α and IL-1β.  Extracellular 17.5 kDa 
secreted IL-1 is produced from a membrane bound form by proteolytic cleavge.  Both the 
isoforms can activate the only receptor (IL1R1) to produce inflammatory molecules like 
prostaglandin E2, collagenase, and phospholipase-A2. IL-1 mainly acts in concert with 
IL-6 and TNFα in a multifunctional way (Arai, et al., 1990).  IL-1β immunostaining was 
seen both in microglia and astrocytes surrounding both diffuse and senile plaques in a Tg 
2576 mouse model of AD and AD brain tissue and is believed to contribute to plaque 
formation (Benzing, et al., 1999; Apelt and Schliebs, 2001).  IL-1 also upregulates 
expression of APP by almost 6-fold in primary human astrocytes (Rogers, et al., 1999). 
 
 
 
1.18.1.4 Interleukin-6 
 
 
 
IL-6 is believed to amplify the inflammatory signaling pathways mediated by IL-
1, and involves the Janus kinase/signal trasducer and activator of transcription (JAK-
STAT) pathway (Cacquevel, et al., 2004).  Significant upregulation of IL-6 mRNA was 
observed in the entorhinal cortex and superior temporal gyrus in AD brain compared to 
non demented controls (Luterman, et al., 2000). 
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1.18.2 Complement proteins 
 
 
 
Complement proteins are a set of heat labile serum proteins which complement 
the cytotoxicity of antibodies and bridge the humoral immune system with the innate 
immune system.  In a classical complement pathway, antigen-antibody interaction 
triggers the binding of the first complement component C1q.  The binding initiates a 
cascade of sequential proteolysis.  The products serve as local inflammatory mediators, 
chemotactic agents and opsonins.  Also it generates membrane attack complex (MAC) on 
the target cell which disturbs ion homeostasis by pore formation in the membrane, 
ultimately causing cell lysis.  Two other complement pathways exist, namely alternate 
and lectin, which slightly differ in the protein products they utilize, but parallel the 
classical pathway (Akiyama, et al., 2000).  Complement proteins of both classical and 
alternative pathways, including C1q, C4, C3, are upregulated in the AD brain as 
compared to controls (Shen 1997), and colocalize with compact, thioflavin positive 
plaques in AD brains as opposed to diffuse, thioflavin negative plaques (Eikelenboom 
and Stam, 1982; Stoltzner, et al., 2000; Strohmeyer, et al., 2000).  Synthesis of C1q was 
stimulated in hippocampal organotypic slice cultures stimulated with Aβ (Fan and 
Tenner, 2004).  C1q can activate the classical pathway by direct binding to fibrillar Aβ 
aggregates within the senile plaque but not to monomeric Aβ, independent of an antibody 
in vitro (Rogers, et al., 1992; Afagh, et al., 1996) and the alternative pathway via 
interactions with C3.  The activation of complement was highly specific by Aβ since 
other proteins similar in size and charge, in both monomeric and aggregated form, failed 
to do so (Bradt, et al., 1998).  In situ hybridization studies in culture and AD brain 
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showed microglia and astrocytes in the vicinity of plaques to be the source of 
complement proteins (Veerhuis, et al., 1999; Fonseca, et al., 2011).  Complement C3a 
and C5a also recruit microglia and astrocytes to the fibrillar Aβ and further prompts a 
robust inflammatory response (Fonseca, et al., 2004; Fonseca, et al., 2011).  Cellular or 
pharmacological inactivation of complement pathways and related downstream signaling 
using transgenic murine models of AD proposed a detrimental role of complement 
towards AD pathogenesis (Maier 2008, Fonseca 2009).  On the other hand, in vivo 
studies on transgenic mouse employing complement C3 inhibitor reduced 
neuropathology, indicating a neuroprotective role of complement system in AD 
pathology.  C1q in the absence of other complement components protects neurons against 
Aβ-induced neurotoxicity both in vitro and in vivo, and the mechanisms might involve 
induction of neurite outgrowth, increased clearance of apoptotic cells and inhibition of 
inflammatory cytokines (Wyss-Coray et al.2002; Mukherjee and Pasinetti 2000 Zhou 
2008, Pisalyaput and Tenner, 2008 Fraser 2010 Benoit 2011).  The role of complement in 
AD pathogenesis thus appears to be more complex. 
 
 
 
1.19 Role of microglia in AD: Concluding remarks 
 
 
 
Ample evidence corroborates the involvement of microglia in AD pathogenesis, 
yet it is not very clear if microglia act to cause protection or toxicity to neurons (Cameron 
and Landreth, 2010).  In fact, considering evidence for both functionalities, it is proposed 
that microglia represent a dynamic phenotype, and are capable of alternating between 
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different states.  This idea is supported by a study that showed that hippocampal 
microglia switch from a phagocytic (alternative) phenotype during early stage to an 
inflammatory (classical) phenotype in later stage during aging of APP/PS1 transgenic 
mice (Jimenez, et al., 2008). 
As discussed in earlier sections microglia seem to act to clear Aβ deposits during 
earlier stages of AD, but upon continued exposure the microglial phagocytic machinery 
gets overburdened and microglia instead become pro-inflammatory.  Unregulated 
production of pro-inflammatory mediators results in chronic inflammation which is 
believed to exacerbate the AD pathology and related neurodegeneration (Perry, et al., 
2010). 
The potential of anti-inflammatory therapy against AD has been explored.  
Several epidemiological studies involving populations from different countries found that 
use of non steroidal anti-inflammatory drugs (NSAIDs) was linked to decreased 
prevalence of AD (McGeer, et al., 1996; McGeer and McGeer, 2007). In fact, 
postmortem analysis of AD-type pathology from non-demented patients using NSAID 
revealed fewer activated microglia than the NSAID non-users, supporting that microglial 
activation is a key factor contributing to AD pathology (Mackenzie, 2000).  NSAIDs 
have also been observed to reduce plaque burden and cognitive deficiencies in transgenic 
animal models of AD, although subsequent clinical trials have been disappointing 
(McGeer and McGeer, 2007).  The efforts have been directed in identifying specific 
targets of inflammatory pathways as both biomarkers for early diagnosis of AD as well as 
treatment for AD (Akiyama, et al., 2000; Weggen, et al., 2001). 
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There is ample in vitro evidence for clustering of activated microglia around 
senile plaques (Dickson, et al., 1988; Cameron and Landreth, 2010). Moreover, gliosis 
correlated linearly with disease severity while plaque burden remained unchanged 
(Serrano-Pozo, et al., 2011).  Recently, sensitive antibodies have detected a halo of 
oligomeric Aβ surrounding senile plaques, supporting the idea that plaques are not only 
comprised of fibrillar Aβ but exhibit a complex composition. It is not very clear which 
exact species of Aβ is responsible for microglial activation (DaRocha-Souto, et al., 2011).  
This is particularly important since burgeoning evidence indicates that smaller, soluble 
oligomers are potent neurotoxins, while fibrils are not as effective (Koffie, et al., 2011).  
Although microglial activation has been a subject of intense research, a clear correlation 
between Aβ-aggregation state and microglial activation is not yet established.  
One of the main reasons could be the lack of homogeneity of Aβ preparations.  
Many in vitro studies investigating Aβ-induced activation of microglia have utilized 
aggregated solutions of Aβ, which represent a polydisperse mixture of soluble and 
insoluble Aβ species.  In such cases, it might not be possible to attribute the biological 
activity to one particular species. 
In this study, we have carefully prepared homogeneous solutions of Aβ(1-42) 
protofibrils, fibrils, monomers and confirmed the aggregation states of Aβ using a variety 
of biophysical and imaging techniques.  Subsequently the optimal aggregation state of Aβ 
involved in mouse microglial activation in vitro was identified.  This finding may be 
biologically relevant if translated in vivo and will open up avenues for development of 
new drug targets against AD. 
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CHAPTER 2 
METHODS 
 
 
 
2.1 Cell culture 
 
 
 
2.1.1 Primary murine microglia isolation and culture 
 
 
 
Primary mixed glial culture was obtained from neonatal C57BL/6 mice (Harlan 
laboratories Inc).  Briefly 3-4 days old post natal mice were euthanized with an overdose 
of inhaled isoflurane (Fisher).  The brains were isolated and meninges were removed by 
rolling the brains over gauze under sterile conditions.  The isolated brains were collected 
in a 50 mL sterile conical tube containing 20 ml of phosphate buffered saline (PBS) 
supplemented with antibiotics and kept on ice.  After all the brains were collected, brain 
tissue was transferred to a 100 mm cell-culture dish, minced using sharp edged forceps in 
a scissor action, and resuspended in 5.0 ml of 0.5% trypsin (Hyclone) followed by 
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incubation at 37⁰C for 20 min to allow further dissociation of the tissue.  Subsequently, 
cells were resuspended in 10 ml complete Dulbecco’s modified Eagle’s medium 
(DMEM, 4.5 g/l glucose, Hyclone) containing 10% heat-inactivated fetal bovine serum 
(FBS) (Hyclone), 4 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 
0.25 μg/mL amphotericin-B (P/S/A triple antibiotic mixture, Fisher), OPI medium 
supplement (oxaloacetic acid-pyruvate-insulin, Sigma-Aldrich), and 0.5 ng/ml 
recombinant mouse granulocyte macrophage- colony stimulating factor (GM–CSF) 
(Invitrogen).  The cell suspension was further triturated using a 10 ml pipette and filtered 
through a 70-μm cell strainer to remove tissue debris (Fisher Scientific).  The resulting 
cell suspension was centrifuged at 200 x g for 5 min at 25⁰C, resuspended in complete 
medium and seeded into 150-cm
2
 flasks (Corning).  Each 150-cm
2
 flask contained 30 ml 
of total cells.  The number of flasks generated out of a single batch of mouse pups was 
dependent on the size of the litter.  Cells were cultured at 37⁰C in 5% CO2 until 
confluency (1-2 weeks).  Microglia typically looked like round cells resting on top of the 
granular astrocytic layer.  Microglia were selectively harvested by overnight shaking of 
the flask at 37⁰C in 5% CO2 (at a speed between 5 and 6 on the shaker in the cell culture 
laboratory) and the medium was collected.  The flasks were replenished with fresh 
growth medium, and incubated further to obtain subsequent batches of microglia.  
Typically, this procedure was repeated 3-4 times for one flask (Esen and Kielian, 2007) 
before the flasks were discarded. 
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2.1.2 BV-2 murine microglial culture 
 
 
 
BV-2 mouse microglial cell line was a gift from Dr Landreth (Case Western 
Reserve University).  The cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, 4.5 g/l glucose) (Hyclone) containing 50 U/ml penicillin, 50 μg/ml 
streptomycin, 50 μM β-mercaptoethanol, and 5% fetal bovine serum.  BV-2 cells were 
typically passaged twice a week.  For passaging, the confluent cells were washed 1 x with 
phosphate buffered saline (PBS) (Hyclone) and 1 ml of 0.25% trypsin was added.  After 
incubating the cells for 10 min at 37⁰C and 5% CO2, 9 ml of growth medium was added 
to inactivate trypsin.  1 ml of resuspended cells were then centrifuged for 7 min at 100 x 
g and resupended in 10 ml of fresh growth medium, added to 75 cm
2
 flask and incubated 
further until next passage.  BV-2 cells were used until passage #50. After that the cells 
were discarded and a new frozen aliquot (frozen in the year 2008 by M.L.D. Udan at 
passage #37-38) was thawed and cultured in the fresh growth medium as described 
above.  However, one washing step was added before the culturing of cells which 
involved centrifugation for 7 min at 100 x g to remove any residual DMSO present in the 
cryopreservation medium. 
 
 
2.1.3 TNFα measurements using ELISA 
 
 
 
Measurement of secreted TNF in the cellular conditioned medium was 
determined by ELISA as previously detailed (Udan, et al., 2008) except that the assay 
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was modified for the measurement of mouse TNFα.  Briefly, 96-well plates were coated 
overnight with 100 μl of 0.4 μg /ml monoclonal anti-mouse TNF capture antibody 
(stock aliquot stored at -20⁰C at 200 μg/ml in PBS), washed with phosphate-buffered 
saline (PBS) containing 0.05% Tween-20 and blocked with PBS containing 1% BSA, 5% 
Sucrose and 0.05% NaN3 following by a wash step.  Successive treatments with washing 
in between were done with samples or standards, 0.2 μg /ml biotinylated polyclonal anti-
mouse TNF detection antibody (stock aliquot stored at -20⁰C at 50 μg/ml in detection 
antibody diluent) in 20 mM Tris with 150 mM NaCl and 0.1% BSA, streptavidin-
horseradish peroxidase (HRP) conjugate, and equal volumes of HRP substrates 3,3',5,5'-
tetramethylbenzidine and hydrogen peroxide.  The reaction was stopped by the addition 
of 1% H2SO4 solution.  The optical density of each sample was analyzed at 450 nm with 
a reference reading at 630 nm using a SpectraMax 340 absorbance plate reader 
(Molecular Devices, Union City, CA).  The concentration of TNF in the experimental 
samples was calculated from a TNF standard curve of 15-2000 pg/ml.  When necessary, 
samples were diluted to fall within the standard curve.  TNFα concentrations for 
absorbance values below the lowest 15 pg/ml standard were determined by extrapolation 
of the standard curve regression line.  
 
 
 
2.1.4 Characterization of primary murine microglia proinflammatory response 
 
 
 
Microglia are known to express a variety of toll-like receptors (TLRs) (Cameron 
and Landreth, 2010).  In order to get an estimate of microglial sensitivity for various TLR 
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ligands, we carried out dose-response experiments for TLR-ligands such as 
lipopolysaccharaide (LPS, TLR4 ligand), Pam3CSK4 (TLR 1 and 2 ligand) and FSL-1 
(TLR 2 and 6 ligand).  LPS (600 μg/ml, Pam3CSK4 (600 μg/ml) and FSL-1 (60 μg/ml) 
were aliquotted, stored at -20⁰C and were further used to make appropriate dilutions for 
addition to the cells.  Primary microglia were harvested by shaking the culture flask as 
described above and medium containing microglia was centrifuged at 200 g for 10 min at 
25⁰C.  Microglia (100 μl) were then plated into 96-well culture plates in a medium 
devoid of GM-CSF for 2 h at 37⁰C in 5% CO2.  The medium was replaced with fresh 
medium without GM-CSF and ligands were added. After 6 or 24 h incubation at 37⁰C, 
the cellular medium was collected and analyzed using ELISA for the production of TNFα 
as described in 2.1.3.  Appropriate dilution of the sample was carried out in order to 
allow the sample values to fall within the standard curve ranging between 15-2000 pg/ml.  
The final concentrations of TLR-ligands (LPS, Pam3CSK4 and FSL-1) used in these 
dose-dependence studies were 100, 30, 10, 3 and 1 ng/ml. 
LPS produced a concentration-dependent TNFα response between the range 1-10 
ng/ml above which the response appeared to plateau (Figure 2.1).  Pam3CSK4and FSL-1 
also produced a concentration dependence response over the range of concentrations 
selected in this study (Figure 2.2 and Figure 2.3).  The extent of TNFα production was 
dramatically altered between 6 and 24 h treatment with ligands, 6 h displaying maximum 
response.  Therefore, the experiments were optimized for 6 h treatment time for 
subsequent studies unless stated otherwise. 
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Figure 2.1  Concentration-dependence of LPS-induced TNFα production by 
primary murine microglia.  Primary murine microglia in complete microglial medium 
without GM-CSF were treated with LPS at a final concentration of 1, 3, 10, 30 and 100 
ng/ml for 6 or 24 h at 37⁰C.  The conditioned medium was collected and analyzed using 
ELISA. 
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Figure 2.2  Concentration-dependence of Pam3CSK4-induced TNFα production by 
primary murine microglia.  Primary murine microglia in complete microglial medium 
without GM-CSF were treated with Pam3CSK4 at a final concentration of 1, 3, 10, 30 and 
100 ng/ml for 6 or 24 h at 37⁰C.  The conditioned medium was collected and analyzed 
using ELISA. 
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Figure 2.3  Concentration-dependence of FSL1-induced TNFα production by 
primary murine microglia.  Primary murine microglia in complete microglial medium 
without GM-CSF were treated with FSL-1 at a final concentration of 1, 3, 10, 30 and 100 
ng/ml for 6 or 24 h at 37⁰C.  The conditioned medium was collected and analyzed using 
ELISA. 
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2.1.5 Characterization of BV-2 microglia proinflammatory response 
 
 
 
Dose-response studies for LPS were also carried out for BV-2 microglia.  BV-2 
microglia (300 μl) were plated at a concentration of 1 x 105 cells/well overnight in a 48-
well plate in the growth medium.  Next day, the medium was replaced with medium 
containing 2% FBS and LPS was added for 6 or 24 h at 37⁰C.  Serial dilutions of LPS 
stock solution (600 μg/ml in sterile water) were prepared to give the final concentrations 
of LPS as 1, 10 and 100 ng/ml for the cellular treatment.  Cellular medium was analyzed 
by ELISA (as described in section 2.1.3).  LPS produced a dose-dependent TNFα 
response at both 6 and 24 h of incubation (Figure 2.4).  Since both 6 and 24 h produced a 
comparable TNFα response for each concentration of LPS, cellular treatment time was 
optimized to 6 h.  LPS at 10 ng/ml and 3 ng/ml were used as positive controls for all the 
cell stimulation studies. 
 
 
 
2.2 Preparation of Aβ 
 
Aβ peptide has a high propensity for aggregation.  Any seeds present in the Aβ 
solution affects the kinetics of Aβ aggregation (Evans, et al., 1995) as well as the 
molecular structure of aggregation species like fibrils (Petkova, et al., 2005) and 
oligomeric intermediates.  Therefore, it is important to remove any-preformed seeds in 
order to obtain a homogenous solution of Aβ.  The treatment of Aβ peptide with 100% 
hexafluoroisopropanol destabilizes the intermolecular hydrogen bonds.  Synthetic  
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Figure 2.4  Concentration-dependence of LPS-induced TNFα response in BV-2 
mouse microglia.  BV-2 microglia were plated overnight in the growth medium 
containing 5% FBS followed by incubation with LPS at a final concentration 1, 10 and 
100 ng/ml for 6 or 24 h. The conditioned medium was analyzed by ELISA for 
quantifying TNFα production 
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Aβ(1-42) peptides (Keck Center, Yale University) were dissolved in 100% 
hexafluoroisopropanol (HFIP) (Sigma) for 1 h at room temperature.  The resulting 1 mM  
Aβ(1-42) stock solution was aliquoted into sterile microcentrifuge tubes, evaporated 
overnight under the fume hood, uncovered, at room temperature. Subsequently, the 
aliquots were vacuum-centrifuged to remove any residual HFIP, and stored at -20⁰C. 
Our studies also utilized crude Aβ(1-42) and Aβ(1-40) peptides synthesized by 
Dr. Fabio Gallazi, University of Missouri-Columbia.  We treated these peptides with 
trifluoroacetic acid (TFA) at a concentration of 1 mM followed by bath sonication for 10 
minutes and its subsequent removal by speed-vacuum centrifugation.  The TFA-
pretreated peptide was further treated with 100% HFIP (final [Aβ] 1 mM) at 37⁰C for 1 h 
to facilitate further disaggregation of peptide as well as removal of residual TFA.  Speed-
vacuum centrifugation was employed to allow evaporation of HFIP.  The lyophilized 
aliquots were then stored at -20⁰C in a container with dessicant. 
1.5 mg Aβ(1-40) E22G mutant peptide was a gift from Dr Wetzel, University of 
Pittsburg and lyophilized in an identical manner as synthetic Aβ(1-42) peptide purchased 
from Keck center, Yale University and 0.75 mg aliquots were prepared and stored -20⁰C 
in a container with dessicant. 
 
 
 
2.2.1 Size exclusion chromatography  
 
We used AKTA-fast protein liquid chromatography (FPLC) along with a size-
exclusion column for isolation of Aβ monomer and protofibrils.  Size exclusion 
chromatography (SEC) separates the protein on the basis of its shape and size in such a 
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way that bigger molecules elute out first followed by the smaller molecules.  AKTA-
FPLCTM
 
is particularly useful for efficient protein purification since it enables a constant 
flow rate for solvent elution via two high-precision pumps (www.gelifesciences.com).   
For experiments, 1.14 mg of lyophilized Aβ(1-42) peptide was dissolved in 50 
mM sodium hydroxide (NaOH, Fisher Scientific) to give a 2.5 mM Aβ solution, and 
further diluted to 250 μM using sterile F-12 cell culture medium (BioWorld, Dublin, 
OH).  F-12 cell culture medium was supplemented with 100 U/ml penicillin, 0.1 mg/ml 
streptomycin and 0.25 μg/mL amphotericin-B (Triple antibiotic mixture, Fisher) and 
filtered through 0.22 μm syringe filter (Fisherbrand) to prevent any bacterial 
contamination in Aβ solutions (called as supplemented F-12).  The Aβ solution was 
centrifuged at 18000 x g for 10 min with a Beckman-Coulter Microfuge®18 and 
immediately subjected to SEC. The centrifugation supernatant was eluted from a 
Superdex 75 HR 10/30 column (GE Healthcare) in supplemented F-12 medium. Prior to 
injection of Aβ, Superdex 75 column was coated with 2 mg bovine serum albumin (BSA, 
Sigma) to prevent any non-specific binding of Aβ to the column matrix.  Aβ was then 
eluted at 0.5 ml/min and elution of Aβ was continuously monitored using UV absorbance 
at 280 nm.  0.5 ml fractions were collected and immediately placed on ice.  The fractions 
eluted in void volume were pooled together and labeled as protofibrils and the fractions 
eluted in the included peak were pooled and labeled as monomer.  Sometimes, the 
individual protofibril fractions were added to the cells separately to compare the TNFα 
production between different fractions within the Aβ(1-42) protofibril peak.  
Concentrations of both protofibrils and monomers were determined directly from the 
absorbance trace using an extinction coefficient of 1450 cm
-1
 M
-1
 at 280 nm.  Isolation of 
85 
 
protofibrils and monomers was also carried out in artificial cerebrospinal fluid (aCSF) 
containing 130 mM sodium chloride (NaCl, Fisher Scientific), 3 mM potassium chloride 
(KCl, Fisher Scientific), 1 mM sodium phosphate dibasic (Na2HPO4 7H2O, Fisher 
Scientific) and 15 mM sodium bicarbonate (NaHCO3, Fisher Scientific) adjusted to pH 
7.8 in a similar manner as described above.  aCSF composition was modified from a 
protocol described in Tzounopoulos et al (Tzounopoulos, et al., 2004). 
For preparation of Aβ(1-40) protofibrils, 1.2 mg Aβ(1-40) crude peptide was 
resuspended in 50 mM NaOH and further diluted in supplemented F-12 medium in the 
similar manner as described before for Aβ(1-42).  Aβ solution was then subjected to SEC 
either immediately or after 24 hour incubation at 25⁰C as described before.  Aβ(1-40) 
E22G (Arctic) mutant protofibrils were prepared using NaOH/supplemeted F-12 in a 
similar manner except that the Aβ solution was incubated for either 3 h or 24 h at room 
temperature prior to SEC. 
Aβ(1-42) monomer was also obtained using an alternative method for Aβ-
aggregation age studies.  For these experiments, 2.2 mg crude Aβ(1-42) peptide was 
resuspended in 6 M guanidium hydrochloride (GuHCl, Fisher Scientific) and 10 mM 
ammonium hydroxide (NH4OH, Fisher Scientific) to give a total volume of 1.0 ml.  Aβ 
solution was then subjected to SEC and eluted using either 1x PBS (Hyclone) or 50 mM 
HEPES buffer (pH 8.0) or 50 mM Tris-Cl buffer (pH 8.0).  Monomer fractions eluted in 
the included peak were sometimes pooled or used individually.  Sometimes, the purified 
monomer was flash-frozen using dry-ice/ethanol mixture and stored at -80⁰C.  
Aggregation reactions were carried out either using freshly purified or flash-frozen SEC-
purified monomer at different temperatures in a time dependent manner as described in 
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chapter 5.  Aliquots were drawn from the Aβ aggregation reactions at 0, 48, 96 and 216 
hours and flash frozen using dry-ice/ethanol mixture and stored at -80⁰C until the 
experiment.  Chaotropic nature of the GuHCl/NH4OH treatment yielded more monomer, 
which was desired for carrying out aggregation studies on SEC-purified Aβ(1-42) 
monomer.   
 
 
 
2.2.2 Aβ(1-42) oligomer and fibril preparation 
 
 
 
Aβ oligomers and fibrils obtained directly from lyophilized aliquots were 
prepared as previously described (Stine, et al., 2003).  Briefly, lyophilized Aβ(1-42) 
aliquots were resuspended in sterile anhydrous dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St. Louis) at 5 mM.  For oligomer preparation the sample was diluted to 100 μM 
in sterile ice-cold F-12 cell culture medium without phenol red (Bioworld, Dublin, OH) 
and incubated for 24 h at 4°C.  For fibril preparation the sample was diluted to 100 μM in 
10 mM HCl and incubated for 24 h at 37°C. 
 
2.2.3 Aβ(1-42) fibril preparation using SEC-purified monomer 
 
SEC purified Aβ(1-42) monomer eluted in supplemented F-12 or aCSF (the 
concentration of Aβ monomer fraction differed slightly between experiments but 
generally 56 μM monomer was used) was incubated at room temperature, with gentle 
agitation for ≤72h.  The aggregated Aβ(1-42) solution was centrifuged at 18000 x g for 
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10 min.  The supernatant was removed and the pellet was resuspended into supplemented 
F-12 or aCSF to match the original starting concentration based on the Aβ(1-42) 
monomer.  The resulting solution was labeled as Aβ(1-42) fibrils.  The total Aβ(1-42) 
solution, 18000 x g supernatant and resuspended pellet was assessed for Thioflavin-T 
(ThT) fluorescence as described in section 2.3 in order to monitor conversion of 
monomer into ThT-positive fibrils. 
 
 
 
2.3 Microglia stimulation experiment with Aβ 
 
 
 
TLRs particularly TLR 2, 4 and 6 have been previously shown to play a role in 
Aβ-induced proinflammatory response (Fassbender, et al., 2004; Walter, et al., 2007; 
Udan, et al., 2008; Stewart, et al., 2010; Liu, et al., 2011).  Therefore, predetermined 
optimal TLR ligand concentrations were utilized as positive controls for our Aβ-cell 
stimulation experiments (Figure 2.1-2.4). For experiment involving Aβ, medium 
containing primary microglia was centrifuged at 200 g for 10 min at 25⁰C.  We 
resuspended and plated the microglia in complete microglial assay medium without GM-
CSF or FBS overnight before the addition of freshly purified monomer, protofibrils or 
pre-formed fibrils.  For cell stimulation studies involving Aβ(1-42) oligomers prepared in 
DMSO/F-12 medium and fibrils prepared in DMSO/ 10 mM HCl (Chapter 4), primary 
microglia were resuspended and plated in medium without serum for 2 h before the 
addition of Aβ and actual Aβ-treatment was also carried out in the medium devoid of 
serum.  Serum-free conditions were adopted from the literature (Reed-Geaghan, et al., 
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2009).  In the experiments investigating the dependence of microglial TNFα response on 
the aggregation age of SEC-purified Aβ(1-42), primary microglia were resuspended and 
plated in a medium without GM-CSF for 2 h followed by incubation of Aβ in a medium 
without GM-CSF but in the presence of 10% heat-inactivated serum as in complete 
microglial growth medium.  For all the cell stimulation experiments primary murine 
microglia (100 μl) were plated at a density of 5 x 105 cells/ml in a sterile 96-well cell 
culture plate.  Prior to addition of Aβ to the cells, medium was always replaced with fresh 
assay medium as described previously.  Freshly purified Aβ (1-42) monomer, 
protofibrils, or preformed fibrils prepared from SEC-isolated monomer were added to the 
cells at a final concentration of 15 μM.  The concentration of monomer and protofibril 
fractions varied slightly from experiment to experiment.  Therefore, the volume of Aβ 
added to achieve a final concentration of 15 μM was slightly different.  Consequently, the 
assay medium was added in such a way that the total volume of cellular treatment was 
100 μl.  The negative control in each experiment consisted of addition of equal volume of 
buffer and assay medium to match the Aβ treatment.  For example, in a typical 
experiment involving 56 μM of Aβ fraction, 27 μl of Aβ was added to 73 μl of assay 
medium whereas for the negative control, 27 μl of buffer was added to 73 μl of assay 
medium.  For experiments involving Aβ(1-42) oligomers prepared in DMSO/F-12 
medium or Aβ(1-42) fibrils prepared in DMSO/ 10 mM HCl 15 μl of Aβ sample was 
added to 85 μl of assay medium to give a final concentration of 15 μM Aβ in cell 
stimulation assays.  For experiments investigating the relationship between Aβ(1-42) 
aggregation age and microglial proinflammatory response, final concentration of Aβ was 
11 μM.  After the addition of 30 μl of Aβcells were incubated at 37⁰C in 5 % CO2.  The 
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medium was collected after 6 h and stored at -20⁰C until analyzed by ELISA.  The 
vehicle containing Aβ was added at the same volume as Aβ and utilized as negative 
control to assess the background cellular response. 
All the BV-2 cellular studies were carried out in identical manner with respect to 
the volume of Aβ and assay medium added to the adhered microglia.  For cellular studies 
described in chapter 3, BV-2 cells were resuspended at a density of 5 x 10
5
 cells/ml in the 
growth medium and seeded (100 μl). in a sterile 96-well cell culture plate overnight.  
Prior to the cellular treatment, medium was replaced with fresh medium without FBS for 
monomer, protofibril and fibril stimulation followed by Aβ stimulation at a final 
concentration of 15 μM for 6 h similar to that of primary microglia.  For studies 
involving Aβ(1-42) oligomers prepared in DMSO/F-12 medium and fibrils prepared in 
DMSO/ 10 mM HCl (Chapter 4), the cellular treatment was carried out in the assay 
medium containing 2% FBS for 6 h.  In Aβ(1-42) aggregation age studies (Chapter 5), 
BV-2 microglia were incubated at 37⁰C for 24 h in 5% CO2  in the presence of Aβ.  The 
cellular conditioned medium was collected after incubation with Aβ and stored at -20⁰C 
and TNFα production was measured using ELISA. 
 
 
 
2.3.1 Polymyxin-B sulfate neutralization assay  
 
 
 
Polymyxin-B sulfate (PMX-B) is a peptide antibiotic active against most gram 
negative bacteria, and was originally isolated from Bacillus polymyxa.  Polymyxins are 
known to display bacetriocidal activities by disrupting the membrane structure due to 
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their amphipathic nature (Storm, et al., 1977).  PMX-B has been used in order to check 
the contamination of Aβ solutions by either gram-negative bacteria or trace levels of 
endotoxins (Meda, et al., 1995; Udan, et al., 2008).  This assay was fairly important 
particularly in the context of Aβ-induced inflammation since it ruled out the possibility of 
false positive inflammatory reactions to Aβ due to contaminating endotoxin. 
This assay was implemented to exclude the presence of endotoxin in a number of 
Aβ-aggregation solutions as detailed before in Udan et al (Udan, et al., 2008).  Both BV-
2 and primary mouse microglia were plated as described before in section 2.1.1 and 2.1.2 
for cell stimulation experiments.  PMX-B was stored as 50 mg/ml stock at -20⁰C, which 
was diluted to a working stock of 600 μg/ml with water.  PMX-B was added to the cells 
at a final concentration of 100 ng/ml followed by addition of 10 ng/ml LPS or 15 μM Aβ 
sample.  The cells were then incubated at 37⁰C for 6 h and the conditioned medium was 
collected for the subsequent analysis using ELISA.  LPS was always used as a positive 
control for PMX-B neutralization assays. 
 
 
 
2.3.2 XTT cell viability and proliferation assay 
 
 
 
Viability of Aβ-treated microglia was determined by using an XTT [2, 3-bis (2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] assay.  XTT is a 
tetrazolium dye (Figure 2.5) that can be reduced via mitochondrial electron transport 
chain in the presence of phenazine methosulfate (PMS) to form a water-soluble formazan 
product.  which in turn is an indicator of cellular health (Scudiero, et al., 1988). 
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Figure 2.5  Reduction of XTT to form a formazan derivative. XTT gets reduced via 
mitochondrial electron transport chain to form a formazan derivative, which absorbs at 
467 nm. 
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XTT assay was also used in a cell free manner to rule out the possibility of any bacterial 
contamination of Aβ(1-42) samples.  XTT is obtained as a yellow color solid.  After 
receipt, XTT solid is divided into ~15 mg aliquots and stored in 15 ml conical tubes at -
20⁰C.  For the use, solid in one conical tube is brought up in sterile RPMI-1640 medium 
without phenol red to give 1 mg/ml solution of XTT under aseptic conditions.  The 
solution (1 mg/ml) is then aliquoted in 0.5 ml aliquots and stored in -20⁰C.  PMS was 
stored in 5 mM (prepared in sterile water) aliquots at -20⁰C.  The aliquoting in the solid 
form was carried out to prevent the bacterial contamination of working stock of XTT.  In 
cellular XTT assay, cells exposed to Aβ for 6 h were further incubated with 0.33 mg/ml 
XTT (diluted in RPMI 1640 medium without phenol red) and 8.3 μM phenazine 
methosulfate (PMS) (Acros, Morris Plains, NJ) for 2 h at 37⁰C in 5% CO2.  The extent of 
XTT reduction was measured by absorbance of reduced form of XTT at 467 nm.  The 
cell free XTT assay was done in parallel to the cell stimulation studies, in the similar 
manner as above except Aβ sample was incubated with a solution containing 0.33 mg/ml 
XTT and 8.3 μM PMS without any cells at the same final concentration of 15 μM for 6 h 
before the absorbance measurements. 
 
 
 
2.4 Thioflavin-T fluorescence measurements 
 
 
 
ThT is a benzathiazole dye as shown in Figure 2.6.  Freshly purified solutions of 
Aβ(1-42), Aβ (1-40) as well as Aβ (1-40) E22G (Arctic) monomer and protofibril 
solutions were monitored by ThT-fluorescence.  Aβ solution was diluted 10-fold into a 5 
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μM ThT solution prepared in 50 mM Tris-HCl buffer (pH 8.0) to make a total volume of 
70 μl.  ThT fluorescence emission scans (460-520 nm) were carried out using a Cary 
Eclipse Fluorescence spectrophotometer at an excitation wavelength of 450 nm.  ThT 
fluorescence values were obtained by integration of emission scan between 470-500 nm.  
The vehicle buffer for Aβ did not show any significant ThT fluorescence when used as a 
negative control in the absence of Aβ. 
 
 
 
2.5 Transmission electron microscopy (TEM) 
 
 
 
SEC-purified Aβ(1-42) as well as Aβ(1-40) protofibrils, Aβ(1-42) fibrils formed 
using SEC-purified monomer, Aβ(1-42) oligomers and fibrils prepared in DMSO/10 mM 
HCl were diluted to 20 μmol/ L in water and 10 μl was applied to 200-mesh formvar 
coated copper grid (Ted Pella Inc.).  Samples were allowed to incubate at room 
temperature for 10 min.  The excess solution was wicked using a tissue wipe. Grids were 
washed two to three times by being placed sample side down on a droplet of water.  
Heavy metal staining was performed by incubation of grid in 2% uranyl acetate (Electron 
MicroscopySciences, Hatfield, PA) for 5 min in a similar manner followed by removal of 
excess solution and air drying.  Affixed samples were visualized with a Philips EM 430 
TEM at 300kev (Courtesy David C. Osborn). 
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Figure 2.6 Structure of Thioflavin-T dye 
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2.6 Atomic Force Microscopy (AFM) 
 
 
 
Aβ(1-42) aggregation solutions (100 μM) were diluted to 10 μM in water. Grade 
V1 mica (Ted Pella, Inc, Redding, CA) was cut into 11 mm circles and affixed to 12 mm 
metal discs.  Aliquots (50 μl) were applied to freshly cleaved mica, allowed to adsorb for 
15 min, washed twice with water, air dried, and stored in a container with desiccant.  
Images were obtained with a Nanoscope III multimode atomic force microscope (Digital 
Instruments, Santa Barbara, CA) in TappingMode
TM
. Height analysis was performed 
using Nanoscope III software on flattened height mode images.  AFM sample preparation 
and imaging was carried out by Lisa K. Gouwens. 
 
 
 
2.7 Dynamic light scattering (DLS) 
 
 
 
Hydrodynamic radius (RH) measurements were made at room temperature with a 
DynaPro Titan instrument (Wyatt Technology, Santa Barbara, CA). Samples (30 μl) were 
placed directly into a quartz cuvette and light scattering intensity was collected at a 90º 
angle using a 10-second acquisition time. Particle diffusion coefficients were calculated 
from auto-correlated light intensity data and converted to RH with the Stokes-Einstein 
equation. Average RH values were obtained with Dynamics software (version 6.7.1). 
Histograms of percent intensity vs. RH were generated by Dynamics data regularization 
and intensity-weighted mean RH values were derived from the regularized histograms.  
DLS measurements were carried out and analyzed by Dr. Michael R. Nichols. 
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2.8 Dot-blot assays 
 
 
 
Dot-blot assays make use of the specificity of antigen-antibody interaction.  Dot-
blot assays can be regarded as a more qualitative assay to detect the presence of antigen 
in a particular sample under investigation.  Dot-blot assays are very similar to western 
blot assays except that the sample is directly adsorbed on the nitrocellulose membrane 
instead of electrophoretic transfer from polyacrylamide gel electrophoresis (PAGE) to the 
membrane.  Therefore, dot-blots are relatively more straightforward and require less time 
than western blots.  The following dot-blot protocol was adopted from Ajit et al (Ajit, et 
al., 2009). 
Nitrocellulose membrane was moistened by immersing in water for 2 minutes.  
The membrane was then allowed to dry for 20 minutes.  2 μl of Aβ sample was spotted 
onto the membrane and allowed to adsorb for 15-20 minutes.  The membrane was then 
blocked for any non-specific binding by incubation in 5.0 ml blocking buffer consisting 
of 10% dried milk in phosphate buffered saline containing 0.2% Tween-20 (called as 
PBST) for 1 h at 25⁰C with gentle agitation.  The membrane was then transferred to 5.0 
ml of primary antibody solution which consists of primary antibody diluted 1:5000 in 
PBST containing 5% dried milk.  Two different primary antibodies were utilized in our 
dot-blot assays.  Ab9 antibody (obtained from Mayo Clinic) recognizes 1-16 residues of 
N-terminus and thereby is capable of recognizing Aβ irrespective of its conformational 
state.  On the other hand, OC-antibody is a conformation-specific antibody developed by 
Charles Glabes laboratory from University of California, Irvine that recognizes fibrillar 
oligomers of Aβ (Kayed, et al., 2007).  The membrane was washed three times (for 5 
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minutes each) with PBST to remove non-specifically bound primary antibody and then 
incubated with secondary antibody diluted 1:1000 in 5.0 ml of PBST containing 5% dried 
milk for 1 h with gentle shaking at 25⁰C.  Separate secondary antibodies were used for 
two different primary antibodies because of their species compatibility.  Anti-mouse IgG 
(HAF007, R&D systems) was used as a secondary antibody for Ab9 whereas anti-rabbit 
IgG (HAF008, R&D systems) was used as secondary antibody for OC.  Washing step 
was repeated three times as described above and membrane was incubated for 1 minute in 
6 ml of ECL-western blotting substrate (Pierce, Thermo Scientific) with vigorous 
shaking.  ECL-western blotting substrate was prepared by mixing equal volumes of 
detection reagent 1 with detection reagent 2.  Excess ECL substrate was removed by 
blotting the membrane on Whatman paper.  The dot blot was developed by exposing the 
film for 20 seconds.   
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CHAPTER 3 
MICROGLIAL ACTIVATION BY Aβ PROTOFIBRILS 
 
 
 
3.1 Introduction 
 
 
 
Alzheimer’s disease (AD) is a neurodegenerative disease more prevalent in the 
elderly population (Thies and Bleiler, 2011).  Extracellular senile plaques and 
intracellular tau tangles represent the two classical hallmarks of the AD brain (Selkoe, 
2011).  Clustering of activated microglia and significant level of endogenous 
inflammatory markers associated with the senile plaques depicts the characteristic 
inflammatory component associated with AD pathology (Finch and Marchalonis, 1996).  
Moreover, such a state of chronic inflammation is believed to contribute towards 
neuronal degeneration observed in AD (McGeer and McGeer, 1998).  Amyloid-β (Aβ) 
protein is a major constituent of senile plaques (Glenner and Wong, 1984).  It is 
ubiquitously generated as a product of sequential proteolytic cleavage of a larger 
precursor protein known as amyloid precursor protein (APP) (Kang, et al., 1987).  Three 
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different proteases such as α, β and γ secretase are involved in the APP cleavage (Sisodia, 
et al., 1990).  Since γ-secretase cleaves APP in a heterogeneous fashion, it give rise to 
carboxy-terminal variants of Aβ protein with varying amino acid length (Edbauer, et al., 
2003).  Aβ(1-42) and Aβ(1-40) are the most common variants, which in their 
unaggregated monomeric form circulates normally in the body at nanomolar 
concentrations (Seubert, et al., 1992; Shoji, et al., 1992).  By some yet unknown event, 
monomeric Aβ starts to aggregate into long fibers, rich in β-sheet structure, forming the 
core of the plaques (Glenner and Wong, 1984).  The aggregation propensity is 
significantly higher for the Aβ variants with longer carboxy terminus (Jarrett, et al., 
1993).  Genetic evidence has shown that mutations in APP alter normal Aβ metabolism, 
thereby causing familial AD (Scheuner, et al., 1996; Selkoe and Podlisny, 2002).  Also, 
active immunization studies using synthetic Aβ and passive immunization studies using 
anti-Aβ antibodies in AD transgenic mice not only prevented amyloid deposition but also 
reduced related neuritic dystrophy and astrogliosis (Schenk, et al., 1999; Janus, et al., 
2000).  These and several other lines of evidence support the amyloid hypothesis, which 
proposes a primary role for Aβ accumulation in the AD pathogenesis (Hardy and 
Higgins, 1992). 
In vitro aggregation studies on Aβ have been particularly useful in understanding 
the mechanistic details of Aβ aggregation.  Starting from its monomeric form, Aβ is 
reported to form a variety of species including dimers, protofibrils, and oligomers during 
fibrillogenesis.  These species differ significantly in their size, morphology, structure and 
solubility (Walsh and Selkoe, 2007).  Interestingly, these species were shown to be 
present in the AD brain by means of specific antibodies (Gong, et al., 2003; Kayed, et al., 
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2003; Shankar, et al., 2008).  Furthermore, they exhibited significant toxicity to neuronal 
cultures in vitro (Hartley, et al., 1999; Dahlgren, et al., 2002; Lacor, et al., 2004; 
O'Nuallain, et al., 2010).  In fact, recent evidence has shown that a significant amount of 
oligomeric Aβ exists within and around the periphery of senile plaques in the AD brain 
(Koffie, et al., 2009; DaRocha-Souto, et al., 2011).  Moreover, oligomeric Aβ appears to 
correlate better with clinical disease severity than total amyloid plaque burden (DaRocha-
Souto, et al., 2011).  Although there is increasing support for the role of oligomers in 
early synaptotoxicity, Aβ fibrils are generally believed to act as a stimulus for microglia-
mediated inflammation in vitro.  In light of the recent detection of oligomeric species in 
the periphery of senile plaques, investigating the nature of stimulus for microglial 
activation needs a revisit, particularly since microglia are found to be clustered around 
the plaques.   
In a study by White et al (2005), oligomeric Aβ(1-42) was found to be more 
effective than fibrils in provoking a proinflammatory response (White, et al., 2005).  In 
fact, both fibrils and oligomers have been shown to produce a qualitatively distinct 
activation profile in microglia when probed using antibodies against different tyrosine 
kinases (Sondag, et al., 2009). 
A number of studies have been carried out on Aβ protofibrils to better understand 
their structure and neurotoxic properties after their original identification in 1997 by 
Walsh and colleagues (Walsh, et al., 1997).  Moreover, the biological relevance of Aβ 
protofibrils became more apparent after identification of their role in a familial AD case.  
In this familial case, a family from northern Sweden was found to harbor an intra-Aβ 
mutation E22G (Arctic), which resulted in the rapid formation and stabilization of 
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protofibrils (Nilsberth, et al., 2001).  However, the role of Aβ protofibrils in microglial 
activation has not been investigated.   
In this study, we prepared Aβ(1-42) protofibrils and investigated their ability to 
provoke a proinflammatory response in murine microglia.  Furthermore, we isolated 
insoluble Aβ(1-42) fibrils, Aβ(1-40) wild type (WT) and Aβ(1-40) E22G (Arctic) 
protofibrils to compare their ability to activate microglia with that of the Aβ(1-42) 
protofibrils.  In our study, we rigorously characterized Aβ preparations to be able to 
correlate aggregation state to microglial proinflammatory response.  
 
 
 
3.2 SEC isolation of Aβ(1-42) protofibrils and monomers 
 
 
 
SEC has been extremely helpful in separating Aβ protofibrils from low molecular 
weight Aβ (Walsh, et al., 1997; Lashuel, et al., 2003).  Walsh and colleagues prepared Aβ 
protofibrils by resuspending Aβ peptide in sodium hydroxide (NaOH) followed by 
dilution using phosphate-buffered saline (PBS) and subjecting the solution to SEC.  
Curvilinear 100-200 nm long protofibrils eluted out in the void volume (Walsh, et al., 
1997).  Use of NaOH allows rapid transition to basic pH preventing the aggregation of 
Aβ around its isoelectric pH (5.5) (Jan, et al., 2010).  We slightly modified the original 
method of Walsh et al to prepare Aβ(1-42) protofibrils.  We resuspended 1.14 mg Aβ(1-
42) peptide in NaOH (concentration of Aβ 2.5 mM), followed by dilution into F-12 cell 
culture medium supplemented with antibiotics (supplemented F-12) to give a 250 μM 
Aβ(1-42) solution.  This solution was centrifuged at 18000 g for 10 minutes and 
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immediately loaded onto Superdex 75 SEC-column and eluted in supplemented F-12 as 
described in the methods.  An elution profile was obtained by monitoring absorbance at 
280 nm and the concentrations of Aβ in various fractions were calculated using an 
extinction coefficient of 1450 M
-1
cm
-1
.  The elution profile typically showed two peaks as 
shown in Figure 3.1.  Protofibrils eluted in the void peak followed by monomers in the 
included peak.  The void peak fractions were pooled and designated as Aβ(1-42) 
protofibrils whereas included peak fractions were pooled and designated as Aβ(1-42) 
monomer for the experiments.  Usually the distribution of protofibrils to monomers was 
equivalent, but the equilibrium was found to be shifted towards increased formation of 
protofibrils with increasing incubation time between resuspension of Aβ(1-42) peptide 
and its loading on the SEC (data not shown).  This shift is in agreement with kinetics of 
Aβ(1-40) protofibril formation reported by Walsh et al (Walsh, et al., 1997).   
F-12 medium has comparable ionic strength (16 mS/cm as estimated by 
conductivity measurements) to PBS (21 mS/cm) used in the original preparation of Aβ 
protofibrils by Walsh et al (Walsh, et al., 1997).  Moreover, the use of cell culture 
medium is physiologically compatible for the subsequent cellular studies yet there were 
some shortcomings for the use of F-12 medium.  Firstly, F-12 medium is slightly pink in 
color and gives a noticeable background absorbance.  This background absorbance 
interfered with the bicinchoninic acid (BCA) assay for estimating protein concentration 
in SEC-isolated protofibril or monomer fractions in F-12 medium.  Secondly, the high 
glucose content in the F-12 medium made it susceptible to bacterial contamination after 
prolonged incubation.  We prevented contamination by incorporating antibiotics in the F-  
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Figure 3.1 Isolation of Aβ(1-42) protofibrils and monomers using size exclusion 
chromatography. Dual peaks are observed following SEC elution of Aβ(1-42) 
reconstituted in NaOH/F-12. Lyophylized Aβ(1-42) (1.1 mg) was brought into solution 
with NaOH followed by supplemented F-12 media (250 μM). The supernatant after 
centrifugation was eluted from a Superdex 75 column and 0.5 ml fractions were 
collected. UV absorbance at 280 nm was monitored during the elution (solid line). 
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12 medium as described before in the methods and also carefully analyzed all of our 
experiments for any traces of bacterial contamination. However, to avoid these potential 
caveats, the use of artificial cerebrospinal fluid (aCSF) was explored for the isolation of 
Aβ(1-42) protofibrils.  Isolation of Aβ(1-42) protofibrils was carried out in an identical 
manner except that aCSF was used to dilute Aβ(1-42) reconstituted in NaOH as well as to 
elute Aβ from SEC.  Our aCSF composition was modified from the compositions 
described in the literature and contained 130 mM sodium chloride (NaCl), 3 mM 
potassium chloride (KCl), 1 mM sodium phosphate dibasic (NaH2PO4) and 15 mM 
sodium bicarbonate (NaHCO3).  Our aCSF preparation had comparable ionic strength (15 
mS/cm based on conductivity measurements) with F-12 medium although was devoid of 
glucose for preventing the likelihood of contamination.  Using aCSF we were able isolate 
Aβ(1-42) protofibrils and monomer, and the SEC-elution profile was identical to that 
with F-12 medium (data not shown). 
Aβ protofibrils are typically high molecular weight species, and therefore, scatter 
a substantial amount of light.  Scattering interferes with accurate concentration 
measurements based on UV in such a way that the concentrations are overestimated.  We 
were able to complement UV concentration measurements of protofibrils and monomers 
in aCSF by the BCA assay (carried out by Ben Ruck), which exhibited little to no 
background absorbance unlike F-12 medium (data not shown).  Furthermore, use of aCSF 
as elution buffer made the concentration estimation by quantitative amino acid analysis 
(QAAA) feasible, since F-12 medium contains a number of amino acids which would 
interfere with QAAA.  QAAA was carried out on our samples by Keck center, Yale 
University, and revealed that the monomer concentration closely matched the 
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concentration based on UV but the protofibril concentrations were overestimated as 
expected by almost 3 times the actual concentration (data not shown). 
 
 
 
3.3 Preparation of Aβ(1-42) fibrils from SEC-isolated monomer 
 
 
 
Our next goal was to prepare homogeneous solutions of Aβ(1-42) fibrils.  Many 
studies have utilized fibrils that are formed by incubating Aβ(1-42) solutions at higher 
temperatures or for longer time.  These solutions can exhibit some degree of 
polydispersity, and the presence of soluble species cannot be completely ruled out.  Some 
fibrillar preparations described in the literature used non-physiological conditions to form 
fibrils, which include acidic pH, low ionic strength and an absence of buffer (Stine, et al., 
2003).  Also, these solutions were prepared using HFIP-treated, lyophilized Aβ(1-42) 
peptide as a starting material.  In this case, the presence of pre-existing seeds or rapid 
formation of seeds cannot be ruled out owing to the high propensity of Aβ(1-42) for 
aggregation (Chapter 5).  So we wanted to take an extra step using SEC to obtain highly 
monomeric Aβ(1-42) solutions for fibril formation.  The monomer fraction obtained 
during protofibril separation using physiologically compatible F-12 medium was further 
subjected to gentle agitation for 72 h at 25⁰C.  After 72 h, the Aβ solution was 
centrifuged at 18000 g for 10 mins to pellet out the insoluble fibrils, and the supernatant 
was removed.  The pellet was resuspended in fresh F-12 cell culture medium to match the 
original monomeric concentration.  Conversion of SEC-isolated monomer to fibrils was 
monitored using ThT-fluorescence.  ThT is a benzothiazole dye which exhibits enhanced 
emission fluorescence at 482 nm when excited at 450 nm upon binding to amyloids 
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(LeVine, 1993).  The presence of β-sheet structure in the aggregates is an important 
element of the amyloid-ThT interaction. ThT fluorescence thus offers a common and 
relatively easy method to monitor the formation of β-sheet-containing aggregates in a 
particular Aβ solution (LeVine, 1993).  However, ThT is also shown to bind nucleic acids 
by intercalation (Canete, et al., 1987).  Khurana et al have shown that ThT can form 
micelles above critical micelle concentration of 4 μM in aqueous solutions (Khurana, et 
al., 2005).  Moreover, they suggested that the benzothiazole group is exposed at the 
surface of micelles, which can form a hydrogen bond with amyloid fibrils via the 
positively charged nitrogen on the thiazole group.  Thus they suggest that the interaction 
between Aβ fibrils and ThT can be both electrostatic and hydrophobic (Khurana, et al., 
2005).  The enhancement of ThT emission fluorescence decreases with decreasing pH of 
the amyloid solution.  Khurana and colleagues suggest that pH modulates the ionic 
interaction that forms ThT micelles, so at lower pH, the micelles are dissolved based on 
AFM analysis (Khurana, et al., 2005).   
ThT measurements of 72 h aggregation solution revaled that >98% ThT-
fluorescence was spun down as a pellet confirming the conversion of monomer into 
fibrils (Figure 3.2).  Furthermore, the fluorescence was recovered after reconstitution of 
the pellet.  Also, this isolation step was able to remove any soluble species from the fibril 
preparation, yielding a homogeneous fibril solution for our experiments. 
 
 
 
 
 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Preparation of Aβ(1-42) fibrils using SEC-isolated Aβ(1-42) monomer. 
SEC-isolated Aβ(1-42) monomer in F-12 cell culture medium was gently agitated for 
approximately 72 h at 25⁰C.  Resulting Aβ solution was then centrifuged at 18000 g for 
10 min, supernatant was removed and the insoluble pellet was resuspended in F-12 cell 
culture medium to match the original concentration of monomer.  Aβ total solution before 
centrifugation, 18000 g supernatant and the resuspended fibril pellet were diluted 10-fold 
in 5 μM ThT in 50 mM tris buffer (pH 8.0).  ThT-fluorescence scans were carried out as 
described in methods.  These data are representative of four different experiments. 
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3.4 Morphological analysis of Aβ(1-42) protofibrils and fibrils prepared from SEC-
isolated monomer by transmission electron microscopy 
 
 
 
We wanted to confirm the isolation of Aβ(1-42) protofibrils and fibrils 
morphologically using TEM.  TEM images of negatively stained protofibrils revealed 
classic curvilinear structures of <100 nm length (Figure 3.3 panel A).  These images are 
consistent with that reported by Walsh et al (Walsh, et al., 1997).  Estimated Aβ(1-42) 
protofibril length was 50 ± 16 nm (standard deviation, std dev) for n=50 measurements 
based on manual length measurements of unambiguous protofibril structures in the TEM 
image.   
Dynamic light scattering (DLS) measurements were carried out on peak 
protofibril fractions from seven separate SEC purifications (measurements carried out 
and analyzed by Dr. Michael R. Nichols). The average hydrodynamic radius (RH) was 21 
± 6 nm (std dev).  Deconvolution of the average RH values into histograms by data 
regularization revealed two predominant peaks of 4.5 ± 0.9 nm and 20.6 ± 6.5 nm. Peak 1 
with the smaller RH value was observed in 4 of 7 protofibril isolations while peak 2 was 
always observed.  Even within isolated Aβ(1-42) protofibrils, a degree of polydispersity 
was present as the peak 2 histogram widths varied from narrow (e.g. 15-20 nm) to broad 
(e.g. 8-41 nm) in different experiments.  
TEM images of negatively stained Aβ(1-42) fibrils revealed long fibers of > 1 μm 
length and 5-10 nm width (Figure 3.3 panel B).  Moreover, these fibrils were found to be 
laterally associated with each other, which might be due to the physiological ionic 
strength and pH of the F-12 cell culture medium.   
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Figure 3.3 Morphological analysis of Aβ(1-42) protofibrils and Aβ(1-42) fibrils 
prepared in F-12 medium.  Panel A. Protofibrils were diluted to 20 μM, applied to a 
copper formvar grid, and imaged by TEM at a magnification of 43,000. The scale bar 
represents 100 nm Panel B. TEM images of Aβ(1-42) fibril pellets (74 μM) (prepared as 
detailed in methods) at a magnification of 25,000. 
A                                    B 
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TEM images of Aβ(1-42) protofibrils and fibrils isolated in aCSF looked similar to those 
isolated in F-12 medium (data not shown).   
 
 
 
3.5 Thioflavin-T fluorescence studies on different aggregation states of Aβ(1-42) 
 
 
 
The utility of ThT fluorescence was discussed earlier in section 3.3 and it was 
used here to study different aggregation states s of Aβ(1-42) peptide including SEC-
isolated monomer, protofibrils and isolated fibrils.  Fibrils displayed the maximum ThT-
fluorescence/mole, which is consistent with their high β-sheet content (Figure. 3.4).  
Protofibrils displayed relatively less yet considerable ThT-fluorescence, whereas 
monomer showed very little to no ThT-fluorescence.  We have observed previously that 
freshly reconstituted Aβ(1-42) peptide possessed considerable ThT fluorescence, which 
suggests against its highly monomeric nature (data shown in chapter 5, figure 5.2).  By 
SEC, we were able to get highly monomeric solutions of Aβ(1-42) based on lack of ThT-
fluorescence (Figure 3.4).  Aβ(1-42) protofibrils and fibrils isolated in aCSF showed 
similar ThT-binding profile (data not shown). 
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Figure 3.4  ThT fluorescence measurements of Aβ(1-42) protofibrils, monomer and 
preformed fibrils Freshly isolated Aβ(1-42) protofibrils, monomers after elution from 
Superdex 75 in supplemented F-12  and preformed fibrils prepared using SEC-isolated 
monomer were diluted 10-fold in 5 μM ThT in tris buffer (pH 8.0) and fluorescence 
emission was measured as described in the Methods. 
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3.6 Aβ(1-42) protofibrils activated microglia but Aβ(1-42) fibrils or monomer did not 
 
 
 
Next, we wanted to investigate the ability of different aggregation states of Aβ(1-
42) namely, protofibrils, monomers and fibrils, to cause microglial activation.  
Production of proinflammatory molecules is one of the important outcomes of microglial 
activation  (Cacquevel, et al., 2004).  Moreover, AD brain is found to have elevated 
levels of tumor necrosis factor α (TNFα), which is a proinflammatory cytokine (Dickson, 
et al., 1993).  Homogeneous solutions of freshly isolated protofibrils, monomers and pre-
formed fibrils were added to the primary or BV-2 mouse microglial cells at a 
concentration of 15 μM under serum-free conditions as detailed in methods.  The cellular 
conditioned medium was collected after 6 h incubation at 37⁰C in 5% CO2 for further 
analysis using ELISA for TNFα production.  Surprisingly, fibrils failed to stimulate 
microglial TNFα production despite their maximum β-sheet content (Figure 3.5).  In fact, 
Aβ(1-42) protofibrils were the most effective inducers of microglial TNFα response, 
whereas Aβ(1-42) monomer was largely ineffective.  BV-2 microglia showed similar 
results (data not shown).  Most of the cell-stimulation experiments utilized freshly 
isolated protofibrils and monomers, yet we have observed that protofibrils continue to 
activate microglia even after continued incubation at 4⁰C after their isolation by SEC 
(data not shown).  However, we have not investigated this systematically.   
Moreover, freshly purified Aβ(1-42) protofibrils induced a dose-dependent pro-
inflammatory response when added at 5, 10, 15 and 20 μM concentration to the primary 
murine microglia (Figure 3.6 panel A) and BV-2 microglia (Figure 3.6 panel B).   
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Figure 3.5 Aβ(1-42) protofibrils are significant stimulators of primary mouse 
microglia while monomer and fibrils fail to stimulate microglia. Primary mouse 
microglia were plated in a medium without serum for 24 h. Freshly purified Aβ(1-42) 
protofibrils, monomers and preformed fibrils were added to the cells at a final 
concentration of 15 μM for 6 h at 37⁰C under serum-free conditions.  The conditioned 
medium was analyzed for TNFα production using ELISA.  Error bars represent the 
average ± std error of n=6. Control treatments with supplemented F-12 media produced 
15 pg/ml TNFα for primary microglia and were subtracted from Aβ-stimulated samples. 
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Figure 3.6 Concentration dependence of Aβ(1-42) protofibril-induced microglial 
TNFα response SEC-isolated Aβ(1-42) protofibrils in supplemented F-12 were 
incubated with primary microglia (Panel A) or BV-2 microglia (Panel B) for 6 h at final 
concentrations of 5, 10, 15, and 20 μM. Secreted TNFα was measured by ELISA in the 
conditioned medium. Data bars represent the average ± std error of n=4-6 trials at each 
concentration for primary microglia and n=6 trials at each concentration for BV-2 
microglia. Control treatments with supplemented F-12 media produced 6 and 17 pg/ml 
TNFα respectively for primary and BV-2 microglia and were subtracted from Aβ-
stimulated samples. Primary and BV-2 microglia were stimulated by Aβ in serum-free 
conditions. 
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SEC-isolated Aβ(1-42) protofibrils in aCSF were not only morphologically 
similar to those in F-12 cell culture medium but also were able to invoke a microglial 
proinflammatory response at the same concentration (15μM) (data not shown).  Also, the 
monomer isolated in aCSF did not activate microglia (data not shown).  These 
observations in turn support our earlier observation that Aβ(1-42) protofibrils act as  
strong inflammatory stimuli (Figure 3.5).  Also, it is likely that the actual protofibril 
concentration in the cellular treatment was much less than 15 μM based on QAAA for 
protofibrils in aCSF.  For both experiments, the background TNFα response was found 
out to be very low as assessed using the buffer vehicle for Aβ and was subtracted from 
Aβ-induced response. 
 
 
 
3.7 Aβ(1-42) protofibril induced TNFα production in non-toxic manner and was 
independent of trace levels of contaminating bacteria or endotoxins 
 
 
 
3.7.1 Aβ(1-42) protofibril induced TNFα production in non-toxic manner 
 
 
Aβ(1-42) protofibrils have been shown to be neurotoxic (Hartley, et al., 1999; 
O'Nuallain, et al., 2010).  We wanted to ensure that Aβ(1-42) protofibril-induced TNFα 
production in murine microglia was solely the result of the Aβ-challenge, rather than any 
compromise in cellular health or cytotoxicity.  Also, conditioned medium of microglial 
cells challenged with Aβ have been previously shown to confer neurotoxicity via TNFα 
(Floden, et al., 2005).  Therefore, it was important to find out if Aβ(1-42) protofibrils are 
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exerting toxicity to microglia themselves.  We made use of the XTT [2, 3-bis (2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cell proliferation assay 
(Scudiero, et al., 1988) to assess microglial health after treatment with Aβ.  As described 
in methods, XTT is a tetrazolium derivative that can be reduced by mitochondrial 
enzymes to a colored product which absorbs at 467 nm.  The intensity of color is directly 
proportional to the mitochondrial metabolism, which in turn reflects the cellular health.  
We incubated BV-2 and primary mouse microglia pretreated for 6 h with Aβ(1-42) 
protofibrils, fibrils or monomer in the presence of XTT as detailed in the methods.  After 
2 h of incubation, the reduced form of XTT was read at 467 nm.  The XTT cell 
proliferation assay showed high absorbance values for microglial cells treated with Aβ(1-
42) protofibrils.  Moreover, there was no significant difference in XTT reduction between 
cells treated with protofibrils and cells treated with buffer vehicle or lipopolysaccharide 
(LPS) (Figure 3.7).  This observation suggests that Aβ(1-42) protofibrils activate 
microglia in a non-toxic manner.  BV-2 microglia pretreated with Aβ(1-42) fibrils were 
non-toxic to microglia as well.  Consequently, the possibility of fibrils being neurotoxic 
was also ruled out.  Similar results were obtained for primary mouse microglia 
confirming the non-toxic nature of Aβ(1-42) protofibrils and fibrils to microglia. 
 
 
3.7.2 Aβ(1-42) preparations were free of traces of endotoxin or bacterial 
contamination 
 
Bacterial endotoxins such as LPS are known to elicit a TNFα response by 
microglia.  To assess the presence of contaminating bacteria, the XTT assay was also  
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Figure 3.7 Aβ(1-42) protofibrils activated microglia in a non-toxic manner. BV-2 
microglia pretreated with Aβ(1-42) protofibrils, monomer or fibrils were incubated with 
XTT and PMS for 2 h at 37⁰C as detailed in methods.  The absorbance was read at 467 
nm.  LPS (3 ng/ml) and F-12 medium was used as control n=6 for samples (black bars), 
n=3 for controls (hatched bars) 
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employed in a cell-free manner.  Different Aβ(1-42) preparations including monomer, 
protofibrils and fibrils were incubated at the same concentration of 15 μM in the presence 
of 0.33 mg/ml XTT and 8.3 μM PMS solution for 6 h as detailed in methods.  In other 
words, the XTT assay was carried out in parallel to cellular treatment in the absence of 
microglia.  So any bacterial presence was expected to reduce XTT which could be 
compared to control wells with sterile buffer vehicle.  We did not see any significant 
reduction of XTT as compared to controls (Figure 3.8) suggesting that our Aβ(1-42) 
preparations are devoid of bacterial contamination. 
The presence of trace levels of endotoxins was also assessed by utilizing a 
polymyxin B neutralization assay (Meda, et al., 1995; Udan, et al., 2008).  Polymyxin B 
is an antibiotic, which neutralizes the endotoxin-induced proinflammatory response by 
binding to endotoxin (Storm, et al., 1977).  Addition of polymyxin-B to the microglia 
(100 ng/ml) was able to block LPS (3 ng/ml)-induced TNFα production, while it had no 
effect on Aβ(1-42) protofibril (15 μM)-induced TNFα production (Figure 3.9). 
 
 
 
3.8 Size-exclusion chromatography isolation of Aβ(1-40) and Aβ(1-40) E22G (Arctic) 
protofibrils  
 
 
 
Aβ(1-42) was able to form classical curvilinear protofibrils immediately after 
reconstitution with NaOH/F-12.  We wanted to examine if other variants of Aβ peptide 
such as Aβ(1-40) and Aβ(1-40) E22G (Arctic) can form protofibrils under similar 
conditions.  Interestingly, Aβ(1-40) peptide (1.2 mg) did not form any protofibrils when  
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Figure 3.8 The preparations of Aβ(1-42) protofibrils, monomer and pre-formed 
fibrils are endotoxin-free.  Freshly purified Aβ(1-42) protofibrils, monomers and fibrils 
prepared using SEC-isolated monomer were incubated with XTT and PMS for 6 h at 
37⁰C.  The final concentration of Aβ was 15 μM.  For the negative control, F-12 cell 
culture medium was incubated with XTT and PMS at the same volume as Aβ sample.  
The reduction of XTT was read at 467 nm. 
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Figure 3.9 Polymyxin B did not affect Aβ(1-42) protofibril-induced TNFα response 
in primary murine microglia.  Primary murine microglia were plated in serum-free 
medium for 24 h.  Freshly purified Aβ(1-42) monomer (M) and protofibrils (PF) were 
added to the microglia at a final concentration of 15 μM.  In some wells, PMX-B was 
added at a final concentration of 100 ng/ml. Lipopolysaccharide (LPS) (3 ng/ml) was 
used as a positive control.  As negative control, F-12 medium was added at the same 
volume as each monomer and protofibril sample.  The cells were incubated for 6 h at 
37⁰C.  The conditioned medium was analyzed using ELISA for TNFα production. 
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separated on SEC right after its reconstitution in NaOH/supplemented F-12 in an 
identical manner as Aβ(1-42).  In fact, all of the Aβ(1-40) peptide eluted as monomer in 
the included peak (Figure 3.10, dashed line).  Incubation of Aβ(1-40) for 24 h at 25⁰C 
was required to generate significant amount of protofibrils after reconstitution in 
NaOH/supplemented F-12 (Figure 3.10, solid line).  Also, most of the ThT-fluorescence 
stayed in the 18000 g supernatant of Aβ(1-40) solution after 24 h (data not shown), which 
indicated the formation of protofibrils, consistent with ThT-binding nature of soluble 
protofibrils.   
The intra-Aβ mutation E22G (Arctic mutation) was first found to be associated 
with AD in a family from Sweden (Nilsberth, et al., 2001).  Interestingly, this mutation 
causes rapid formation of protofibrils (Nilsberth, et al., 2001).  In our studies, Aβ(1-40) 
E22G (Arctic) mutant resuspended in NaOH/F-12 was able to form protofibrils as soon 
as 3 h after incubation at 25⁰C.  However, prolonged incubation for 24 h did not 
significantly change the amount of protofibrils formed (Figure 3.11).  In agreement with 
Lashuel et al, we observed that E22G mutation was able to accelerate the formation of 
protofibrils as compared to the wild type Aβ(1-40) (Lashuel, et al., 2003). 
 
 
3.9 Biophysical and morphological characterization of Aβ(1-40) and Aβ(1-40) E22G 
(Arctic) protofibrils 
 
 
Both Aβ(1-40) and Aβ(1-40) E22G protofibrils exhibited greater ThT 
fluorescence per mole than the monomers, similar to Aβ(1-42) protofibrils (Figure 3.12 
Panel A and C).   
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Figure 3.10 Aβ(1-40) protofibrils require longer incubation for formation. Aβ(1-40) 
was reconstituted and prepared for SEC as described in the Methods. Aβ(1-40) solutions 
were eluted on Superdex 75 immediately (dashed line) or after a 24 hr incubation at 25°C 
(solid line). Fractions containing protofibrils and monomers were immediately placed on 
ice for further characterization. Concentrations were determined by UV absorbance. 
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Figure 3.11 SEC-isolation of Aβ(1-40)E22G (Arctic) protofibrils. Aβ(1-40) E22G was 
reconstituted and prepared for SEC as described in the Methods. Aβ(1-40) solutions were 
eluted on Superdex 75 after 3 h incubation at 25°C (solid line) or after a 24 h incubation 
at 25°C (dashed line). Fractions containing protofibrils and monomers were immediately 
placed on ice for further characterization. Concentrations were determined by UV 
absorbance. 
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Figure 3.12  Structure and morphology of Aβ(1-40) and Aβ(1-40) E22G (Arctic) 
protofibrils.  Panel A  Freshly purified Aβ(1-40) protofibrils and monomers were diluted 
in 5 μM ThT in tris buffer (pH 8.0) and ThT fluorescence measurements were carried out 
as described in methods and normalized to 5 μM [Aβ]. Panel B.  TEM image of a sample 
taken from the Aβ(1-40) protofibril peak. Sample was diluted to 20 μM Aβ, applied to a 
copper formvar grid as described in the Methods, and imaged at a magnification of 
43,000. The scale bar represents 100 nm. Panel C. Freshly purified Aβ(1-40) E22G 
(Arctic) protofibrils and monomers were diluted in 5 μM ThT in tris buffer (pH 8.0) and 
ThT fluorescence measurements were carried out as described in methods and 
normalized to 5 μM [Aβ]. Panel D. TEM image of a sample taken from the Aβ(1-40) 
E22G (Arctic) protofibril peak.  Sample (22 μM) applied to a copper formvar grid as 
described in the Methods, and imaged at a magnification of 43,000.  The scale bar 
represents 100 nm. 
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Aβ(1-40) protofibrils displayed curvilinear structures < 100 nm in length when analyzed 
using TEM (Figure 3.12 Panel B).  Estimated Aβ(1-40) protofibril length was 27 ± 11 nm  
(standard deviation, std dev) for n=50 measurements based on manual length 
measurements of unambiguous protofibril structures in the TEM image.  Length 
measurements revealed that Aβ(1-40) protofibrils were significantly shorter than  
Aβ(1-42) protofibrils.  Aβ(1-40) E22G (Arctic) protofibrils appeared to have similar 
curvilinear structure (Figure 3.12 Panel D) as both Aβ(1-42) and Aβ(1-40) protofibrils 
although the image quality was not good enough to carry out manual length 
measurements.  Qualitatively, Aβ(1-40) E22G protofibrils appeared to have lengths 
between 50-100 nm. 
 
 
 
3.10 Neither Aβ(1-40) nor Aβ(1-40) E22G (Arctic) protofibrils stimulated significant 
microglial proinflammatory response 
 
 
 
Previously we have shown that Aβ(1-42) protofibrils are potent activators of 
microglia (Figure 3.5).  Next, we wanted to investigate microglial activation by Aβ(1-40) 
and Aβ(1-40) E22G (Arctic) protofibrils.  Both BV-2 and primary murine microglia were 
stimulated either with 15 μM Aβ(1-40) protofibrils or 15 μM Aβ(1-40) E22G protofibrils 
isolated by SEC.  Conditioned medium after 6 h treatment was analyzed for TNFα 
production by ELISA.   
Interestingly, both freshly purified Aβ(1-40) (Figure 3.13 Panel A) and Aβ(1-40) 
E22G (Arctic) protofibrils (Figure 3.13 Panel B) failed to stimulate primary murine  
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Neither Aβ(1-40) nor Aβ(1-40) E22G (Arctic) were potent activators of 
microglia. Panel A. Freshly purified Aβ(1-40) protofibrils or pre-isolated Aβ(1-42) 
protofibrils were added to the primary murine microglia at a final concentration of 15 μM 
for 6 h at 37⁰C under serum-free conditions.  The conditioned medium was analyzed by 
ELISA for TNFα production.  Panel B. Freshly purified Aβ(1-40) E22G (Arctic) 
protofibrils or pre-isolated Aβ(1-40) or Aβ(1-42) were added to the primary microglia at 
15 μM for 6 h at 37⁰C under serum-free conditions.  The conditioned medium is analyzed 
for TNFα production by ELISA. 
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microglia in comparison to Aβ(1-42) protofibrils.  The only caveat is that the Aβ(1-42) 
protofibrils used in these studies were not freshly purified because of the logistics of the 
experimental span.  We were still able to see a marked difference between Aβ(1-42) 
protofibrils and freshly purified Aβ(1-40) or Aβ(1-40) E22G (Arctic) protofibrils.   
LPS (3 ng/ml) was used as a positive control and was able to stimulate microglial TNFα 
production.  All the protofibril samples were carefully checked for any traces of bacterial 
contamination by means of cell-free XTT assay as described in methods.  No significant 
difference in XTT reduction was observed between Aβ samples and their respective 
controls indicating that they are free of any bacterial contamination (Figure 3.14).  A 
cellular XTT proliferation assay carried out in parallel to cellular stimulation studies 
showed that none of the protofibrils were toxic to the primary murine microglia (Figure 
3.15). 
 
 
 
3.11 Aβ(1-42) protofibril-induced microglial TNFα response was influenced by serum 
concentration in the assay medium 
 
 
 
Microglial TNFα response to LPS is known to be influenced by the concentration 
of serum in the cellular medium during treatment (Cooper, et al., 2002).  It was 
interesting to find out if serum concentration also has an effect on Aβ(1-42) protofibril-
induced TNFα production.  Serum is believed to have a complex composition with a 
variety of proteins.  Some of the serum proteins like Apo E appear to have effects on Aβ-  
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Figure 3.14 Aβ(1-40) and Aβ(1-40) E22G (Arctic) protofibrils are endotoxin-free.  
15μM freshly purified Aβ(1-40) E22G (Arctic), pre-formed Aβ(1-40) WT, pre-formed 
Aβ(1-42) protofibrils) were incubated further with XTT and PMS for 6 h at 37⁰C.  XTT 
solution was used to assess the background reduction.  The reduction of XTT was 
monitored at 467 nm.  Solid data bars represent Aβ samples and shaded bars represent 
respective buffer controls or XTT as labeled. 
A
b
s
 X
T
T
re
d
 
0.00
0.04
0.08
A 40
Arctic
A 42
WT
A 40
WT
XTT
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Aβ(1-40) and Aβ(1-40) E22G (Arctic) protofibrils are non-toxic to 
mouse microglia.  Primary murine microglia  pre-incubated with 15μM freshly purified 
Aβ(1-40) E22G (Arctic), pre-formed Aβ(1-40) WT, pre-formed Aβ(1-42) protofibrils, 
LPS(3 ng/ml) were incubated further with XTT and PMS for 2 h at 37⁰C.  F-12 medium 
was used as negative control.  The reduction of XTT was monitored at 467 nm.  Solid 
data bars represent Aβ or LPS treated cells and shaded bars represent respective buffer 
controls 
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aggregation.  It is commonplace to use serum-free or reduced serum medium during cell 
stimulation assays involving Aβ (Sondag, et al., 2009).   
We plated BV-2 microglia in a medium containing 5% FBS (BV-2 microglial 
growth medium) overnight.  Next day, the medium was removed and replenished with 
media containing 5% (same as growth medium), 2% or 0% FBS.  These assay media 
were identical to the growth medium except for the serum content.  Prior to 
replenishment, the microglial cells were washed 1X with the respective assay medium.  
Aβ(1-42) protofibrils were isolated in aCSF and added to the microglia at 15 μM final 
concentration for 6 h.   
Subsequent analysis of conditioned medium by ELISA showed that serum 
concentration does influence Aβ(1-42) protofibril-induced TNFα production (Figure 
3.16).  We observed that the extent of TNFα response was maximum in the serum-free 
medium followed by medium containing 2% FBS.  The extent of response was reduced 
under 5% serum conditions.  Similar results were observed for primary murine microglia.  
Moreover, presence or absence of serum during plating of primary microglia did not 
seem to have any effect on the Aβ(1-42) protofibril-induced TNFα production.  The exact 
reason for this discrepancy was not investigated in the current study. 
 
 
 
3.12 Discussion 
 
 
 
This study reports the robust activation of murine microglia by Aβ(1-42) 
protofibrils.  SEC purified Aβ(1-42) protofibrils were able to cause a significant TNFα  
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Figure 3.16  Both Aβ(1-42) protofibril and LPS-induced microglial TNFα 
production is influenced by serum conditions during Aβ or LPS-stimulation. Panel 
A. BV-2 microglia were plated overnight in a medium containing 5% serum.  Freshly 
purified Aβ(1-42) protofibrils isolated in aCSF were added to the BV-2 microglia at a 
final concentration of 15 μM under 5, 2 or 0% serum conditions for 6 h at 37⁰C. The 
TNFα production was measured by ELISA.  Panel B. BV-2 microglia were plated 
overnight in a medium containing 5% serum.  LPS (3 ng/ml) was added to BV-2 
microglia for 6 h under 5, 2 or 0% serum conditions.  The conditioned medium was 
analyzed by ELISA for TNFα production. 
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production in murine microglia while Aβ(1-42) fibrils isolated from SEC-purified 
monomer were largely ineffective.  Previously we have reported that soluble fibrillar  
precursors are optimal proinflammatory stimulus for THP-1 monocytes (Ajit, et al., 
2009).  Since protofibrils are considered as the latest precursor during fibril formation, 
the current study is in agreement with our findings in THP-1 monocytes.   
Although THP-1 monocytes are regarded as a well-accepted model system for microglia 
(Combs, et al., 2001), the current investigation of Aβ-induced inflammation in microglial 
cell system is biologically more relevant in the context of Alzheimer’s disease. 
In vitro aggregation studies have identified different oligomeric intermediates of 
Aβ, which possess distinct structure and biological activity.  Importantly, specific 
antibodies developed against these oligomers were able to react with Aβ deposits within 
the AD brain (Gong, et al., 2003; Kayed, et al., 2003; Lasagna-Reeves and Kayed, 2011).  
Thus amyloid plaques are no longer considered to be solely fibrillar, but in fact, are 
believed to represent an environment where multiple Aβ species are in complex dynamic 
equilibrium.  Recent studies using multiphoton imaging have shown rapid recruitment of 
microglia to the nascent plaques in a mouse model of AD (Meyer-Luehmann, et al., 
2008).  Upon exposure to Aβ, microglia undergo activation and secrete significant 
amount of proinflammatory molecules resulting into a state of chronic inflammation in 
the AD brain (Dickson, et al., 1993).  Several studies have indicated a close association 
of microglia with amyloid plaque (Dickson, et al., 1988; Eikelenboom, et al., 2011).  Due 
to the complex plaque environment, it is possible that multiple Aβ species can cause 
microglial activation.  In fact, oligomers and fibrils have been shown to cause differential 
activation of microglia (Parvathy, et al., 2009; Sondag, et al., 2009).   
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Our study demonstrates that SEC-isolated Aβ(1-42) protofibrils act as an effective 
stimulus for microglial proinflammatory response.  Original Aβ protofibril preparation by 
Walsh et al consisted of the use of phosphate buffered saline (PBS) (Walsh, et al., 1997).  
We modified this procedure by replacing PBS with physiological F-12 cell culture 
medium having a higher ionic strength.  This method resulted into classic curvilinear 
protofibrils, < 100 nm in length, consistent with those observed by Walsh et al.  Our 
protofibril preparation showed considerable ThT-fluorescence in agreement with their β-
sheet content as shown by hydrogen-deuterium exchange studies (Kheterpal, et al., 2003).  
Our isolated fibril preparation exhibited the maximum ThT-fluorescence, but it failed to 
produce any TNFα response in murine microglia.  This finding is different from many 
other studies where fibrils were shown to activate microglia (McDonald, et al., 1997; 
Combs, et al., 2001; Stewart, et al., 2010).  One explanation for this observation may lie 
in our fibril preparation, which involved centrifugation of the aggregation solution 
followed by resuspension of insoluble fibrils, and therefore was devoid of any soluble 
species (Figure 3.2).  Many of the studies investigating Aβ-induced inflammation have 
used solution conditions which are likely to result in polydisperse Aβ solutions.  Such 
polydisperse solutions may lead to inconsistencies in the experimental results, making it 
less straightforward to interpret the exact species responsible for the biological effect.   
Previously, microglia have been shown to interact with Aβ via multiple receptors 
including scavenger receptors (El Khoury, et al., 1996) and toll-like receptors (TLRs) 
(Walter, et al., 2007; Udan, et al., 2008).  CD36 forms a heterotrimeric complex with 
TLR4 and TLR6 and has been found to mediate an Aβ fibril-induced proinflammatory 
response (Stewart, et al., 2010). Moreover, this study did not observe an Aβ fibril-
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mediated proinflammatory response via TLR2.  However, more recently, TLR2 was 
shown to be a primary receptor for Aβ-oligomer induced inflammation (Liu, et al., 2011).  
It may be possible that different receptors mediate the interaction between Aβ and 
microglia at different stages of disease progression.  The receptors mediating Aβ-
protofibril induced signaling have not been investigated.  It is possible that protofibrils 
share the same receptor molecules with fibrils for interaction with microglia due to 
similarity in their structures (Kheterpal, et al., 2006).   
Interestingly, the current study also shows the difference between Aβ(1-42) 
protofibrils and Aβ(1-40) or Aβ(1-40) E22G (Arctic) protofibrils in their ability to 
stimulate microglia.  Arctic mutation E22G is an intra-Aβ mutation that causes a familial 
form of AD.  This mutant peptide displayed enhanced rate of formation of protofibrils as 
compared to Aβ(1-40)WT (Nilsberth, et al., 2001).  Interestingly, the arctic mutation did 
not influence the ability of Aβ(1-40) protofibrils to evoke a TNFα response comparable 
to Aβ(1-42).  In contrast to Aβ(1-42), both WT and Arctic Aβ(1-40) were ineffective in 
stimulating microglia at a concentration of 15 μM.  Morphological analysis using TEM 
revealed that protofibrils of all Aβ variants used in this study were curvilinear structures, 
which were soluble at 18000 g.  However, manual length measurements of unambiguous 
protofibrils in the TEM image have indicated that Aβ(1-40) protofibrils are significantly 
shorter than Aβ(1-42) protofibrils.  One important caveat in such cellular stimulation 
studies is that the stability of the Aβ aggregation state is usually assumed over the course 
of stimulation.  It is possible that in a complex cellular environment, the structure of Aβ 
added might change significantly over time.  Therefore, one possibility for such a 
discrepancy might be related to the differences in their stability during the course of 
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cellular treatment.  However, we observed differences in the kinetics of protofibril 
formation between different Aβ variants, and the findings were similar to a study by 
Lashuel et al (Lashuel, et al., 2003).   
Together, the current study demonstrates that Aβ(1-42) protofibrils activate 
murine microglia significantly while the insoluble fibrils formed under physiological pH 
and higher ionic strength failed to do so.  Furthermore, the ability to produce a substantial 
TNFα response was limited only to Aβ(1-42) protofibrils whereas protofibrils of Aβ(1-
40) WT or Arctic mutant of Aβ(1-40) prepared in a similar manner did not stimulate 
microglia.   
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CHAPTER 4 
MICROGLIAL ACTIVATION BY STINE ET AL Aβ(1-42) OLIGOMER-FORMING 
AND FIBRIL-FORMING CONDITIONS 
 
 
 
4.1 Introduction 
 
 
 
Amyloid plaques and neurofibrillary tangles (NFTs) are signature proteinaceous 
lesions found in the brain of Alzheimer’s disease (AD) patients (Selkoe, 2004).  
Amyloid-β (Aβ) protein is a major component of amyloid plaques (Glenner and Wong, 
1984) whereas hyperphosphorylated tau protein constitutes NFTs (Grundke-Iqbal, et al., 
1986).  Both of these constituent proteins are found in the human body in unaggregated 
monomeric forms under normal conditions, yet it is their aggregated form that marks the 
AD pathology (Grundke-Iqbal, et al., 1985; Seubert, et al., 1992; Shoji, et al., 1992).  
Although the complete mechanism of how AD pathogenesis is initiated is not entirely 
clear, genetic evidence points towards Aβ aggregation as a central event in the process 
(Hardy and Higgins, 1992).  Amyloid precursor protein (APP) undergoes sequential 
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proteolysis by three secretases named α,β and γ to form Aβ protein of varying amino acid 
length at the carboxy-terminus (Sisodia, et al., 1990).  Aβ protein is a highly amphipathic 
molecule and has a propensity to aggregate into long fibrils.  Based on in vitro 
aggregation studies, Aβ can form a variety of intermediate oligomeric species of a wide 
range of sizes and structures such as protofibrils, amyloid-derived diffusible ligands 
(ADDLs) and annular protofibrils (Walsh, et al., 1997; Lambert, et al., 1998; Dahlgren, et 
al., 2002; Kayed, et al., 2003; Stine, et al., 2003; Kayed, et al., 2009).  It is not very clear 
if all the intermediate species results into fibril formation or they represent off-pathway 
end products.  Many of these studies have modulated solution conditions to generate a 
particular Aβ species.  Some of the solution conditions include non-physiological buffers 
and small quantities of organic solvents (Kayed, et al., 2003; Stine, et al., 2003; Kayed, et 
al., 2009).  The contribution of such excipients towards Aβ aggregation is not very clear.  
However, antibodies developed against such intermediates were able to react with Aβ 
deposits in the AD brain indicating their biological relevance (Gong, et al., 2003; Kayed, 
et al., 2003; Lasagna-Reeves and Kayed, 2011).  There is increasing evidence that 
although fibrillar Aβ forms the core of the plaque, oligomeric species are present within 
and surrounding the plaques, making the plaque environment more complex than once 
thought (DaRocha-Souto, et al., 2011).  Although studies of Aβ oligomers have led to 
increased understanding of the mechanisms involved in AD pathogenesis, some caveats 
remain to be addressed.  In the absence of high resolution structures of different 
oligomeric species, a lot of structural characterization is based on gel-based techniques 
(Bitan, et al., 2005).  However, considerably more structural characterization is available 
for protofibrils based on hydrogen-deuterium exchange studies (Kheterpal, et al., 2003).  
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Moreover, there is discrepancy in the nomenclature of different oligomers.  The current 
nomenclature of oligomers is loosely based on the morphology.  The structural 
relationship between different oligomers is still quite unclear. 
Apart from the fact that Aβ oligomers have been detected in the AD brain, they 
also exhibit biological activity in vitro.  Aβ oligomers have been shown to be potent 
synaptotoxins, which inhibit long term potentiation, alter synaptic transmission(Lambert, 
et al., 1998; Hartley, et al., 1999; Dahlgren, et al., 2002).  Other than being neurotoxic, 
Aβ also results in the activation of brain immune cells such as microglia and induces 
significant inflammatory processes (Meda, et al., 1995; McDonald, et al., 1997; Combs, 
et al., 2001).  Extensive inflammation is another characteristic of AD pathology apart 
from the presence of proteinaceous lesions in the brain of an individual (Dickson, et al., 
1988).  Inflammation in AD is marked by activation of glial cells (astrocytes and 
microglia) to produce a plethora of inflammatory molecules, a condition referred to as 
gliosis (Akiyama, et al., 2000; Apelt and Schliebs, 2001).  Some of these inflammatory 
molecules include tumor necrosis factor α (TNFα), interleukin 1β (IL-1β), and  reactive 
oxygen species (ROS) (Akiyama, et al., 2000).  Recently, oligomeric Aβ was found to be 
positively correlated with gliosis, while the total plaque burden reached a plateau 
(Serrano-Pozo, et al., 2011).  Activated microglia are found in the close proximity of 
plaque periphery, which was recently shown to be immunoreactive to anti-oligomeric Aβ 
antibody (DaRocha-Souto, et al., 2011).  Aβ(1-42)-oligomers were found to be more 
effective than fibrils in provoking a proinflammatory response in rat astrocytes in vitro 
(White, et al., 2005).  Oligomers might provide an explanation to explain the early 
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synaptic and inflammatory changes even before the development of mature amyloid 
plaques (Rahimi, et al., 2008; Hyman, 2011).   
In this study, we compared microglial activation between soluble Aβ(1-42) 
oligomers formed in F-12 cell culture medium and Aβ(1-42) fibrils formed under acidic 
conditions.  We prepared the Aβ aggregation solutions based on the original protocol by 
LaDu and colleagues (Stine, et al., 2003).  We have further extended the biophysical 
analysis of oligomers and fibrils by the use of thioflavin-T (ThT) fluorescence 
measurements, size-exclusion chromatography (SEC) and imaging techniques. 
 
 
 
4.2 Preparation of Aβ(1-42) oligomers and fibrils based on Stine et al 
 
 
 
Aβ aggregation is influenced by a variety of physical factors including pH, 
temperature, ionic strength, mechanical strength and nature of excipient.  Lambert et al 
originally prepared amyloid-derived diffusible ligands (ADDLs) by resuspending Aβ(1-
42) in dimethyl sulfoxide (DMSO) followed by further dilution using F-12 cell culture 
medium without phenol red in the presence or absence of ApoJ protein (Lambert, et al., 
1998).  F-12 medium is a common cell culture medium which has physiological pH and 
ionic strength (16 mS/cm as determined by conductivity measurement).  This medium 
contains a variety of amino acids and co-factors like other cell culture media 
(www.invitrogen.com).  LaDu and colleagues optimized the oligomer-forming and fibril 
forming conditions for Aβ(1-42).  Their oligomeric preparation is similar to the ADDLs 
preparation but was devoid of ApoJ protein (Stine, et al., 2003).  Moreover, they 
extensively characterized the oligomer and fibril forming conditions using various 
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biophysical techniques.  We took advantage of Stine et al protocol to prepare Aβ(1-42) 
oligomers and fibrils (Stine, et al., 2003).   
Synthetic Aβ(1-42) peptide was dissolved in 100% hexafluoroisopropanol (HFIP) 
to give 1 mM Aβ solution.  The solution was incubated at 1 h at 25⁰C followed by 
aliquotting.  HFIP was allowed to evaporate overnight under the chemical fume hood.  
Any residual HFIP was removed by vacuum-centrifuging for approximately 1 h, and the 
aliquots were stored at -20⁰C.  For making Aβ(1-42) oligomers, one aliquot was 
resuspended in anhydrous DMSO to give 5 mM Aβ, followed by further dilution into ice-
cold F-12 cell culture medium without phenol red at a final concentration of 100 μM.  
This solution was vortexed for 15 seconds and further incubated at 4⁰C for 24 h to form 
Aβ(1-42) oligomers. 
For preparation of Aβ(1-42) fibrils, a HFIP-pretreated and lyophilized Aβ aliquot 
was resuspended at 5 mM concentration in DMSO as described above.  The Aβ solution 
was then diluted into 10 mM HCl (pH was determined to be 2.3 and ionic strength 4 
mS/cm using conductivity measurements) to give a final concentration of 100 μM, 
vortexed for 15 seconds and incubated at 37⁰C for 24 h to form fibrils. 
 
 
 
4.3 Morphological analysis of Aβ(1-42) oligomers and fibrils using atomic force 
microscopy (AFM) 
 
 
 
We carried out morphological analysis of our oligomer and fibril preparation 
using AFM.  10 μl of Aβ oligomers or fibrils (10 μM) was applied on freshly cleaved 
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mica and imaged by AFM (Sample preparation and subsequent imaging was done by 
Lisa K. Gouwens) (Figure 4.1).  Aβ oligomer preparation contained small punctate 
globular species.  Moreover, it was completely devoid of any fibrillar structures.  Heights 
of oligomers were 3.1 ± 1.2 nm for n=100 measurements. The fibril preparation 
contained long flexible fibers (heights 2.7 ± 0.9 nm for n=100 measurements).  The 
lengths of fibrils were > 1 μm. 
 
 
 
4.4 ThT-fluorescence studies on Aβ(1-42) oligomers and fibrils  
 
 
 
Thioflavin-T fluorescence studies (discussed previously in Chapter 3 Section 3.3) 
were carried out on both Aβ(1-42) oligomer and fibril preparations after 24 h (Figure 
4.2).  Fibril displayed maximum ThT-binding.  Oligomers showed lesser yet considerable 
ThT fluorescence.  Interestingly, we observed that Aβ solutions exhibited considerable 
ThT fluorescence right after their reconstitution into either oligomer forming medium or 
fibril forming medium.  Particularly, the extent of ThT fluorescence for oligomer 
preparation did not change over the course of 24 h at 4⁰C.  On the contrary, fibril 
preparation showed a significant change over 24 h.   
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Figure 4.1 Aβ(1-42) structures formed in oligomer- or fibril-forming conditions are 
morphologically distinct. Aliquots of lyophyllized Aβ(1-42) were reconstituted to 100 
μM as described in the Methods to generate oligomers or fibrils. After 24 hr incubation at 
the given temperatures, aliquots of the solutions were diluted to 10 μM, applied to mica 
and imaged by AFM. Representative images are shown for oligomers (Panel A, 5 μm x 5 
μm) and fibrils (Panel B, 10 μm x 10 μm). 
A                                         B 
143 
 
 
 
 
 
 
 
 
 
 
Figure 4.2  Aβ(1-42) Oligomers and fibril preparations are structurally different. 
ThT fluorescence measurements (n=8 for oligomers and n=10 for fibrils) were obtained 
for each preparation at a final concentration of 10 μM Aβ(1-42) right after reconstitution 
(0 h) or after 24 h incubation at 4⁰C for oligomers (Panel A) and 37⁰C for fibrils (Panel 
B) 
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4.5 Aβ(1-42) oligomers induced microglial TNFα response to a larger extent than Aβ(1-
42) fibrils 
 
 
 
Cell stimulation experiments were carried out using Aβ(1-42) oligomers and 
fibrils on BV-2 and primary mouse microglia.  BV-2 microglia were plated in a 96-well 
cell culture plate in the growth medium containing 5% serum for overnight at 37⁰C.  
Aβ(1-42) oligomer or fibril solution was added at a final concentration of 15 μM for 6 h 
under reduced serum conditions (2% serum).  Primary microglia were treated with 
oligomers and fibrils in the identical manner as BV-2 microglia except that primary 
murine microglia were plated in a serum-free medium for 2 h prior to the treatment with 
Aβ under serum-free conditions.  When the conditioned medium for both BV-2 and 
primary microglia was analyzed using TNFα ELISA, we observed that Aβ(1-42) 
oligomers were more effective in stimulating microglial TNFα production than Aβ(1-42) 
fibrils (Figure 4.3).  Despite possessing higher ThT-fluorescence, fibril preparations were 
significantly weaker in stimulating microglial proinflammatory response (Figure 4.2 and 
4.3). 
 
 
 
4.6 Aβ(1-42) oligomers were not toxic to microglia 
 
 
 
TNFα response can be induced as a result of compromised cellular health 
associated with toxicity.  We wanted to investigate if Aβ(1-42) oligomers are stimulating 
the release of microglial TNFα as a result of their toxicity.  We made use of XTT [2, 3- 
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Figure 4.3  Aβ(1-42) oligomers stimulate microglia more effectively than fibrils. 
Solutions of Aβ(1-42) oligomers and fibrils were incubated with microglia at a final 
concentration of 15 μM for 6 hrs. Secreted TNFα was measured by ELISA in the 
conditioned medium collected from treated primary murine microglia (Panel A) and 
(Panel B) BV-2 murine microglia. Data bars represent the average ± standard (std) error 
of n=30 trials (oligomers and fibrils) for primary microglia and n=32 trials (oligomers) 
and n=33 trials (fibrils) for BV-2 microglia. Control treatments in the presence of 0.3 % 
DMSO in F-12 media or 1.5 mM HCl produced 40 and 15 pg/ml TNFα respectively for 
primary and BV-2 microglia and were subtracted from Aβ-stimulated samples. Primary 
and BV-2 microglia were stimulated in serum-free and 2% FBS medium respectively. 
Statistical differences between oligomers and fibrils for both sets of data had p values 
<0.001. 
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bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cell proliferation 
assay (Scudiero, et al., 1988) to assess microglial health after treatment with Aβ.  As 
described in methods, XTT is a tetrazolium derivative which can be reduced by 
mitochondrial enzymes to a colored product which absorbs at 467 nm.  The intensity of 
color is directly proportional to the mitochondrial metabolism which in turn reflects the 
cellular health.  We incubated BV-2 and primary mouse microglia pretreated for 6 h with 
Aβ(1-42) oligomers in the presence of XTT as detailed in methods.  After 2 h of 
incubation, the reduced form of XTT was read at 467 nm.  We observed no significant 
difference in XTT reduction between cells treated with oligomers and cells treated with 
buffer vehicle (Figure 4.4).  This observation suggests that Aβ(1-42) oligomers were not 
toxic to the microglia.  Primary murine microglia pretreated with Aβ(1-42) fibrils were 
also able to metabolize XTT comparable to buffer control ruling out the possibility of 
fibrils being toxic to microglia.  Similar results were obtained for BV-2 mouse microglia.  
This data supports our observation that microglial TNFα production is an outcome of 
immune response stimulation with Aβ oligomers rather than a response from dying cells.   
 
 
 
4.7 Characterization of Aβ(1-42) oligomers by size-exclusion chromatography (SEC) and 
their morphological analysis by electron microscopy (EM) 
 
 
 
Apart from the morphological analysis by atomic force microscopy (AFM), Stine 
et al also characterized Aβ(1-42) oligomers formed in DMSO/F-12 medium by Western 
Blot.  They observed that Aβ(1-42) oligomer preparations at 0 h consisted mainly of  
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Figure 4.4 Both Aβ(1-42) oligomers and fibrils stimulated microglial 
proinflammatory response in a non-toxic manner. Primary murine microglia 
pretreated with Aβ(1-42) oligomers or fibrils were incubated with XTT and PMS for 2 h 
at 37⁰C as detailed in methods.  The absorbance was read at 467 nm.  The Aβ vehicle was 
used as control n=6 for samples (black bars), n=3 for controls (hatched bars) 
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monomer, trimer and tetramers, while after 24 h incubation the preparation showed 
higher oligomers (30-60 kDa) and increased trimer and tetramer bands.  The caveat in 
getting full structural details like the state of oligomerization from SDS-PAGE 
experiments is that Aβ forms SDS-resistant species due to its amphipathic nature (Bitan, 
et al., 2005).  Therefore, we further analyzed this oligomeric preparation by SEC under 
non-denaturing conditions.  Importantly, we wanted to compare the elution profile of 
Aβ(1-42) protofibril preparation (discussed in Chapter 3) to that of the oligomer 
preparation described in this study based on SEC.  We wanted to get an idea about the 
size distribution of Aβ(1-42) oligomers as compared to that of the protofibril preparation 
based on the SEC-elution profile.  We separated oligomers formed in F-12 medium with 
a Superdex 75 SEC-column.  The elution profile was monitored by absorbance at 280 
nm.  We observed that SEC of oligomers yielded an elution profile consisting of dual 
peaks (Figure 4.5).  The void peak containing higher molecular weight species (>70000 
molecular weight) followed by the included peak, which contained mostly low molecular 
weight species like monomer and dimer (Walsh, et al., 1997; Chromy, et al., 2003).  This 
elution profile was qualitatively identical to that of Aβ(1-42) protofibril preparation 
containing NaOH/F-12.  However, we also observed a small shoulder peak right next to 
the void peak for the oligomer elution.  When imaged using TEM, however, we did not 
find any evidence of Aβ structure in the shoulder peak.  We were not able to identify if 
that was a ghost peak related to an SEC-artifact.  Previously, Chromy et al carried out 
SEC analysis of Aβ(1-42) oligomers using F-12 as a running buffer on a Superdex 75 
column.  They reported that the oligomers eluted in a single peak shortly after the void 
volume, followed by a monomer peak.  Although we observed a small hump next to the  
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Figure 4.5 Size-exclusion chromatography separation of Aβ(1-42) oligomers formed 
using DMSO/F-12 medium.  Dual peaks are observed following SEC elution of Aβ(1-
42) reconstituted in DMSO/F-12. Lyophylized Aβ(1-42) was brought into solution with 
DMSO (5 mM) followed by supplemented F-12 media (100 μM). The supernatant after 
centrifugation was eluted from a Superdex 75 column and 0.5 ml fractions were 
collected. UV absorbance at 280 nm was monitored during the elution (solid line). 
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void volume, the majority of the high molecular weight Aβ species eluted out in the void 
volume peak, unlike that of Chromy et al.  The Aβ(1-42) protofibril and oligomer 
preparations were similar in that both contained a significant amount of unaggregated 
LMW Aβ.  However, there are some caveats which make the comparison between size 
distributions of oligomers and protofibrils less straightforward.  Firstly, our protofibril 
preparation was 2.5-fold more concentrated than the oligomer preparation (100 μM).  
Secondly, the protofibril preparation was separated by SEC right after reconstitution and 
centrifugation, unlike the 24 h incubation in the case of oligomers.  It is possible that both 
concentration and time of incubation governed the type of oligomers formed.  Moreover, 
since both protofibrils and oligomers elute out in the void peak, it is not possible to 
further distinguish between those two peaks by a Superdex 75 column.   
Although protofibrils were originally characterized morphologically by TEM 
(Walsh, et al., 1997; Walsh, et al., 1999), analysis of oligomers mostly relied on AFM 
(Stine, et al., 2003).  We have observed that the mica surface used for AFM sample 
preparation may not allow adsorption of all Aβ species uniformly due to surface 
properties.  We therefore took advantage of TEM to compare morphological differences 
between protofibrils and oligomers eluted in the void peak.  We prepared TEM samples 
of void peak oligomers (10 μM) using negative staining (Figure 4.6, Imaging carried out 
by David C. Osborn).  Based on TEM images, the oligomeric structures appear to 
resemble the curvilinear protofibrils.  However, they looked significantly smaller than 
that of the protofibrils.  Based on the TEM image showed in Figure 4.6, oligomer length 
was estimated to be less than 50 nm.   
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Figure 4.6 Morphological characterization of oligomers eluted in the void volume by 
TEM. Aβ(1-42) oligomers were subjected to SEC as shown in figure 4.5. Aβ oligomers 
(10 μM) eluted out in the void volume (Fraction 13) was adsorbed on formvar coated 
copper grids, negatively stained with 2% Uranyl acetate followed by imaging using 
Philips EM 430 TEM at 300kev. Scale bar is 100 nm. 
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4.8 Characterization of Aβ(1-42) fibrils formed under Stine et al conditions 
 
 
 
Solid state nuclear magnetic resonance (NMR) studies have shown that Aβ fibrils 
formed under different conditions have subtle differences in their molecular structure 
(polymorphic). Moreover, slight structural differences can further translate into 
differential toxicity to neurons (Petkova, et al., 2005).  As discussed previously in 
Chapter 3, we prepared Aβ(1-42) fibrils starting from a SEC-purified monomer eluted in 
F-12 medium by gentle agitation for approximately 72 h at room temperature.  The 
resultant fibrils were isolated by centrifugation at 18000 g. These fibrils were > 1 μm 
long, and laterally associated with each other likely due to the higher ionic strength of F-
12 medium (16 mS/cm) and agitation.  The fibrils described in Chapter 3 failed to 
stimulate a microglial proinflammatory response when added to either BV-2 or primary 
mouse microglia at 15 μM (based on original monomer concentration).  The extent of 
TNFα production was comparable to the background TNFα response in all the 
experiments.  On the other hand, while TNFα production induced by fibrils prepared 
under acidic conditions (DMSO/dilute HCl) was lower than oligomers, it was 
considerably higher than the background response.  From this data, it appeared that fibrils 
formed quiescently under low pH (pH 2.3) versus those formed at physiological pH with 
gentle agitation possessed differential ability to stimulate microglia.  Moreover, 10 mM 
HCl displayed considerably lower ionic strength (4 mS/cm) than that of F-12 medium (16 
mS/cm) as estimated by conductivity measurements.  However, we did not compare these 
two fibril preparations side by side in the same experiment.  Nevertheless it is possible 
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that changes at the structural level get translated into structure-specific activity (Petkova, 
et al., 2005). 
We wanted to investigate additional differences between these two different fibril 
preparations.  We already have shown that the fibrils formed in physiological pH and 
high ionic strength could readily spin down.  We wanted to investigate if that holds true 
for fibrils formed under acidic conditions.  Even after centrifugation at 18000 g, 
significant ThT fluorescence (79%) stayed in the supernatant suggesting that these fibrils 
were highly soluble (data not shown).  We imaged the Aβ solution before and after 
centrifugation to determine whether the supernatant contained the fibrillar structures.  
Both the total and supernatant solution showed abundant long fibrils.  Morphologically, 
these fibrils appeared different than those formed in F-12 medium (Figure 4.7 and 
Chapter 3, Figure 3.3 Panel B).  First and the foremost, fibrils formed in low pH 
conditions appeared more flexible.  Secondly, the degree of lateral association was 
minimal under acidic conditions and low ionic strength unlike fibrils formed in F-12 
medium.  Moreover, AFM images of the fibrils formed at low pH showed presence of 
some globular species along with long fibrillar structures (Figure 4.1 Panel B).  
Therefore, next we wanted to examine if the fibrils prepared in dilute HCl had residual 
soluble protofibrillar structures in the supernatant.  To investigate this, we subjected 
18000 g fibril supernatant to SEC separation.  Interestingly, UV did not show any protein 
eluting out of the column (data not shown).  This, in turn suggested that the long fibrils 
were not able to pass through the column but instead might have been trapped by the 
filter on top of the column.  Thus, based on SEC results, this fibril preparation was 
devoid of any protofibrillar structures.  The difference in the biological activities of two  
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Figure 4.7 Morphological characterization of Aβ(1-42) fibrils prepared under acidic 
conditions. Aβ(1-42) was reconstituted using DMSO at 5 mM followed by its dilution 
into 10 mM HCl at 100 μM. The solution was further incubated at 37⁰C for 24 h.  Panel 
A. After 24 h total fibril solution were diluted to 20 μM using water and 10 μl was 
adsorbed on formvar coated copper grids, negatively stained with 2% Uranyl acetate 
followed by imaging using TEM at a magnification of 59000 X. Scale bar is 50 nm. 
Panel B.  The total Aβ(1-42 fibril solution was centrifuged at 18000 g for 10 min. The 
supernatant was diluted to 20 μM (The supernatant concentration was assumed to be 100 
μM since very small amount of Aβ pelleted out). and adsorbed on the formvar-coated 
copper grids, negatively stained and imaged using TEM at a magnification of 59000 X. 
Scale bar is 50 nm. 
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different preparations of fibrils may be intrinsic to the molecular structure of fibrils rather 
than residual soluble protofibrils in fibril preparation formed under acidic conditions.  
These results in turn emphasize the effect of solution conditions on the structure and 
biological activity of fibrils. 
 
 
 
4.9 Discussion 
 
 
 
The current study demonstrates that soluble Aβ(1-42) oligomers were more 
effective than fibrils in inducing TNFα production in murine microglia. Our findings are 
consistent with a study by White et al (2005) in which oligomers were better than fibrils 
in stimulating a proinflammatory response in rat astrocyte culture.  Both our study and 
that by White et al prepared Aβ(1-42) oligomer and fibrils solutions based on a protocol 
described by (Stine, et al., 2003). We further analyzed the oligomers and fibrils 
biophysically with ThT fluorescence, SEC and TEM imaging.   
In this study, Aβ(1-42) was reconstituted in DMSO at 5 mM and the resulting Aβ 
solution was diluted to 100 μM with either F-12 medium or dilute HCl to form oligomers 
or fibrils respectively.  Oligomers were formed at 4⁰C while the fibrils were generated at 
37⁰C after incubation at 24 h.  Thus, by modulating the solution and temperature 
conditions, Aβ(1-42) was able to form different species.  These species not only 
possessed distinct morphologies as assessed by AFM but produced quantitatively 
different microglial TNFα response.  Oligomer preparation was mostly globular and 
devoid of any fibrillar structures based on AFM in agreement with Stine et al.  Moreover, 
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these oligomers exhibited substantial ThT fluorescence suggesting a considerable degree 
of β-sheet structure (Figure 4.2).  Fibrils possessed maximum ThT fluorescence but were 
only weak activators of microglia as compared to oligomers.  Our recent study discussed 
in Chapter 3 have demonstrated that Aβ(1-42) protofibrils are potent activators of murine 
microglia.  Moreover, isolated fibrils formed using SEC-purified monomer in F-12 
medium possessing maximum ThT binding were as ineffective as SEC-purified monomer 
possessing little to no ThT binding.  Both these studies suggest that Aβ as an 
inflammatory stimulus might require an intermediate structure formed during 
fibrillogenesis.  Such an intermediate species will likely have size and β-sheet character 
intermediate between monomer and fibril.  Together, both these studies show a 
significant role for Aβ(1-42) protofibrils and oligomers in microglia-mediated 
inflammation.  There is burgeoning evidence suggesting that smaller, soluble Aβ species 
have potent early synaptotoxic properties (Koffie, et al., 2011).  In fact, oligomeric Aβ 
was found to be correlated to astroglial inflammatory response as well as clinical disease 
severity as compared to total Aβ burden in a mouse model of AD (DaRocha-Souto, et al., 
2011; Serrano-Pozo, et al., 2011).  Thus, intermediate Aβ species can offer a possible 
explanation for early neurodegeneration and inflammation observed well before the 
plaque formation in AD mouse models as well as AD patients (Rahimi, et al., 2008). 
Most of the previous studies investigating Aβ-induced microglial activation 
utilized fibrillar preparations.  Fibrils have been shown to induce a proinflammatory 
response via a number of receptors including heterotrimeric the TLR4-TLR6-CD36 
complex, TLR2, 4 and CD14.  Sondag et al (2009) showed that although both fibrils and 
oligomers can activate microglia, the activation profile is qualitatively distinct for each 
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stimulus with respect to tyrosine kinase signaling pathways.  Fibrils have long been 
believed to act as inflammatory stimulus particularly due to the clustering of microglia 
and upregulation of inflammatory molecules surrounding the plaques.  In the context of a 
recent study showing the presence of oligomeric Aβ in the plaque periphery (DaRocha-
Souto, et al., 2011), our in vitro findings in murine microglia might be biologically 
relevant. 
The isolated fibrils prepared from SEC-purified Aβ(1-42) monomer under 
physiological pH conditions (described in Chapter 3) failed to produce any TNFα 
response in murine microglia while the fibrils prepared under aqueous, non-buffered 
acidic conditions produced a small yet noticeable response.  The difference in pH and 
ionic strength significantly affected the solubility of the fibrils.  Fibrils formed at lower 
pH and little ionic strength were flexible and extremely soluble compared to the insoluble 
fibrils formed at physiological pH and high ionic strength.  It is possible that solution 
conditions influenced the ability of fibrils to act as a proinflammatory stimulus by 
changing the structure at the molecular level required for interaction with microglial 
receptors.  In fact, Petkova et al (2005) have shown that altering the solution conditions 
not only changed the structure of fibrils as assessed by solid state NMR but also 
influenced their ability to confer toxicity. 
Oligomers described in the current study were analyzed previously by Western 
Blotting and contained higher oligomeric structures (30-60 kDa) along with trimers and 
tetramers (Stine, et al., 2003).  Aβ forms SDS-resistant species and in some cases, SDS 
can lead to artificial oligomerization of amphipathic proteins limiting the use of western 
blot analysis for characterization of the oligomerization state (Bitan, et al., 2005).  Native 
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gel electrophoresis is an alternative for SDS-PAGE.  However, different oligomeric 
species can have identical mass to charge ratio, making the native gel data inferior to the 
SDS-PAGE resolution (Bitan, et al., 2005).  AFM is another morphological technique 
that was extensively used to characterize oligomers.  Commonly, AFM utilizes a mica 
surface for sample adsorption.  It has been thought that not all Aβ species are capable of 
uniform adsorption on mica surface, and the adsorption is governed by surface properties 
of various Aβ species (Bitan, et al., 2005).  To overcome these limitations, we extended 
the biophysical characterization of these oligomers by SEC and TEM.  SEC showed an 
elution profile for oligomers which was qualitatively identical to our protofibril 
preparation.  Both protofibrils and oligomers separated out in a void peak on a Superdex 
75 SEC-column (>70000 molecular weight cut off).  Chromy and colleagues observed a 
dual peak for Aβ(1-42) oligomers using Superdex 75 (Chromy, et al., 2003). However, in 
our hands, Aβ(1-42) oligomers eluted out in the void volume instead of shortly after the 
void volume as described by Chromy et al.  We did observe a small shoulder peak after 
the void volume, but we could not detect any Aβ structures in the TEM images nor 
observe a significant DLS signal.  Overall, DLS measurements carried out on the void 
peak showed smaller hydrodynamic radius values as compared to Aβ(1-42) protofibrils.  
Chromy and colleagues also described oligomers to be distinct from protofibrils at least 
for up to 24 h (Chromy, et al., 2003).  Our dual SEC-profile was more comparable to that 
observed by Hepler et al (Hepler, et al., 2006).  They used multi-angle light scattering 
(MALS) in-line with SEC to measure the molecular weight of the Aβ species and found 
out that the void peak in fact contained Aβ species of very high molecular weight 
(ranging between 100 kDa-150 kDa) (Hepler, et al., 2006) compare to that reported by 
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western blotting (Lambert, et al., 1998; Chromy, et al., 2003).  Both protofibril and 
oligomer preparation have utilized solvents like NaOH or DMSO during the first step of 
Aβ reconstitution.  NaOH being a strong base helps to cross the isoelectric pH of Aβ 
rapidly and thus results into highly monomeric solution (Jan, et al., 2010).  Similarly, 
DMSO is a highly polar solvent to yield a highly soluble monomeric Aβ solution (Stine, 
et al., 2003).  After the initial reconstitution, both preparations use the same F-12 medium 
without phenol red to get the final Aβ aggregation solution.  One of the major differences 
in the preparation of protofibrils and oligomers is that protofibril preparation is 2.5-fold 
more concentrated than oligomer preparation.  It is a well established fact that the Aβ 
concentration has a profound effect on the aggregation (Lomakin, et al., 1997; Harper, et 
al., 1999).  So based on the current study, it is possible that the formation of Aβ oligomer 
or protofibrils is dependent on the concentration of aggregation solution.  However, it is 
clear that both oligomers and protofibrils have early synaptotoxic (Hartley, et al., 1999; 
Dahlgren, et al., 2002; O'Nuallain, et al., 2010) as well as proinflammatory properties 
(Chapter 3) (White, et al., 2005).  Investigating the concentration-dependence of Aβ(1-
42) aggregation under protofibril and oligomer-forming conditions using non-denaturing 
techniques like SEC, native PAGE and imaging might provide mechanistic insight into 
the formation of these intermediates. 
Together, this study shows that soluble, oligomeric Aβ(1-42) rather than fibrils 
act as effective proinflammatory stimulus in murine microglia.  Moreover, this study 
emphasizes that solution conditions and concentration have significant effect on the Aβ 
aggregation in the context of soluble intermediates formed.   
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CHAPTER 5 
DEPENDENCE OF Aβ(1-42)AGGREGATION AGE ON MICROGLIAL 
PROINFLAMMATORY RESPONSE 
 
 
 
5.1 Introduction 
 
 
 
Alzheimer’s disease is characterized by the presence of extracellular deposits of 
amyloid-β (Aβ) protein known as senile plaques and intraneuronal tau tangles in the brain 
of an individual (Selkoe, 2004).  Although development of tau tangles correlates well 
with the severity of AD, Aβ accumulation is considered to be the initial trigger for 
neuronal degeneration during the earlier stages of AD (Selkoe, 1994; Koffie, et al., 2011).  
Besides the signature proteinaceous lesions, AD neuropathology also involves innate 
immune mechanisms as evident by the presence of activated microglia clustered around 
the senile plaques along with a number of inflammatory proteins such as complements, 
immunoglobulins and cytokines (Ishii and Haga, 1984; Dickson, et al., 1988). This 
observation is further corroborated by upregulation of inflammatory cytokines and severe 
glial inflammatory reactions (gliosis) surrounding Aβ-deposits (Akiyama, et al., 2000).  
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Furthermore, gliosis coincided with neuronal loss during in vivo studies using transgenic 
animal models of AD (Ingelsson, et al., 2004; DaRocha-Souto, et al., 2011) . In vitro 
studies have confirmed that Aβ acts as a potent inflammatory stimulus which causes 
overexpression of a number of proinflammatory markers, including tumor necrosis factor 
α (TNFα) and interleukin-1β (IL-1β) by the cells of monocytic/macrophage lineage 
including microglia and monocytes (Meda, et al., 1995; Combs, et al., 2001; Stewart, et 
al., 2010). 
Aβ displays a high propensity to aggregate into fibrils.  Aβ aggregation follows 
nucleation-dependent polymerization kinetics (Jarrett and Lansbury, 1992).  In this type 
of kinetics, several monomer units form a nucleus which upon elongation ultimately 
gives rise to long fibrils (Jarrett and Lansbury, 1992).  During fibrillogenesis, Aβ is 
known to adopt a variety of conformational states having different size, shape and a 
different degree of β-sheet structure (Bitan, et al., 2003).  Markers of neuronal 
degeneration as well as inflammation were observed in the close vicinity of neuritic 
plaques (Dickson, et al., 1988; Tsai, et al., 2004).  Since Aβ fibrils were found to be a 
major component of dense-core plaques (Glenner and Wong, 1984; Masters, et al., 
1985b), fibrils were largely believed to be responsible for such a degenerating pathology 
(Hardy and Higgins, 1992).  However, total amyloid plaque burden did neither correlated 
well with the neuronal loss nor with disease severity (Naslund, et al., 2000).  Moreover, a 
number of cognitively normal individuals displayed significant amyloid plaque burden 
(Morris, et al., 2009).  This evidence argues against the fibrils as important players in the 
AD related neurodegeneration (Hardy and Selkoe, 2002).  Further support for this 
argument came from the recent studies employing highly sensitive, conformation-specific 
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antibodies against oligomeric Aβ revealing a complex plaque environment in which 
different species of Aβ are in a dynamic equilibrium within and around the periphery of 
the plaques in a mouse model of amyloid deposition (Koffie, et al., 2009).  Moreover, 
oligomeric Aβ surrounding the plaques correlated with 60% of excitatory synaptic loss  
(Koffie, et al., 2009).  This finding provided support to a number of in vitro studies in 
which small, soluble oligomers resulted in significant neuronal degeneration, as measured 
by inhibition of long-term potentiation (Lambert, et al., 1998; Walsh, et al., 2002), 
decrease in neuronal viability (Dahlgren, et al., 2002) and early alterations in electrical 
activity of neurons (Hartley, et al., 1999).  In agreement with the above findings, 
oligomers were found to colocalize with markers of postsynaptic densities using 
hippocampal neuronal culture (Lacor, et al., 2004).  In subsequent studies,  Hyman and 
colleagues showed that oligomeric Aβ correlates not only with neuronal loss but also 
with the inflammatory reactions of brain immune cells such as astrocytes and microglia 
(astrocytosis and microgliosis) in a transgenic mouse model of AD (Koffie, et al., 2009; 
DaRocha-Souto, et al., 2011).  Interestingly, they observed a linear increase in gliosis as 
the disease progressed, despite the total amyloid load reaching a plateau (Serrano-Pozo, 
et al., 2011).  In fact, gliosis was found to be the best correlate of cognitive decline in a 
stereology based quantification study using a large number of AD and control brain 
samples (Serrano-Pozo, et al., 2011). Together, these studies suggest a role for astrocytes 
and microglia in the neurodegenerative pathology of AD rather than being innocent 
bystanders. 
Structural polymorphism of Aβ is also believed to underlie its ability to act as an 
inflammatory stimulus (Ajit, et al., 2009).  In vitro studies have shown that both fibrils 
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and oligomers can activate primary microglia (Sondag, et al., 2009). However, Sondag et 
al observed a qualitative difference in the activation profile of microglia depending on the 
aggregation state of Aβ (Sondag, et al., 2009).  In a study by White et al oligomeric Aβ 
was more effective in inducing a proinflammatory response in rat astrocyte culture, while 
fibrils were not as effective (White, et al., 2005).  Several in vitro studies investigating 
involvement of cell surface receptors and downstream signaling elements in Aβ-mediated 
proinflammatory response have provided evidence for fibrils as an effective 
inflammatory stimulus (McDonald, et al., 1997; Walter, et al., 2007; Stewart, et al., 
2010).  However, unlike Aβ-induced neurodegeneration, the neuroinflammation field still 
lacks a consensus regarding the structure-activity relationship in the context of Aβ-
induced microglial inflammation.  Knowledge of Aβ-induced inflammatory response is 
important in order to develop effective therapeutic targets against AD (Hyman, 2011). 
Previously we have reported that soluble fibrillar precursors formed during 
fibrillogenesis of Aβ(1-42)  were able to provoke maximum TNFα response in THP-1 
monocytes (Ajit, et al., 2009).  THP-1 cells belong to the same lineage as microglia, 
hence have been used as a model system for studying Aβ-induced microglial response 
(Klegeris and McGeer, 2001; Udan, et al., 2008; Ajit, et al., 2009).  However, it has been 
argued that microglia, being the resident immune cells of the brain, is a more biologically 
relevant model system to study Aβ-induced inflammation.  Therefore, we investigated the 
optimal aggregation state for Aβ(1-42)-induced microglial TNFα response. 
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5.2 Preparation of Aβ(1-42) for microglial cell stimulation experiments  
 
 
 
The highly amphipathic character of Aβ peptide underlies its high propensity to 
form β-sheet rich aggregates (Broersen, et al., 2011).  The process of aggregation is 
governed by a number of physical parameters that include pH, temperature, 
concentration, ionic strength, and time of incubation.  The conditions used for preparation 
of Aβ are crucial to produce the desired structure or aggregation state of the peptide (Jan, 
et al., 2010).  Highly fluorinated alcohol such as 100% hexafluoroisopropanol (HFIP) has 
been shown to dissociate preformed aggregates of Aβ by destabilizing the hydrogen 
bonds (Nichols, et al., 2005).  However, low concentrations of HFIP have been reported 
to induce not only α-helical conformations but also turns and β-hairpins via 
intramolecular hydrogen bond formation in Aβ (Buck, 1998).  
The aggregation state of Aβ can also influence its ability to induce a 
proinflammatory response (Ajit, et al., 2009).  For my experiments using mouse 
microglia, I prepared aggregate-free solutions of Aβ by HFIP pretreatment of the 
purchased peptide followed by complete removal of HFIP using vacuum centrifugation 
as described in Ajit et al (Ajit, et al., 2009).  The resulting lyophilized peptide was then 
reconstituted in water to give 100 μM solution of Aβ(1-42) (Ajit, et al., 2009).  The 
solution was then aggregated at 4⁰C for 24, 48, 96 and 216 h.  Aβ(1-42) aggregated in 
such a manner produces distinct morphologies described in Ajit et al (2009) using atomic 
force microscopy (AFM) images.  In those studies Aβ exhibited punctate morphology 
right after its reconstitution and slowly progressed towards formation of fibrils by 48-96 
h.  There was a significant increase in the number of fibrils over time.  At each 
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aggregation time point, including 0 h, an aliquot was drawn and flash frozen using a dry 
ice /ethanol mixture and stored at -80⁰C until used for the experiment.  Flash-freezing of 
the Aβ aggregation solution was carried out due to the logistics of the microglia treatment 
as described in the Methods.  Primary microglia need two days for their harvest and 
subsequent plating in order to be ready for the cell stimulation experiment.  The Aβ 
aggregation age time points were separated by a two day period, making the microglial 
cell treatments difficult to manipulate.  Moreover, the yield of microglia and the 
sensitivity of microglia to positive controls (for example lipopolysaccharide as described 
in the Methods) vary from batch to batch (data not shown).  We thought that assessing 
different aggregation states of Aβ on the same batch of cells will minimize the variability 
in the cellular response and will also allow convenient manipulation of microglial cell 
culture.  Thus, frozen aliquots were thawed rapidly and added to the primary murine 
microglia plated in a 96 well cell-culture plate at a final concentration of 15 μM for 6 and 
24 h.  When the conditioned medium of the cellular treatment was analyzed using ELISA 
for TNFα production, we observed that primary murine microglia produced TNFα 
response did not vary significantly over the time course of the Aβ-aggregation age 
(Figure 5.1).  The magnitude of TNFα response remained essentially comparable 
irrespective of the aggregation age of Aβ.  Moreover, the trend did not change 
significantly between 6 and 24 h treatment (6 or 24 h) (Figure 5.1).  This observation was 
quite different from our previous studies on THP-1 monocytes (Ajit, et al., 2009).  Aβ(1-
42) prepared and aggregated in the identical manner produced a consistent trend in the 
monocyte proinflammatory response over the time course of Aβ aggregation.  Ajit et al  
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Figure 5.1 Dependence of primary microglial TNFα response on the aggregation age 
of Aβ(1-42). Aβ(1-42) was resuspended in sterile water at 100 μM and aggregated at 
4⁰C. Aliquots were drawn at 0, 48, 96 and 216 h of aggregation and flash frozen with 
ethanol/dry-ice mixture. All the aliquots were thawed and treated at the same time with 
primary microglia plated in a 96-well plate for 6 or 24 h at a final concentration of 15 
μM.  Cellular medium was analyzed using TNFα ELISA. 
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observed that Aβ(1-42) corresponding to an intermediate aggregation state correlated 
with maximum proinflammatory response.   
Aβ(1-42) preparation in water results into a low pH solution (pH 3).  We wanted 
to compare our preparation under acidic conditions to that of physiological conditions.  
Aβ(1-42) was resuspended in NaOH, followed by dilution in phosphate buffered saline to 
give 100 μM solution and aggregated in a time dependent manner.  Dissolution of Aβ in 
NaOH allows rapid transition to basic pH, followed by slow dilution in neutral buffer.  
This process minimizes the aggregation of Aβ at its isoelectric pH (pI 5.5).  However, we 
did not see any correlation between Aβ-aggregation age and subsequent TNFα production 
by primary microglia by changing the aggregation conditions close to physiological 
conditions (data not shown). 
Since Aβ-aggregation is temperature dependent, we boosted the temperature of 
Aβ(1-42)/water aggregation reaction to 37⁰C.  The increase in temperature increased the 
extent of aggregation (as measured by ThT fluorescence) compared to aggregation 
reactions carried out at 4⁰C and also formed fibrils more rapidly (Ajit, et al., 2009).  
Aβ(1-42) fibrils are reported to act as a pro-inflammatory stimulus for microglia 
(McDonald, et al., 1997; Yates, et al., 2000; Combs, et al., 2001; Walter, et al., 2007).  
We thought if fibrils activate microglia, we would see an increase in microglia-stimulated 
TNFα response over the time course of Aβ-aggregation.  We observed such an increase, 
which seemed to correlate with the age-dependent aggregation of Aβ(1-42) based on ThT 
fluorescence studies (Figure 5.2).  However, there were two concerns.  Firstly, we saw 
high ThT fluorescence values for the freshly reconstituted peptide.  Ideally, freshly 
reconstituted peptide should be mostly monomeric hence should exhibit little to no ThT  
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Figure 5.2  Dependence of primary microglial TNFα response and Thioflavin-T 
fluorescence of Aβ on the aggregation age of Aβ(1-42).  Aβ(1-42) was resuspended in 
sterile water and incubated at 37⁰C. Aliquots were drawn at 0, 48, 96, and 216 h and 
flash-frozen using ethanol/dry-ice mixture. The aliquots were thawed at the same time 
and added to primary microglia plated in 96-well plate for 6 h at a final concentration of 
15 μM.  TNFα production was quantified by ELISA. 
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fluorescence.  We thought that higher ThT values might suggest either the presence of 
preformed aggregates even after HFIP pretreatment or rapid formation of aggregates rich 
in β-sheet structure.  Secondly, at any given time the aggregation reaction might represent 
a polydisperse mixture of different Aβ species in equilibrium.  This makes the structure-
activity correlation studies less straightforward to interpret.  For these reasons we decided 
to further purify Aβ solutions in order to obtain highly-enriched monomeric samples 
using size-exclusion chromatography.   
 
 
 
5.3 Isolation of Aβ(1-42) monomer using SEC 
 
 
 
Size exclusion chromatography is a non-denaturing technique that separates the 
proteins on the basis of its size and shape.  This technique is valuable in separating Aβ-
monomers from aggregated Aβ species (Walsh, et al., 1997; Jan, et al., 2010).  We 
expected that Aβ monomer solution obtained using SEC will be free of any pre-existing 
aggregates.   
Previous studies have utilized guanidine hydrochloride (GuHCl) to denature the 
Aβ aggregates (Jan, et al., 2010).  Crude synthetic Aβ(1-42) peptide (pretreated with 
trifluoroacetic acid/HFIP protocol as detailed in the methods) was resuspended in 6 M 
GuHCl and 10 mM NH4OH to give 1.0 ml solution.  The resultant solution was 
centrifuged at 18000 g followed by separation of monomer using SEC.  The SEC-
separation profile as shown in Figure 5.3 was obtained by monitoring UV absorbance at 
280 nm.  This treatment resulted in greater monomer yield and less yield of aggregated  
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Figure 5.3  Size exclusion chromatography profile of Aβ(1-42).  Aβ(1-42) was 
resuspended in 6 M GuHCl and 10 mM NH4OH at a concentration of 1 mg/ml. The 
peptide was immediately eluted at a flow rate of 0.5 ml/min using 50 mM Tris-HCl 
buffer (pH 8.0). SEC-profile was obtained by monitoring UV absorbance at 280 nm. 
Fractions 21-24 labeled as monomer were collected on ice and flash-frozen using 
ethanol/dry-ice mixture and stored -80⁰C.  
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Aβ in the void peak.  Different elution buffers like 50 mM Tris-HCl (pH 8.0), 50 mM 
HEPES (pH 7.8) and 1x PBS were used for separation.  Since the monomer yields were a 
little better with Tris-HCl buffer (data not shown), we optimized the SEC separation of 
Aβ(1-42) in Tris-HCl buffer.  Moreover, a number of previous studies have studied 
aggregation of Aβ in Tris-HCl buffer (Nichols, et al., 2002; Nichols, et al., 2005). 
 
 
 
5.4 Aggregation of SEC-isolated Aβ(1-42) monomer 
 
 
 
As per our expectations, SEC-purified Aβ(1-42) monomer exhibited little to no 
ThT fluorescence values (Figure 5.4), confirming that SEC effectively separated the pre-
existing aggregates to yield a highly pure monomeric solution. These monomeric 
fractions were collected, sometimes pooled together and aggregated as described before 
in section 5.2 in a time dependent manner.  Aliquots were drawn at 0, 48, 96 and 216 h, 
flash frozen using dry ice/ethanol mixture and stored at -80⁰C until needed for cell 
treatment experiments.  For the experiments, aliquots were thawed rapidly, used for 
microglial cell stimulation studies and also used to carry out ThT fluorescence scans. 
 
 
 
5.5 Thioflavin-T fluorescence increases with Aβ(1-42) aggregation 
 
 
 
ThT fluorescence measurement is used to estimate the amount of β-sheet structure 
present in a particular Aβ solution (as discussed previously in Chapter 3, Section 3.3).  
172 
 
We were able to monitor the progress of Aβ aggregation by carrying out ThT-
fluorescence measurements at different time points during the course of aggregation.  
Since Aβ-aggregation is dependent on temperature, pH and concentration, it is possible 
that these parameters might influence the type and amount of intermediates that form 
during Aβ-aggregation process.  So we determined the effects of modulating these 
conditions on Aβ-aggregation by using ThT fluorescence.  Our objective for these 
experiments was to investigate if microglial pro-inflammatory response was susceptible 
to the changes in the aggregation kinetics of Aβ(1-42) monomer, which would provide 
more information about the optimal Aβ species.  
 
 
 
5.5.1 Effect of temperature on aggregation of SEC-purified Aβ(1-42) monomer as 
monitored by ThT-fluorescence 
 
 
 
Three separate aliquots from the same SEC-isolated Aβ(1-42) monomer fraction 
eluted in 50 mM Tris-HCl buffer (pH 8.0) were subjected to time-dependent aggregation 
at three different temperatures such as 4, 25 and 37⁰C.  As discussed previously, the 
aliquots were drawn on 0, 48, 96 and 216 h and flash frozen using dry ice/ethanol 
mixture.  Aliquots were thawed and diluted 10-fold in Tris-HCl buffer (pH 8.0) 
containing 5 μM ThT in a cuvette for ThT fluorescence measurements.  Tris-HCl buffer 
did not show significant ThT fluorescence by itself.  Aβ(1-42) aggregated in a 
temperature-dependent manner.  The extent of ThT binding did not change significantly 
over time for the aggregation reactions carried out at 4 and 25⁰C. However, at 37⁰C 
Aβ(1-42) displayed a typical aggregation curve with a lag phase followed by a significant 
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increase in ThT-fluorescence (Figure 5.4). ThT-fluorescence appeared to reach a plateau 
towards the later time points of aggregation as reported before (Jarrett and Lansbury, 
1992; Harper and Lansbury, 1997).  
 
 
 
5.5.2 Effect of elution buffer on the aggregation of SEC-purified Aβ(1-42) monomer as 
monitored by ThT fluorescence  
 
 
We wanted to use SEC isolated monomer for the aggregation studies followed by 
cellular stimulation studies. This required generation of a sufficient quantity of SEC-
purified Aβ monomer. Therefore, it was essential to optimize SEC isolation of Aβ(1-42) 
peptide to get maximum recovery of monomer.  Moreover, we wanted to make sure that 
the buffer, in which Aβ is eluted, does not interfere with the aggregation of Aβ. 
Aβ(1-42) peptide was eluted in different buffers including PBS, 50 mM HEPES 
and 50 mM Tris-HCl buffer during SEC. The isolated monomer was subjected to 
aggregation at 37⁰C. Although all monomer solutions showed an increase in ThT 
fluorescence over time, the extent of ThT fluorescence was maximum for the monomer 
eluted in Tris-HCl buffer (Figure 5.5).  Also Tris-HCl is a common buffer used for SEC-
isolation of Aβ monomer (Nichols, et al., 2002; Nichols, et al., 2005).  Furthermore, the 
recovery of Aβ(1-42) monomer was the highest in Tris-HCl buffer.  Recovery was lower 
in HEPES buffer and therefore, we were not able to compare the aggregation reactions at 
equivalent concentrations of Aβ.  This led us to use Tris-HCl buffer in all of our SEC 
experiments described in Chapter 5.  
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Figure 5.4 Effect of temperature on ThT-fluorescence of Aβ(1-42).  SEC-purified 
Aβ(1-42) monomer (36 μM based on UV measurements) eluted in 50 mM Tris-HCl 
buffer (pH 8.0) was divided into 3 parts. The monomer was incubated at 4, 25 or 37⁰C 
and aliquots were drawn at 0, 48, 96 and 216 h, flash frozen using ethanol/dry-ice 
mixture. The aliquots were thawed and diluted 10-fold into 5 μM ThT in Tris-HCl buffer 
( pH 8.0) and fluorescence scans were carried out as described in methods. 
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Figure 5.5 Effect of SEC-elution buffer on ThT-fluorescence of Aβ(1-42) 
aggregation. SEC-purified Aβ(1-42) monomer in three different buffers were aggregated 
at 37⁰C. Aliquots were drawn at different time points, flash-frozen with dry-ice/ethanol 
mixture and stored at -80⁰C. All the aliquots were thawed and ThT-fluorescence 
measurements were obtained as described in methods. The concentrations of Aβ(1-42) 
aggregation reactions were 36, 37 and 12 μM for Tris-HCl, PBS and HEPES 
respectively. 
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5.5.3 Dependence of the concentration of SEC-purified Aβ(1-42) monomeron its 
aggregation as monitored by ThT-fluorescence  
 
 
One of the important factors which governs aggregation is the concentration of 
Aβ. Aβ is considered to exhibit properties similar to detergents due to its amphipathic 
nature.  Like detergents, a critical concentration of Aβ monomer is required to form 
micellar aggregates, which act as nucleation sites for further elongation (Lomakin, et al., 
1996; Lomakin, et al., 1997).  Below its critical concentration, Aβ exists as monomer.  
Above its critical concentration, there is an equilibrium between monomer and fibrils.  
The critical concentration of Aβ(1-42) is in the lower micromolar range, which is five-
fold less than that of its carboxy terminal variant Aβ(1-40) (Soreghan, et al., 1994; 
Harper and Lansbury, 1997).  
We were interested in studying the concentration dependence of Aβ(1-42) 
aggregation using SEC isolated seed-free monomer at 37⁰C.  We carried out a number of 
such aggregation experiments with varying Aβ(1-42) concentrations.  In most of the 
experiments, ThT fluorescence showed an increase over time as described in Section 
5.5.1. As the concentration of monomer increases, the lag time of aggregation should 
decrease (Harper and Lansbury, 1997), thereby decreasing the time required to attain half 
of maximal ThT fluorescence (t½) (measure of lag time of aggregation).  Therefore, we 
expected to see a negative correlation between t½ and concentration of Aβ(1-42) 
monomer.  However, we did not see any correlation (r
2
=2.16 x 10
-3
 using Sigmaplot 
curve fitting parameters) between concentration of monomer and t½, which was 
calculated manually by extrapolation using individual aggregation curves (Figure 5.6) 
(discussed further in section 5.8). 
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Figure 5.6 Dependence of ThT-fluorescence on the concentration of Aβ(1-42). SEC-
purified Aβ(1-42) monomer in Tris-HCl buffer (pH 8.0) was aggregated at different 
concentrations at 37⁰C in a time dependent manner. The time corresponding to half of the 
maximum ThT fluorescence was designated as t1/2 and plotted against concentration of 
the aggregation reaction. (--) represents the linear fit for the data using SigmaPlot 10.0 
software. 
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5.6 Lack of correlation between Aβ(1-42) aggregation age as measured by ThT 
fluorescence and Aβ-induced proinflammatory response 
 
 
 
30 μl of Aβ(1-42) aggregation solutions (36 μM) prepared as described in Section 
5.4.1, were added to primary mouse microglia and BV-2 mouse microglia.  The final 
concentration of Aβ was 11 μM in the cellular treatment.  After 6 h incubation, the 
medium was collected and analyzed for the production of TNFα by ELISA to identify the 
Aβ(1-42) aggregation species which activates microglia most effectively. 
 
 
5.6.1 Aβ(1-42)-induced proinflammatory response in primary murine microglia was 
dependent on the temperature at which Aβ was incubated 
 
 
 
As described in section 5.5.1, SEC-isolated Aβ(1-42) monomer was aggregated in 
a time-dependent manner at 3 different temperatures 4, 25 and 37⁰C.  The aggregation 
solutions were tested for their ability to produce TNFα in BV-2 mouse microglia for 24 h. 
Temperature not only influenced the aggregation of Aβ(1-42) monomer (Figure 5.7 and 
Figure 5.8) but also had a significant effect on the ability of Aβ to stimulate TNFα 
production. 
 
 
5.6.2 Aβ(1-42)-induced proinflammatory response in primary murine microglia 
correlated with increased aggregation  
 
SEC-purified Aβ(1-42) monomer in Tris buffer (pH 8.0) was aggregated at 37⁰C 
over time and ThT fluorescence was used to monitor progress of aggregation.  Primary  
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Figure 5.7 Dependence of microglial proinflammatory response on the aggregation 
age of Aβ(1-42). Aβ(1-42) monomer (36 µM) eluted in Tris-HCl buffer was incubated at 
37°C for up to 216h. BV-2 microglia were exposed to a final Aβ(1-42) concentration of 
10.6 µM for 24h. Cellular medium was analyzed for TNFα production using ELISA. 
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Figure 5.8 Correlation between Aβ-induced microglial proinflammatory response 
and ThT-fluorescence over time. Aβ(1-42) monomer (36 µM) was incubated at 37°C 
for up to 216 h. Aliquots were analyzed for ThT binding and proinflammatory activity in 
primary microglia. Cells were exposed to a final Aβ(1-42) concentration of 11 µM for 6 h 
and medium was analyzed using TNFα ELISA. 
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mouse microglia were treated with 11 μM of aggregated Aβ for 6 h.  Freshly isolated 
Aβ(1-42) monomer was unable to stimulate TNFα production.  Interestingly, the extent 
of TNFα production increased with increase in ThT-fluorescence over time.  TNFα 
response was maximum when microglia were treated with 216 h aggregated Aβ(1-42) 
which correlated well with ThT-fluorescence (Figure 5.8).  We have seen previously that 
freshly reconstituted Aβ(1-42) is essentially fibril-free based by AFM analysis, yet is able 
to transition to fibrillar structures by 96 h of aggregation at 37⁰C.  Also AFM indicated 
that as time progressed further, the existing smaller punctuate species disappeared 
completely to give predominantly long fibrils (Ajit, et al., 2009).  Based on this 
observation, we thought that Aβ(1-42) fibrils might be responsible for the microglial 
activation. 
 
 
 
5.6.3 Aggregation of Aβ(1-42) as measured by ThT fluorescence was not sufficient to 
stimulate a consistent proinflammatory response in primary microglia  
 
 
 
As described in previous section 5.6.2, we saw that Aβ(1-42)-induced TNFα 
production correlated with ThT-fluorescence over time, suggesting the role of aggregated 
Aβ(1-42) rather than unaggregated, monomeric Aβ(1-42) in inducing a microglial 
proinflammatory response.  However, surprisingly, when we repeatedly studied the 
dependence of Aβ-aggregation age on microglial TNFα response under the same exact 
experimental conditions as described in 5.6.2, Aβ(1-42) failed to induce any TNFα 
response.  Furthermore, we observed no correlation between the Aβ-aggregation age and 
microglial TNFα response despite the fact that ThT-fluorescence showed a time 
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dependent increase over time (Figure 5.9).  We did not see a consistent, reproducible 
microglial response between different experiments.  Another factor which made the 
analyses less straightforward is the variable microglial TNFα response to Tris-HCl buffer 
(pH 8.0).  The background response in some cases was comparable to water treated cells, 
but in other experiments Tris background signal was very high, making the Aβ-induced 
microglial TNFα response hard to interpret (discussed further in section 5.8). 
 
 
 
5.7 No correlation was found between Aβ(1-42) induced proinflammatory response and 
extent of reactivity to OC-antibody 
 
 
 
OC-antibody is a conformation dependent antibody developed by Charles Glabes 
laboratory that specifically recognizes Aβ species that have an element of fibril structure 
(Kayed, et al., 2007).  We have previously reported that SEC-purified Aβ(1-42) fraction, 
which is non-reactive to OC-antibody, failed to stimulate THP-1 monocytes (Ajit, et al., 
2009).  Moreover, Aβ(1-42)-induced TNFα response was diminished, when Aβ(1-42) 
solution was immunodepleted using OC-antibody (Ajit, et al., 2009).  We wanted to 
investigate whether OC-reactivity is sufficient to produce TNFα response in a microglial 
cell system as well.   
We made use of a dot blot technique to qualitatively detect the presence of OC-
positive Aβ species in a particular aggregation solution of Aβ(1-42).  The dot-blot 
technique is more useful for qualitative information, although the densitometry analysis 
of the dots developed by the use of chemiluminiscence can be used to get some idea into 
quantitative 
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Figure 5.9 Lack of correlation between microglial proinflammatory response and 
ThT-fluorescence of Aβ(1-42) over the time course of aggregation. Aβ(1-42) 
monomer (36 µM) was incubated at 37°C for up to 216h and aliquots were drawn at time 
points shown above.  Aliquots were analyzed for ThT binding and proinflammatory 
activity in primary microglia. Cells were exposed to a final Aβ(1-42) concentration of 11 
µM for 6 h. 
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Figure 5.10 Change in OC-immunoreactivity of Aβ(1-42) at 37⁰C over time. 2 μl of 
aggregated Aβ42 (62 μM) at different time points was probed with anti-fibrillar 
oligomeric OC-antibody in the dot blot assay as described in the methods. 
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analysis in a similar manner as Western blots.  Surprisingly, freshly purified Aβ(1-42) 
monomer, although showing negligible ThT-fluorescence, was immunoreactive to OC 
antisera for a wide range of concentrations (data not shown).  Furthermore, increasing the 
time of aggregation had no effect on OC-reactivity.  We observed changes in the intensity 
of dots over the course of aggregation, although no specific trend was obvious (Figure 
5.10).  OC-reactivity did not seem to correlate with microglial cell stimulation, 
irrespective of whether we observed a significant TNFα response or not in a particular 
experiment (data not shown).  However, this result does not rule out the possibility that 
OC-immunoreactivity is essential for microglial stimulation because of several reasons.  
OC-antibody is known to recognize a wide range of sizes.  It is possible that only one or a 
few OC-positive species, when present at a particular critical concentration, can act as a 
potent stimulus.  Variability in Aβ(1-42) aggregation reactions could be attributed to the 
concentration of monomer or concentration of seed structures formed rapidly during 
elution of the peptide. 
 
 
 
5.8 Discussion 
 
 
 
Understanding microglial activation in response to Aβ has gained a lot of 
importance particularly since microglia are emerging as one of the cell types displaying a 
highly dynamic phenotype and versatile functions in the normal brain as well as in the 
degenerating brain (Nimmerjahn, et al., 2005; Perry, et al., 2010).  Recent evidence using 
multiphoton imaging has shown rapid recruitment of microglia to the nascent plaques in a 
transgenic mice model of AD (Meyer-Luehmann, et al., 2008) and more recently both 
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microgliosis and astrocytosis were found to be very well correlated with neuronal loss 
(Serrano-Pozo, et al., 2011). These and other studies have strongly supported a role for 
microglia in AD pathogenesis.  Aβ acts as a potent proinflammatory stimulus as shown in 
a number of in vitro studies (Meda, et al., 1995; McDonald, et al., 1997; Combs, et al., 
2000; Combs, et al., 2001; Klegeris and McGeer, 2001; Stewart, et al., 2010). In vitro 
studies have been useful in studying Aβ-induced stimulation of microglia, since it allows 
for the flexibility to manipulate not only Aβ aggregation state but also the factors 
influencing Aβ aggregation.  Although, in vitro knowledge does not always directly 
translate to in vivo processes, it does provide information which can form a basis for 
further in vivo testing.  In the present in vitro study, we attempted to investigate an 
optimal aggregation state of Aβ(1-42) that provokes the maximum proinflammatory 
response in murine microglia, and it appears that homogeneity and concentration of the 
Aβ(1-42) aggregation reaction have a substantial role in producing the optimal 
proinflammatory aggregation state. 
In this study, we did not observe a consistent correlation between aggregation of 
SEC-purified Aβ(1-42) monomer and subsequent microglial TNFα production.  In fact, 
some of our experiments showed that microglial TNFα response increases with 
increasing time of incubation of Aβ, which correlated with the extent of ThT 
fluorescence.  This observation suggested that fibrils might be the optimal 
proinflammatory stimulus for murine microglia.  But on the other hand, we also observed 
no specific trend in the microglial TNFα response despite the increase in ThT 
fluorescence of Aβ(1-42) as a function of time.  This observation was surprising because 
in our previous studies using THP-1 monocytes, we were able to identify an intermediate 
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aggregation state of Aβ(1-42) (corresponding to 72-96 h incubation) as optimal for 
producing TNFα response.  All the physical factors like temperature, concentration, time 
of incubation and pH that allowed for more fibril formation, in fact, diminished the TNFα 
response by THP-1 monocytes.  AFM analysis of these aggregation reactions suggested 
that soluble fibrillar precursors, but not fibrils, are optimal for producing a 
proinflammatory response in THP-1 monocytes (Ajit, et al., 2009).  However, the present 
study had some differences than the study carried out in THP-1 monocytes.  In this study, 
we prepared Aβ(1-42) in different ways.  Firstly, we tried to replicate our preparation of 
recombinant Aβ(1-42) in water as described in Ajit et al (Ajit, et al., 2009), but it failed to 
produce any consistent microglial stimulation.  One of the potential concerns was the 
batch to batch variation in the purchased Aβ(1-42) peptide.  Previously, we have seen that 
some batches of purchased Aβ(1-42) produced a significant cellular response while other 
batches failed to do so, despite using the identical condition for preparation of Aβ (Jan, et 
al., 2010).  Also, in primary and BV-2 microglia, to minimize the cellular variation 
between different harvests, Aβ(1-42) was aliquoted at different time points, flash frozen 
using dry ice/ethanol mixture and all the aliquots were thawed on the day of cellular 
treatment unlike our study in THP-1 monocytes.  The effects of flash-freezing on Aβ 
aggregation were not clear.   
To rule out the presence of pre-formed seeds even after HFIP treatment, we took a 
step further to purify Aβ(1-42) monomer from the pre-existing aggregated Aβ using SEC 
right after its reconstitution (Jan, et al., 2010). Although, SEC was successful in 
separating highly purified monomer exhibiting little to no ThT fluorescence from the 
preformed aggregates, it led to the dilution of Aβ, yielding solutions of Aβ(1-42) 
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monomer of 36-40 μM (much less than the 100 μM concentration in the Ajit et al study) 
for the subsequent aggregation and cell stimulation studies.  Concentration has a 
profound effect on the aggregation of Aβ as discussed before in section 5.4.3.  We were 
not able to rule out the possibility that the concentration played a major role in both the 
qualitative and quantitative formation of a particular proinflammatory conformation state.  
Another important caveat in these studies was that the background TNFα response to the 
elution buffer, Tris-HCl 50 mM (pH 8.0), differed dramatically from experiment to 
experiment, making the data difficult to interpret.  Overall, Aβ(1-42) failed to induce a 
reproducible proinflammatory response in murine microglia under identical conditions 
irrespective of the peptide source being freshly reconstituted peptide or SEC-purified 
monomer. 
In our Aβ(1-42) aggregation studies starting with SEC-purified monomer (as 
described in section 5.4.3), we observed only weak correlation between concentration and 
t½ (time required to achieve half maximal ThT fluorescence).  One of the reasons could 
be that the Aβ(1-42) preparations were less homogenous between different experiments.  
Aβ follows a nucleation-dependent polymerization kinetics, therefore, the overall rate of 
Aβ fibrillogenesis is dependent on both the rate of nucleation and rate of elongation 
(Jarrett and Lansbury, 1992).  Moreover, the concentration of Aβ influences both the rate 
of nucleation as well as the rate of elongation (Lomakin, et al., 1996; Lomakin, et al., 
1997).  ThT binding measurements have been commonly used to estimate Aβ 
aggregation.  However, this method preferentially detects large polymeric structures and 
does not provide any information on rate of nucleation and rate of elongation (Lomakin, 
et al., 1997).  The weak correlation between Aβ aggregation as measured by ThT 
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fluorescence and concentration of Aβ might reflect a lack of sensitivity of ThT 
measurements for detection of early aggregation events.  Also SEC-purifications of Aβ 
monomer yielded slightly different monomer concentrations between different 
experiments.  Therefore, it is possible that the monomeric solution used to carry out 
aggregation reactions were less homogenous in the context of nucleation events, which 
influence the overall aggregation rate.  Furthermore, the rate of nucleation and elongation 
as well as monomer concentration together might influence the qualitative and 
quantitative formation of oligomeric intermediates responsible for proinflammatory 
activity.  Thus, lack of homogeneity might in turn be responsible for the inconsistency in 
cellular studies as well.  In fact, we were able to prepare and separate Aβ(1-42) 
protofibrils at high Aβ-concentrations (250 μM) using SEC, which were able to invoke 
highly reproducible TNFα response in both primary and BV-2 murine microglia.  Our 
own preparations of protofibrils and that described by others (Walsh, et al., 1997; Walsh, 
et al., 1999; Lashuel, et al., 2003) have also utilized higher concentrations of Aβ (100-
200 μM) in order to allow protofibril formation.  It is possible that Aβ(1-42) aggregation 
reactions described in this particular study were limited in the concentration of monomer 
to produce protofibrils in substantial amounts to evoke an effective proinflammatory 
response. 
Lastly, we took advantage of the conformation-specific OC-antibody that 
recognizes all Aβ-species that contain elements of fibril structure. In our previous study, 
we observed that immunodepletion of Aβ(1-42)-aggregation solution with the OC-
antibody abrogated the TNFα response by THP-1 monocytes (Ajit, et al., 2009).  In our 
dot-blot assays, we probed solutions of Aβ(1-42) for the presence of OC-
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immunoreactivity as a function of time of aggregation.  Surprisingly, we did not see any 
correlation between OC-immunoreactivity and ThT-fluorescence or Aβ-induced TNFα 
response in murine microglia.  In fact, Aβ(1-42) monomer right after its elution from 
SEC was immunoreactive to OC-antibody although it showed little to no ThT 
fluorescence.  This observation indicates that OC-antibody might be very sensitive in 
detecting early aggregation events of Aβ even before more common measures like ThT-
fluorescence can detect it.  Since dot-blot assays are more qualitative in nature, we were 
not able to investigate the concentration-dependence of Aβ on the OC-reactivity directly.  
Moreover, OC-antibody can detect Aβ-species of wide range of sizes and structures 
(Kayed, et al., 2007), making the identification and separation of OC-positive species 
difficult.  Future studies looking at the concentration of OC-positive species using an 
ELISA will yield more quantitative information regarding Aβ-aggregation. 
Together, this study underscores the need to use homogenous Aβ(1-42) solutions 
in order to study structure-activity relationship in the context of Aβ-induced 
proinflammatory response in mouse microglia.  This study also opens up avenues to 
utilize conformation-specific OC-antibody to probe early Aβ(1-42) aggregation events. 
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